

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 May 2003 (08.05.2003)

PCT

(10) International Publication Number
WO 03/038049 A2

(51) International Patent Classification⁷: **C12N**
(21) International Application Number: PCT/US02/34645
(22) International Filing Date: 29 October 2002 (29.10.2002)
(25) Filing Language: English
(26) Publication Language: English

(30) Priority Data:
60/340,689 29 October 2001 (29.10.2001) US

(71) Applicant (for all designated States except US): **RENO-VIS, INC.** [US/US]; 270 Littlefield Avenue, South San Francisco, CA 94080 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HEINTZ, Nathaniel** [US/US]; 441 Fowler Avenue, Pelham Manor, NY 10803 (US). **SERAFINI, Tito, A.** [US/US]; 1835 Mulberry Drive, San Mateo, CA 94403 (US). **SHYJAN, Andrew, W.** [US/US]; 177 Barford Avenue, San Carlos, CA 94070 (US).

(74) Agents: **ANTLER, Adriane, M.** et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.


(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD FOR ISOLATING CELL-TYPE SPECIFIC MRNAS



(57) Abstract: The invention provides methods for isolating cell-type specific mRNAs by selectively isolating ribosomes or proteins that bind mRNA in a cell type specific manner, and, thereby, the mRNA bound to the ribosomes or proteins that bind mRNA. Ribosomes, which are riboprotein complexes, bind mRNA that is being actively translated in cells. According to the methods of the invention, cells are engineered to express a molecularly tagged ribosomal protein or protein that binds mRNA by introducing into the cell a nucleic acid comprising a nucleotide sequence encoding a ribosomal protein or protein that binds mRNA fused to a nucleotide sequence encoding a peptide tag. The tagged ribosome or mRNA binding protein can then be isolated, along with the mRNA bound to the tagged ribosome or mRNA binding protein, and the mRNA isolated and further used for gene expression analysis. The methods of the invention facilitate the analysis and quantification of gene expression in the selected cell type present within a heterogeneous cell mixture, without the need to isolate the cells of that cell type as a preliminary step.



WO 03/038049 A2

METHOD FOR ISOLATING CELL-TYPE SPECIFIC mRNAs

5 This application claims the benefit of application no. 60/340,689 filed October 29, 2001, the entire disclosure of which is incorporated herein by reference in its entirety.

1. TECHNICAL FIELD

10 The present invention relates to methods for isolating cell-type specific mRNAs by isolating ribosomes in a cell-type specific manner. According to the methods of the invention, ribosomes or proteins that bind mRNA of the selected cell type are molecularly tagged and isolated, and the mRNA bound to the ribosomes or proteins that bind mRNA is then isolated and analyzed. The methods of the invention facilitate the analysis and quantification of gene expression in the selected cell type present within a heterogeneous cell mixture, without the need to isolate the cells of that cell type as a preliminary step.

2. BACKGROUND OF THE INVENTION

20 An important paradigm in the development of new diagnostics and therapies for human diseases and disorders is the characterization of the gene expression of defined cell types. The cellular complexity of many tissues (such as the nervous system), however, poses a challenge for those seeking to characterize gene expression at this level. The enormous heterogeneity of a tissue such as the nervous system (thousands of neuronal cell types, with non-neuronal cells outnumbering neuronal cells by an order of magnitude) is a barrier to the identification and analysis of gene transcripts present in individual cell types. One way to overcome this barrier is to tag gene transcripts directly or indirectly, *i.e.*, mRNA, present in a particular cell type, in such a manner as to allow facile isolation of the gene transcripts without the need to isolate the individual cells of that cell type as a preliminary step. We describe such a technology here.

30 3. SUMMARY OF THE INVENTION

 The invention provides methods for isolating cell-type specific mRNAs by selectively isolating ribosomes or proteins that bind mRNA in a cell type specific manner, and, thereby, the mRNA bound to the ribosomes or proteins that bind mRNA. Ribosomes, which are riboprotein complexes, bind mRNA that is being actively translated in cells. According to the methods of the invention, cells are engineered to express a molecularly

tagged ribosomal protein or protein that binds mRNA by introducing into the cell a nucleic acid comprising a nucleotide sequence encoding a ribosomal protein or proteins that bind mRNA fused to a nucleotide sequence encoding a peptide tag. The peptide tag can be any non-ribosomal protein peptide or non-mRNA binding protein peptide that is specifically
5 bound by a reagent that either does not recognize a component of the cell fraction from which the tagged ribosomes or proteins that bind mRNA are to be isolated, for example, from a whole cell lysate or post-mitochondrial fraction (or any other ribosome or polysome preparation or other preparation containing the tagged protein that binds mRNA being analyzed). In a preferred embodiment, the polysome preparation is a membrane-associated
10 polysome preparation. Specifically, the peptide tag may be an epitope that is recognized by an antibody that does not specifically bind any epitope expressed in a cell or ribosome/polysome fraction from an unengineered cell. As defined herein, specific binding is not competed away by addition of non-specific proteins, *e.g.*, bovine serum albumen (BSA). The tagged ribosomal protein or mRNA binding protein is then expressed
15 selectively in a cell population of interest (for example, by operably linking the nucleotide sequence encoding the tagged ribosomal protein or mRNA binding protein to a cell-type specific promoter and/or other transcriptional element). In a preferred embodiment, the tagged ribosomal protein or mRNA binding protein is overexpressed.

Monosomes or polysomes (which are, respectively, single or multiple ribosomes in a
20 complex with a single mRNA) or other mRNA-containing complex are isolated selectively from the cell population of interest through the use of the tagged ribosomal protein subunit or other mRNA binding protein. As used herein, isolated means that the ribosomes are separated from other cell components, specifically that the ribosomes are substantially free of untagged ribosomes and of RNA (particularly mRNA) not bound by ribosomes or mRNA
25 binding protein. In particular, the composition is 50%, 60%, 70%, 80%, 90%, 95% or 99% tagged ribosome or mRNA binding protein and associated mRNA. The mRNA species that are bound to the cell-type specific ribosomes or mRNA binding protein are then isolated, and can subsequently be profiled and quantified, to analyze gene expression in the cell. In a specific embodiment, because nascent polypeptides are attached to isolated monosomes and
30 polysomes, the methods of the invention can also be used to isolate newly synthesized polypeptides from a cell type of interest (*e.g.*, for proteomic applications), for example, using antibodies that specifically recognize an epitope on a specific polypeptide being synthesized by the cell.

In preferred embodiments, the invention provides transformed organisms (including
35 animals, plants, fungi and bacteria), *e.g.*, a transgenic animal such as a transgenic mouse,

that expresses one or more tagged ribosomal protein(s) or mRNA binding protein(s) within a chosen cell type. The invention also provides cultured cells that express one or more tagged ribosomal proteins or mRNA binding proteins. Cell-type specific expression is achieved by driving the expression of the tagged ribosomal protein using the endogenous
5 promoter of a particular gene, wherein the expression of the gene is a defining characteristic of the chosen cell type (*i.e.*, the promoter causes gene expression specifically in the chosen cell type). Thus, "cell-type" refers to a population of cells characterized by the expression of a particular gene. In a preferred embodiment, a collection of transgenic mice expressing tagged ribosomal proteins within a set of chosen cell types is assembled. Additionally, since
10 the level of expression of the tagged ribosomal protein or mRNA binding protein within a cell may be important in the efficiency of the isolation procedure, in certain embodiments of the invention, a binary system can be used, in which the endogenous promoter drives expression of a protein that then activates a second expression construct. This second expression construct uses a strong promoter to drive expression of the tagged ribosomal
15 protein or mRNA binding protein at higher levels than is possible using the endogenous promoter itself.

In specific embodiments, the invention provides molecularly tagged ribosomes, preferably bound to mRNA, that are bound to an affinity reagent for the molecular tag. In more specific embodiments, the molecularly tagged ribosomes are bound to an affinity
20 reagent which is bound to a solid support. In other particular embodiments, the invention provides molecularly tagged ribosomal proteins and mRNA binding proteins of the invention (and the ribosomes, ribosomal-mRNA complexes, and mRNA binding protein-mRNA complexes containing them); nucleic acids comprising nucleotide sequences encoding a molecularly tagged ribosomal protein or mRNA binding protein of the
25 invention; vectors and host cells comprising these nucleic acids and tagged proteins and ribosomes of the inventions.

The methods of the invention are advantageous because they permit the isolation of gene transcripts, or mRNA, present in a particular cell type, as defined by the common expression of a given gene, in such a manner as to allow their facile isolation without the
30 need to isolate the individual cells of that cell type as a preliminary step.

Additionally, in specific embodiments, the methods of the invention may be used to isolate other organelles or subcellular structures by molecularly tagging proteins integral to those organelles or structures. In a particular embodiment, the methods of the invention are used to isolate cell specific mRNAs for secreted, membrane bound and lysosomal proteins by
35 isolating tagged membrane bound ribosomes.

4. DESCRIPTION OF THE FIGURES

FIG. 1. Polysomes from cells transfected with plasmids expressing tagged versions of ribosomal proteins S6 (lane 2, in duplicate), L32 (lane 4, in duplicate), and L37 (lane 5, in duplicate) contain proteins that are reactive to the anti-streptag II antibodies. These proteins correspond to the predicted molecular weights of the S6 (34 kDa), L32 (52kDa), and L37 (9kDa) ribosomal proteins. The S6 and L37 proteins appear to be more abundantly represented in the polysomal fraction compared to the L32 protein. Tagged S20 (lane 3, in duplicate) does not appear to be present in the polysomal fraction. Polysomes from untransfected cells (lane 1, in duplicate) do not display any immunoreactive material.

FIG. 2. Ribosomal RNA is present (arrow) in material immunoprecipitated from tagged S6 (lane 2) transfectants. Such RNA is also present at low levels in material from tagged L37 transfectants (lane 3). Such RNA is not present in material from untransfected cells (lane 1).

5. DETAILED DESCRIPTION OF THE INVENTION

The invention provides methods for isolating cell-type specific mRNAs by selectively isolating ribosomes, or other proteins that bind mRNA, in a cell type specific manner, and, thereby, the mRNA bound to the ribosomes or mRNA binding proteins. Ribosomes, which are riboprotein complexes, bind mRNA that is being actively translated in cells. According to the methods of the invention, preferably, cells are engineered to express a molecularly tagged ribosomal protein or mRNA binding protein by introducing into the cell a nucleic acid comprising a nucleotide sequence encoding a ribosomal protein or mRNA binding protein fused to a nucleotide sequence encoding a peptide tag. The peptide tag can be any peptide that is not from a ribosomal protein or mRNA binding protein and that is specifically bound by a reagent that does not recognize a component, other than the peptide tag, of the cell fraction from which the tagged ribosomes or mRNA binding proteins are to be isolated, for example, from a whole cell lysate or post-mitochondrial fraction (or any other ribosome or polysome preparation or preparation containing mRNA binding protein bound to mRNA being analyzed). For example, the peptide tag may be an epitope that is recognized by an antibody that does not specifically bind any epitope expressed in a cell or ribosome/polysome fraction (or other fraction) from an unengineered cell. As defined herein, specific binding is not competed away by addition of non-specific proteins, *e.g.*, bovine serum albumen (BSA).

The tagged ribosomal protein or mRNA binding protein is then expressed selectively in a cell population of interest (for example, by operably linking the nucleotide sequence

encoding the tagged ribosomal or mRNA binding protein to a cell-type specific promoter, enhancer and/or other transcriptional element). The fused nucleotide sequences may be under the control of a transcriptional element (*e.g.*, promoter or enhancer) that activates transcription specifically in the cell type of choice (for example, transcriptional regulatory elements that control expression of the gene, the expression of which characterizes the cell type of choice, termed herein the “characterizing gene”). In a preferred embodiment, the tagged ribosomal or mRNA binding protein is overexpressed. Cell-specific polysomes (or other fraction containing the tagged mRNA binding protein) containing the tag are purified, exploiting affinity of a purification reagent (*e.g.*, an antibody or other biological compound that binds the tag) for the tag. The purification reagent can then be isolated itself or be bound to another structure, *e.g.*, a bead, that can be isolated from other components in the cell, and bound mRNA is isolated from purified polysomes for subsequent gene expression analysis.

5.1. MOLECULAR TAGGING OF RIBOSOMES AND mRNA BINDING PROTEINS

The invention provides methods for isolating cell-type specific mRNA using molecularly tagged ribosomal proteins that become incorporated into the ribosomes of a particular cell type or molecularly tagged mRNA binding proteins that are expressed in a particular cell type of interest. Specifically, ribosomes and mRNA binding proteins can be molecularly tagged by expressing in the cell type of interest a ribosomal fusion protein or mRNA binding protein fusion protein containing all or a portion of a ribosomal or mRNA binding protein (preferably, the portion has the biological activity of the native ribosomal protein or mRNA binding protein, *i.e.*, can function in an intact ribosome to carry out translation or binds mRNA) fused to (for example, through a peptide bond) a protein or peptide tag that is not a ribosomal protein or mRNA binding protein or portion thereof, or, preferably, found in the organism in which the tagged protein is being expressed. Such expression can be carried out by introducing into cells, or into an entire organism, a nucleic acid encoding the molecularly tagged ribosomal protein or mRNA binding protein, under the control of transcriptional regulatory elements that direct expression in the cell type of choice, or putting the expression of the ribosomal or mRNA fusion protein under the control of an endogenous promoter by homologous recombination or in a bacterial artificial chromosome (“BAC”).

The invention further provides methods for isolating cell-type specific mRNA by tagging proteins that bind to mRNA, preferably actively translated mRNA. In a preferred

embodiment, the protein that binds mRNA is not poly A binding protein. In another embodiment, the protein that binds mRNA is a CAP binding protein or a processing factor that binds the 3' untranslated region of the mRNA. In certain other embodiments, the ribosome or mRNA binding protein is molecularly tagged by engineering the ribosome or mRNA binding protein to bind a small molecule, *e.g.*, a peptide, that is not significantly bound by the unengineered ribosome or mRNA binding protein.

The nucleic acid encoding the ribosomal protein or other mRNA binding protein fused to the peptide tag can be generated by routine genetic engineering methods in which a nucleotide sequence encoding the amino acid sequence for the peptide tag sequence is engineered in frame with the nucleotide sequence encoding a ribosomal protein or mRNA binding protein. This can be accomplished by any method known in the art, for example, via oligonucleotide-mediated site-directed mutagenesis or polymerase chain reaction and other routine protocols of molecular biology (*see, e.g.*, Sambrook *et al.*, 2001, Molecular Cloning, A Laboratory Manual, Third Edition, Cold Spring Harbor Laboratory Press, N.Y.; and Ausubel *et al.*, 1989, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y., both of which are hereby incorporated by reference in their entirety). In certain embodiments, the method of Walles-Granberg *et al.* (Biochim. Biophys. Acta, 2001, 1544(1-2): 378-385, which is incorporated herein by reference in its entirety) is used.

The nucleotide sequence encoding the peptide tag is preferably inserted in frame such that the tag is placed at the N- or C-terminus of the ribosomal protein, since these portions of proteins are often accessible to detection or purification reagents. The peptide tag, however, may be inserted into any portion of the ribosomal protein such that when the protein is incorporated into an intact ribosome, the insertion of the tag does not prevent ribosomal function and the tag is accessible in the intact ribosome to the purification reagent to be used in the isolation. If a mRNA binding protein is used, the tag may be inserted into any portion of the protein such that the protein binds mRNA and the tag is accessible to the purification reagent.

Encoded peptide tags can be any non-ribosomal protein (or non-mRNA binding) peptide or protein (or portion thereof) that is not present and/or accessible in the cell of interest (or the cell fraction from which the tagged ribosomes or mRNA binding protein are to be affinity isolated) for which there exists an affinity reagent that recognizes the peptide and that is accessible to solution (and thereby, the peptide tag) in the intact ribosomes or mRNA binding protein bound to mRNA.

Molecular tagging with epitopes ("epitope tagging") is well known in the art (reviewed in Fritze CE, Anderson TR. Epitope tagging: general method for tracking recombinant proteins. *Methods Enzymol.* 2000;327:3-16; Jarvik JW, Telmer CA. Epitope tagging. *Annu Rev Genet.* 1998;32:601-18). An epitope tag can be any peptide protein that is not normally present and/or accessible in the cell of interest (or other cells that will be contacted with the reagent that binds the tag) for which there exists an antibody that recognizes the protein, and that is accessible to solution in the intact ribosomes or mRNA binding protein-mRNA complexes.

Peptide tags can include those for which methods/reagents exist that allow facile identification of the tagged ribosomal protein or mRNA binding protein, but are unlikely to inhibit or interfere with function of the tagged ribosomal protein or mRNA binding protein. The tag may be of any length that permits binding to the corresponding binding reagent, but does not interfere with the tagged proteins binding to the mRNA. In a preferred embodiment, the tag is about 8, 10, 12, 15, 18 or 20 amino acids, is less than 15, 20, 25, 30, 40 or 50 amino acids, but may be 100, 150, 200, 300, 400 or 500 or more amino acids in length. The tag may be bound specifically by a reagent that does not bind any component of: (1) the cell of interest; or (2) a polysomal preparation of interest; or (3) whatever cellular fraction of interest is being contacted by the reagent that binds the tag. Molecular tags may include, by way of example, and not by limitation, protein A fragments; myc epitopes (Evan *et al.*, *Mol. Cell Biol.* 5(12):3610-3616); Btag (Wang *et al.*, 1996, *Gene* 169(1): 53-58; and polyhistidine tracts (Bornhorst *et al.*, 2000, *Purification of proteins using polyhistidine affinity tags*, *Methods Enzymol* 326:245-54). Other preferred tags include, but are not limited to:

(1) a portion of the influenza virus hemagglutinin protein (Tyr-Pro-Tyr-Asp-Val-Pro-Asp-Tyr-Ala; SEQ ID NO: 1). The reagent used for purification is a monoclonal antibody recognizing the tagged protein (12CA5) (Wilson IA, Niman HL, Houghten RA, Cherenson AR, Connolly ML, Lerner RA. The structure of an antigenic determinant in a protein. *Cell.* 1984 Jul;37(3):767-78).

(2) a portion of the human c-myc gene (Glu-Gln-Lys-Leu-Ile-Ser-Glu-Glu-Asp-Leu; SEQ ID NO: 2). The reagent used for purification is a monoclonal antibody recognizing the tagged protein (9E10) (Evan GI, Lewis GK, Ramsay G, Bishop JM. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product. *Mol Cell Biol.* 1985 Dec;5(12):3610-6).

(3) a portion of the bluetongue virus VP7 protein (Gln-Tyr-Pro-Ala-Leu-Thr; SEQ ID NO: 3). The reagent used for purification is a monoclonal antibody recognizing the

tagged protein (D11 and/or F10) (Wang LF, Yu M, White JR, Eaton BT. BTag: a novel six-residue epitope tag for surveillance and purification of recombinant proteins. *Gene*. 1996 Feb 22;169(1):53-8)

(4) a FLAG peptide (e.g., Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys; SEQ ID NO: 4).

- 5 The reagent used for purification are monoclonal antibodies recognizing the tagged protein (e.g., M1 and/or M2) (Sigma) (Hopp *et al.*, U.S. Patent No. 4,703,004, entitled "Synthesis of protein with an identification peptide" issued October 27, 1987; Brizzard BL, Chubet RG, Vizard DL. Immunoaffinity purification of FLAG epitope-tagged bacterial alkaline phosphatase using a novel monoclonal antibody and peptide elution. *Biotechniques*. 1994 Apr;16(4):730-5; Knappik A, Pluckthun A. An improved affinity tag based on the FLAG peptide for the detection and purification of recombinant antibody fragments. *Biotechniques*. 1994 Oct;17(4):754-761)

(5) a Strep-tag peptide (e.g., Ala-Trp-Arg-His-Pro-Gln-Phe-Gly-Gly; SEQ ID NO:

- 5). In a preferred embodiment, a strep-tag peptide is used. The reagent used for
15 purification is one of several optimized versions of streptavidin that recognizes the tagged protein (IBA GmbH) (Skerra *et al.*, U.S. Patent No. 5,506,121, entitled Fusion peptides with binding activity for streptavidin, issued April 9, 1996 ; Skerra A, Schmidt TG. Applications of a peptide ligand for streptavidin: the Strep-tag. *Biomol Eng*. 1999 Dec 31;16(1-4):79-86; Skerra A, Schmidt TG. Use of the Strep-Tag and streptavidin for detection and purification
20 of recombinant proteins. *Methods Enzymol*. 2000;326:271-304).

Any ribosomal protein or mRNA binding protein can be molecularly tagged for use in the methods of the invention, as described in this section, provided that when the ribosomal protein is molecularly tagged and incorporated into a ribosome, the ribosome can bind mRNA and, preferably, translate the mRNA into protein, or, when the mRNA binding
25 protein is molecularly tagged, it can bind mRNA. In addition, the tag of the tagged ribosomal protein or mRNA binding protein must be accessible to the purification reagent, so that the reagent can be used to purify the intact ribosomes or mRNA binding protein-mRNA complexes. Preferably, the ribosomal protein or mRNA binding protein to be tagged is from the same species as the cell that is to express the molecularly tagged protein.

- 30 Nucleic acids encoding the molecularly tagged ribosomal proteins and mRNA binding proteins of the invention may be produced using routine genetic engineering methods and cloning and expression vectors that are well known in the art. Nucleic acids encoding the ribosomal protein or mRNA binding protein to be molecularly tagged may be obtained using any method known in the art. The sequences for many ribosomal and
35 mRNA binding proteins are known (see Table 2 in Section 5.2 below providing GenBank

accession numbers for many human and murine ribosomal proteins). Nucleic acids may be obtained, for example, by PCR using oligonucleotide primers based upon the published sequences. Other related ribosomal and mRNA binding proteins (for example from other species) may be obtained by low, medium or high stringency hybridization of appropriate nucleic acid libraries using the ribosomal or mRNA binding protein in hand as a probe. The nucleic acids encoding the desired ribosomal or mRNA binding protein may then be incorporated into a nucleic acid vector either appropriate for additional molecular manipulations and/or for incorporation and expression in the host cells of interest. The nucleotide sequences encoding the peptide tag may likewise be obtained using methods well known in the art. For example, if the tag is fairly short, a nucleic acid encoding the tag and appropriate for generating a fusion protein with the ribosomal or mRNA binding protein may be constructed using oligonucleotides to form the double stranded nucleic acid encoding the peptide tag. The synthetic nucleic acid may then be cloned and used for generating fusion proteins with ribosomal proteins or mRNA binding proteins.

In certain embodiments, a nucleic acid molecule encoding a molecularly tagged ribosomal protein is intended for a particular expression system, in which the codon frequencies reflect the tRNA frequencies of the host cell or organism in which the protein is expressed. Codon optimization allows for maximum protein expression by increasing the translational efficiency of a gene of interest. Codon optimization is a standard component of custom gene design, and may be obtained from commercial service providers (*e.g.*, Aptagen, Inc., Herndon, VA; Integrated DNA Technologies, Skokie, IL).

The nucleic acid encoding a molecularly tagged ribosomal protein may be a synthetic nucleic acid in which the codons have been optimized for increased expression in the host cell in which it is produced. The degeneracy of the genetic code permits variations of the nucleotide sequence, while still producing a polypeptide having the identical amino acid sequence as the polypeptide encoded by the native DNA sequence. The frequency of individual synonymous codons for amino acids varies widely from genome to genome among eukaryotes and prokaryotes. The overall expression levels of individual genes may be regulated by differences in codon choice, which modulates peptide elongation rates.

Native codons may be exchanged for codons of highly expressed genes in the host cells. For instance, the nucleic acid molecule can be optimized for expression of the encoded protein in bacterial cells (*e.g.*, *E. coli*), yeast (*e.g.*, *Pichia*), insect cells (*e.g.*, *Drosophila*), or mammalian cells or animals (*e.g.*, human, sheep, bovine or mouse cells or animals).

Restriction enzyme sites critical for gene synthesis and DNA manipulation can be preserved or destroyed to facilitate nucleic acid and vector construction and expression of

the encoded protein. In constructing the synthetic nucleic acids of the invention, it may be desirable to avoid sequences that may cause gene silencing. The codon optimized sequence is synthesized and assembled, and inserted into an appropriate expression vector using conventional techniques well known to those of skill in the art.

5 In a preferred embodiment, a synthetic nucleic acid encoding a molecularly tagged ribosomal protein comprises at least one codon substitution in which non-preferred or less preferred codon in the natural gene encoding the protein has been replaced by a preferred codon encoding the same amino acid. The relative frequency of use for each codon can vary significantly between species, although certain codons are infrequently used across
10 species (Zhang *et al.*, 1991, Low-usage codons in *Escherichia coli*, yeast, fruit fly, and primates. *Gene*, 105:61-72). For instance in humans the preferred codons are: Ala (GCC); Arg (CGC); Asn (AAC); Asp (GAC); Cys (TGC); Gln (CAG); Gly (GGC); His (CAC); Ile (ATC); Leu (CTG); Lys (AAG); Pro(CCC); Phe (TTC); Ser (AGC); Thr (ACC); Tyr (TAC); and Val (GTG). Less preferred codons are: Gly (GGG); Ile (ATT); Leu (CTC); Ser
15 (TCC); Val (GTC); and Arg (AGG). All codons that do not fit the description of preferred codons or less preferred codons are non-preferred codons.

In general, the degree of preference of a particular codon is indicated by the prevalence of the codon in highly expressed genes. Codon preference for highly expressed human genes are as indicated in Table 1. For example, "ATC" represents 77% of the Ile
20 codons in highly expressed mammalian genes and is the preferred Ile codon; "ATT" represents 18% of the Ile codons in highly expressed mammalian genes and is the less preferred Ile codon. The sequence "ATA" represents only 5% of the Ile codons in highly expressed human genes and is a non-preferred Ile codon. Replacing a codon with another codon that is more prevalent in highly expressed human genes will generally increase
25 expression of the gene in mammalian cells. Accordingly, the invention includes replacing a less preferred codon with a preferred codon as well as replacing a non-preferred codon with a preferred or less preferred codon.

In a particularly preferred embodiment, the nucleic acid has been optimized for expression of the encoded protein in human or mammalian cells or organisms.

30

35

Table 1. Codon Frequency (Percentage) in highly expressed human genes

Ala			
5	GC	C	53
		T	17
		A	13
		G	17
Arg			
10	CG	C	37
		T	7
		A	6
		G	21
	AG	A	10
		G	18
Asn			
	AA	C	78
		T	22
Asp			
20	GA	C	75
		T	25
Leu			
25	CT	C	26
		T	5
	TT	A	3
		G	58
		A	2
		G	6
Lys			
30	AA	A	18
		G	82
Pro			
35	CC	C	48
		T	19
		A	16

		G	17
	Phe		
	TT	C	80
		T	20
5	Cys		
	TG	C	68
		T	32
	Gln		
	CA	A	12
10		G	88
	Glu		
	GA	A	25
		G	75
	Gly		
15	GG	C	50
		T	12
		A	14
		G	24
	His		
20	CA	C	79
		T	21
	Ile		
	AT	C	77
		T	18
25		A	5
	Ser		
	TC	C	28
		T	13
		A	5
30		G	9
	AG	C	34
		T	10
	Thr		
	AC	C	57
35		T	14

		A	14
		G	15
	Tyr		
	TA	C	74
5		T	26
	Val		
	GT	C	25
		T	7
		A	5
10		G	64

In particular embodiments, the invention provides fusion proteins (including isolated or purified fusion proteins) containing all or a functional portion of a ribosomal protein or mRNA binding protein and a peptide tag, as described above, as well as intact ribosomes and complexes of mRNA and mRNA binding protein (including isolated and purified intact ribosomes and complexes). The invention further provides nucleic acids comprising nucleotide sequences encoding the ribosomal and mRNA binding protein fusions with peptide tags of the invention, vectors containing these nucleic acids, and host cells containing nucleic acids encoding the ribosomal and mRNA binding protein fusion proteins of the invention.

5.2. SELECTION OF RIBOSOMAL PROTEIN FOR TAGGING

Any ribosomal protein or mRNA binding protein may be molecularly tagged for use in the methods of the invention. The ribosome containing the tagged protein should bind mRNA and, preferably, also translate the mRNA into protein, and the peptide tag in the intact ribosome should be accessible to the corresponding isolation reagent. Likewise, if an mRNA binding protein is used, the tagged mRNA binding protein should bind mRNA, and the peptide tag should be accessible to the corresponding isolation reagent. Accordingly, selection of an appropriate ribosomal protein for tagging can be based upon accessibility to affinity reagents such as antibodies against N- and C-termini or other portions of the proteins in intact ribosomes (Syu WJ, Kahan L. Both ends of Escherichia coli ribosomal protein S13 are immunochemically accessible in situ. J Protein Chem. 1992 Jun;11(3):225-30; reviewed in Syu WJ, Kahan B, Kahan L. Detecting immunocomplex formation in sucrose gradients by enzyme immunoassay: application in determining epitope accessibility on ribosomes. Anal Biochem. 1991 Jul;196(1):174-7). However, accessibility

does not imply that once tagged, the ribosomal protein will function appropriately. One assay of proper function of a tagged variant is the determination, via immunohistochemistry, that the tagged protein displays expected subcellular localization when expressed in cultured cells. The determination that the tag appears in a preparation of polysomes isolated from
5 transfected cells is an indication that ribosomal function is not greatly perturbed by the incorporation of the tagged protein into the organelle. See *e.g.*, Rosorius *et al.*, 2000, Human Ribosomal Protein L5 Contains Defined Nuclear Localization and Export Signals, J. Biol. Chem. 275(16): 12061–12068, and Russo *et al.*, 1997, Different Domains Cooperate to Target the Human Ribosomal L7a Protein to the Nucleus and to the Nucleoli, J. Biol.
10 Chem. 272(8): 5229–5235, both of which are hereby incorporated by reference in their entireties.

More thorough evaluations of any possible perturbation of ribosomal function involves comparisons of cellular physiology in transfected and untransfected cells. For example, comparisons of relative protein or mRNA abundances in transfected and
15 untransfected cells would be such measures of cellular physiology. An appropriate ribosomal protein will be one which, when tagged, is incorporated into ribosomes, allows those ribosomes to function without unduly affecting cellular physiology, and which has the tag positioned so as to be accessible to affinity purification reagents.

The methods of Herfurth *et al.* (1995, Determination of peptide regions exposed at
20 the surface of the bacterial ribosome with antibodies against synthetic peptides. Biol Chem Hoppe Seyler 376(2):81-90; which is hereby incorporated by reference in its entirety) may be used to determine before tagging which parts of particular ribosomal proteins are accessible in the intact ribosome.

Once accessibility is determined, one can determine whether ribosomes containing
25 the tagged riboprotein are functional using routine assays well known in the art. Analogous tests for accessibility of the tag in tagged mRNA binding proteins and formation and function of the mRNA binding protein-mRNA complex will be apparent to the skilled artisan for identifying and designing appropriate tagged mRNA binding proteins for use in the present invention.

30 Ribosomal proteins or protein subunits or mRNA binding proteins suitable for use in the methods of the invention are preferably of the same species as the host cell to be transformed, but in certain embodiments, may be of a different species.

Ribosomal proteins or protein subunits suitable for use in the methods of the invention include, but are not limited to mouse and human ribosomal proteins in Tables 2

35

and 3. In Tables 2 and 3, the GenBank accession number is followed by a description of the ribosomal protein as it appears in GenBank:

TABLE 2

Mouse Ribosomal Proteins

BC006068 - ribosomal protein L10, clone IMAGE:3593057, mRNA
gi|13543840|gb|BC006068.1|BC006068[13543840]

U17332 - ribosomal protein L9 (musl9) mRNA, partial cds
gi|687603|gb|U17332.1|MMU17332[687603]

U17331 - mutant ribosomal protein L9 (musl9mu) mRNA, partial cds
gi|687601|gb|U17331.1|MMU17331[687601]

AY043296 - ribosomal protein S3 (Rps3) gene, complete cds
gi|15421126|gb|AY043296.1|[15421126]

BC013165 - ribosomal protein L9, clone MGC:6543 IMAGE:2655358, mRNA, complete cds
gi|15341947|gb|BC013165.1|BC013165[15341947]

BC012641 - ribosomal protein S11, clone MGC:13737 IMAGE:4019309, mRNA, complete cds
gi|15215035|gb|BC012641.1|BC012641[15215035]

NM_021338 - ribosomal protein L35a (Rpl35a), mRNA
gi|15042946|ref|NM_021338.2|[15042946]

Y16430 - mRNA for ribosomal protein L35a
gi|15024263|emb|Y16430.2|MMY16430[15024263]

AF043285 - ribosomal protein S7 (rpS7) gene, complete cds
gi|2811283|gb|AF043285.1|AF043285[2811283]

BC010721 - ribosomal protein S3, clone MGC:6565 IMAGE:2811930, mRNA, complete cds

gi|14715106|gb|BC010721.1|BC010721[14715106]

- 5 BC010604 - ribosomal protein S6, clone MGC:6573 IMAGE:3481640, mRNA, complete cds

gi|14714896|gb|BC010604.1|BC010604[14714896]

BC009100 - ribosomal protein S4, X-linked, clone MGC:6575 IMAGE:3482299,

- 10 mRNA, complete cds

gi|14318605|gb|BC009100.1|BC009100[14318605]

BC005790 - ribosomal protein L5, clone IMAGE:2811648, mRNA

gi|14710611|gb|BC005790.1|BC005790[14710611]

15

BC008223 - ribosomal protein L31, clone MGC:6449 IMAGE:2599150, mRNA, complete cds

gi|14198320|gb|BC008223.1|BC008223[14198320]

- 20 BC007139 - ribosomal protein L22, clone MGC:6121 IMAGE:3487607, mRNA, complete cds

gi|13938045|gb|BC007139.1|BC007139[13938045]

BC003896 - ribosomal protein L17, clone MGC:6758 IMAGE:3594373, mRNA,

- 25 complete cds

gi|13278089|gb|BC003896.1|BC003896[13278089]

BC003829 - laminin receptor 1 (67kD, ribosomal protein SA), clone MGC:6243
IMAGE:3600738, mRNA, complete cds

- 30 gi|13277920|gb|BC003829.1|BC003829[13277920]

BC002145 - ribosomal protein S23, clone MGC:7260 IMAGE:3484753, mRNA, complete cds

gi|12805350|gb|BC002145.1|BC002145[12805350]

35

BC002110 - ribosomal protein L24, clone MGC:6606 IMAGE:3488279, mRNA,
complete cds

gi|12805288|gb|BC002110.1|BC002110[12805288]

- 5 BC002088 - ribosomal protein S25, clone MGC:6338 IMAGE:3487037, mRNA,
complete cds

gi|12805250|gb|BC002088.1|BC002088[12805250]

- BC002062 - ribosomal protein L29, clone MGC:6127 IMAGE:3590425, mRNA,
10 complete cds

gi|12805206|gb|BC002062.1|BC002062[12805206]

BC002060 - ribosomal protein L30, clone MGC:6114 IMAGE:3489311, mRNA,
complete cds

- 15 gi|12805202|gb|BC002060.1|BC002060[12805202]

BC002044 - ribosomal protein S17, clone MGC:6030 IMAGE:3484265, mRNA,
complete cds

gi|12805170|gb|BC002044.1|BC002044[12805170]

20

BC002014 - ribosomal protein S7, clone MGC:5812 IMAGE:3484169, mRNA, complete
cds

gi|12805114|gb|BC002014.1|BC002014[12805114]

- 25 AF374195 - ribosomal protein L6 (Rpl6) gene, complete cds

gi|14210105|gb|AF374195.1|AF374195[14210105]

NM_011292 - ribosomal protein L9 (Rpl9), mRNA

gi|14149646|ref|NM_011292.1|[14149646]

30

AF227523 - ribosomal protein L3 (Rpl3) gene, partial cds

gi|13383337|gb|AF227523.1|AF227523[13383337]

NM_011289 - ribosomal protein L27 (Rpl27), mRNA

- 35 gi|8567399|ref|NM_011289.1|[8567399]

NM_019647 - ribosomal protein L21 (Rpl21), mRNA
gi|9789992|ref|NM_019647.1|[9789992]

5 NM_011029 - laminin receptor 1 (67kD, ribosomal protein SA) (Lamr1), mRNA
gi|6754967|ref|NM_011029.1|[6754967]

NM_023133 - ribosomal protein S19 (Rps19), mRNA
gi|12963510|ref|NM_023133.1|[12963510]

10 NM_022891 - ribosomal protein L23 (Rpl23), mRNA
gi|12584985|ref|NM_022891.1|[12584985]

AF287271 - ribosomal protein L23 (Rpl23) mRNA, complete cds
gi|9502281|gb|AF287271.1|AF287271[9502281]
15

AF158022 - ribosomal protein L23 (Rpl23) gene, complete cds
gi|5354204|gb|AF158022.1|AF158022[5354204]

NM_018853 - ribosomal protein, large, P1 (Rplp1), mRNA
20 gi|9256518|ref|NM_018853.1|[9256518]

NM_020600 - ribosomal protein S14 (Rps14), mRNA
gi|10181111|ref|NM_020600.1|[10181111]

25 NM_019865 - ribosomal protein L44 (Rpl44), mRNA
gi|9845294|ref|NM_019865.1|[9845294]

NM_018730 - ribosomal protein L36 (Rpl36), mRNA
gi|9055321|ref|NM_018730.1|[9055321]
30

NM_016959 - ribosomal protein S3a (Rps3a), mRNA
gi|8394217|ref|NM_016959.1|[8394217]

NM_016738 - ribosomal protein L13 (Rpl13), mRNA
35 gi|7949126|ref|NM_016738.1|[7949126]

NM_013765 - ribosomal protein S26 (Rps26), mRNA
gi|7305446|ref|NM_013765.1|[7305446]

5 NM_013647 - ribosomal protein S16 (Rps16), mRNA
gi|7305444|ref|NM_013647.1|[7305444]

NM_013721 - ribosomal protein L7a (Rpl7a), mRNA
gi|7305442|ref|NM_013721.1|[7305442]

10 NM_013762 - ribosomal protein L3 (Rpl3), mRNA
gi|7305440|ref|NM_013762.1|[7305440]

NM_009438 - ribosomal protein L13a (Rpl13a), mRNA
gi|7110730|ref|NM_009438.1|[7110730]

15 NM_011300 - ribosomal protein S7 (Rps7), mRNA
gi|6755375|ref|NM_011300.1|[6755375]

20 NM_012052 - ribosomal protein S3 (Rps3), mRNA
gi|6755371|ref|NM_012052.1|[6755371]

NM_011297 - ribosomal protein S24 (Rps24), mRNA
gi|6755369|ref|NM_011297.1|[6755369]

25 NM_011296 - ribosomal protein S18 (Rps18), mRNA
gi|6755367|ref|NM_011296.1|[6755367]

NM_011295 - ribosomal protein S12 (Rps12), mRNA
gi|6755365|ref|NM_011295.1|[6755365]

30 NM_012053 - ribosomal protein L8 (Rpl8), mRNA
gi|6755357|ref|NM_012053.1|[6755357]

35 NM_011291 - ribosomal protein L7 (Rpl7), mRNA
gi|6755355|ref|NM_011291.1|[6755355]

NM_011290 - ribosomal protein L6 (Rpl6), mRNA
gi|6755353|ref|NM_011290.1|[6755353]

5 NM_011287 - ribosomal protein L10A (Rpl10a), mRNA
gi|6755349|ref|NM_011287.1|[6755349]

NM_009098 - ribosomal protein S8 (Rps8), mRNA
gi|6677812|ref|NM_009098.1|[6677812]

10 NM_009096 - ribosomal protein S6 (Rps6), mRNA
gi|6677808|ref|NM_009096.1|[6677808]

NM_009095 - ribosomal protein S5 (Rps5), mRNA
gi|6677806|ref|NM_009095.1|[6677806]

15 NM_009094 - ribosomal protein S4, X-linked (Rps4x), mRNA
gi|6677804|ref|NM_009094.1|[6677804]

NM_009093 - ribosomal protein S29 (Rps29), mRNA
20 gi|6677802|ref|NM_009093.1|[6677802]

NM_009092 - ribosomal protein S17 (Rps17), mRNA
gi|6677800|ref|NM_009092.1|[6677800]

25 NM_009091 - ribosomal protein S15 (Rps15), mRNA
gi|6677798|ref|NM_009091.1|[6677798]

NM_009084 - ribosomal protein L37a (Rpl37a), mRNA
gi|6677784|ref|NM_009084.1|[6677784]

30 NM_009083 - ribosomal protein L30 (Rpl30), mRNA
gi|6677782|ref|NM_009083.1|[6677782]

NM_009082 - ribosomal protein L29 (Rpl29), mRNA
35 gi|6677780|ref|NM_009082.1|[6677780]

- NM_009081 - ribosomal protein L28 (Rpl28), mRNA
gi|6677778|ref|NM_009081.1|[6677778]
- 5 NM_009080 - ribosomal protein L26 (Rpl26), mRNA
gi|6677776|ref|NM_009080.1|[6677776]
- NM_009079 - ribosomal protein L22 (Rpl22), mRNA
gi|6677774|ref|NM_009079.1|[6677774]
- 10 NM_009078 - ribosomal protein L19 (Rpl19), mRNA
gi|6677772|ref|NM_009078.1|[6677772]
- NM_009077 - ribosomal protein L18 (Rpl18), mRNA
gi|6677770|ref|NM_009077.1|[6677770]
- 15 NM_009076 - ribosomal protein L12 (Rpl12), mRNA
gi|6677768|ref|NM_009076.1|[6677768]
- Y12431 - mRNA for ribosomal protein S5
20 gi|3717977|emb|Y12431.1|MMRPS5[3717977]
- AF236069 - ribosomal protein L29 gene, complete cds
gi|7800211|gb|AF236069.1|AF236069[7800211]
- 25 AF283559 - ribosomal protein S2 mRNA, complete cds
gi|10179939|gb|AF283559.1|AF283559[10179939]
- AB037665 - rpl38 mRNA for ribosomal protein L38, complete cds
gi|9650959|dbj|AB037665.1|AB037665[9650959]
- 30 X83590 - mRNA for ribosomal protein L5, 3'end
gi|619503|emb|X83590.1|MMRPL5[619503]
- AF260271 - 60S ribosomal Protein L9 mRNA, complete cds
35 gi|7862171|gb|AF260271.1|AF260271[7862171]

AF216207 - ribosomal protein S19 (Rps19) gene, complete cds
gi|7648817|gb|AF216207.1|AF216207[7648817]

5 AF214527 - ribosomal protein L27 (RPL27) mRNA, complete cds
gi|6708473|gb|AF214527.1|AF214527[6708473]

AB020237 - gene for ribosomal protein L27A, complete cds
gi|4760603|dbj|AB020237.1|AB020237[4760603]

10 AF091511 - ribosomal protein L8 (Rpl8) gene, partial cds
gi|3851578|gb|AF091511.1|AF091511[3851578]

U89419 - strain BALB/c 60S acidic ribosomal protein P0 mRNA, partial cds
gi|3642675|gb|U89419.1|MMU89419[3642675]

15 U89418 - strain BALB/c ribosomal protein S2 (LLRep3) mRNA, partial cds
gi|3642670|gb|U89418.1|MMU89418[3642670]

U89417 - strain BALB/c ribosomal protein L3 mRNA, partial cds
20 gi|3642668|gb|U89417.1|MMU89417[3642668]

U89414 - strain BALB/c ribosomal protein S3 mRNA, partial cds
gi|3642662|gb|U89414.1|MMU89414[3642662]

25 U67771 - ribosomal protein L8 (RPL8) mRNA, complete cds
gi|1527177|gb|U67771.1|MMU67771[1527177]

K02060 - ribosomal protein L32-3A (3A) gene, complete cds
gi|3228365|gb|K02060.1|MUSRPL3A[3228365]

30 Y08307 - mRNA for ribosomal protein S14
gi|1565267|emb|Y08307.1|MMMRPS14[1565267]

U78085 - ribosomal protein S5 mRNA, complete cds
35 gi|1685070|gb|U78085.1|MMU78085[1685070]

D25213 - rpS17 mRNA for ribosomal protein S17, complete cds
gi|893394|dbj|D25213.1|MUSRPS17[893394]

5 U93864 - ribosomal protein S11 mRNA, complete cds
gi|1938405|gb|U93864.1|MMU93864[1938405]

U93863 - ribosomal protein L21 mRNA, complete cds
gi|1938403|gb|U93863.1|MMU93863[1938403]

10 U93862 - ribosomal protein L41 mRNA, complete cds
gi|1938401|gb|U93862.1|MMU93862[1938401]

M62952 - ribosomal protein L19, complete cds
gi|198642|gb|M62952.1|MUSL19RP[198642]
15

L31609 - clone mcori-1ck9, S29 ribosomal protein mRNA, complete cds
gi|1220417|gb|L31609.1|MUSS29RP[1220417]

U67770 - ribosomal protein S26 (RPS26) mRNA, complete cds
20 gi|1527175|gb|U67770.1|MMU67770[1527175]

X54067 - SURF-3 gene for ribosomal protein L7a (rpL7a)
gi|54209|emb|X54067.1|MMSURF3[54209]

25 Z32550 - gene for ribosomal protein L35a
gi|563529|emb|Z32550.1|MMRPL35[563529]

X73829 - mRNA for ribosomal protein S8
gi|313297|emb|X73829.1|MMRPS8[313297]
30

X73331 - mRNA for ribosomal protein L37a
gi|312413|emb|X73331.1|MMRP37A[312413]

X60289 - mRNA for ribosomal protein S24
35 gi|311296|emb|X60289.1|MMRPS24[311296]

- Y00348 - mRNA for ribosomal protein S6
gi|54009|emb|Y00348.1|MMRPS6[54009]
- 5 X15962 - mRNA for ribosomal protein S12
gi|54005|emb|X15962.1|MMRPS12[54005]
- X74856 - L28 mRNA for ribosomal protein L28
gi|488834|emb|X74856.1|MMRNAL28[488834]
- 10 X76772 - mRNA for ribosomal protein S3
gi|439521|emb|X76772.1|MMRIBPS3[439521]
- X57960 - mRNA for ribosomal protein L7
gi|53911|emb|X57960.1|MMRBPRL7A[53911]
- 15 X57961 - mRNA for ribosomal protein L7
gi|55488|emb|X57961.1|MRBPRL7B[55488]
- X75895 - mRNA for ribosomal protein L36
20 gi|443801|emb|X75895.1|MML36[443801]
- U28917 - 60S ribosomal protein (A52) mRNA, complete cds
gi|899444|gb|U28917.1|MMU28917[899444]
- 25 M73436 - ribosomal protein S4 (Rps4) mRNA, complete CDS
gi|200863|gb|M73436.1|MUSRSP4[200863]
- L24371 - clone FVB41, ribosomal protein S4 gene, partial cds
gi|402310|gb|L24371.1|MUSRPS4B[402310]
- 30 M77296 - ribosomal protein S4 (Rps4) gene, partial cds
gi|200798|gb|M77296.1|MUSRPS4A[200798]
- M29016 - ribosomal protein L7 (rpL7) mRNA, 5' end
35 gi|200786|gb|M29016.1|MUSRPL7R[200786]

M29015 - ribosomal protein L7 (rpL7) gene, complete cds
gi|200784|gb|M29015.1|MUSRPL7A[200784]

5 M23453 - ribosomal protein L32' (rpL32') gene, complete cds
gi|200778|gb|M23453.1|MUSRPL32A[200778]

L04128 - ribosomal protein L18 (rpL18) mRNA, complete cds
gi|398049|gb|L04128.1|MUSRPL18A[398049]

10 L04280 - ribosomal protein (Rpl12) mRNA, complete cds
gi|398047|gb|L04280.1|MUSRPL12A[398047]

M35397 - ribosomal protein L32' (L32') gene, complete cds
gi|200773|gb|M35397.1|MUSRP32A[200773]

15 M85235 - ribosomal protein mRNA, complete cds
gi|200769|gb|M85235.1|MUSRP[200769]

20 U11248 - C57BL/6J ribosomal protein S28 mRNA, complete cds
gi|508265|gb|U11248.1|MMU11248[508265]

M76762 - ribosomal protein (Ke-3) gene, exons 1 to 5, and complete cds
gi|198577|gb|M76762.1|MUSKE3A[198577]

25 M76763 - ribosomal protein (Ke-3) mRNA, complete cds
gi|198579|gb|M76763.1|MUSKE3B[198579]

M11408 - S16 ribosomal protein gene, complete cds
gi|435544|gb|M11408.1|MUSRPS16[435544]

30 K02928 - ribosomal protein L30 gene, complete cds
gi|435126|gb|K02928.1|MUSRPL30[435126]

35

TABLE 3
Human Ribosomal Proteins

-
- 5 NM_000994 - ribosomal protein L32 (RPL32), mRNA
gi|15812220|ref|NM_000994.2|[15812220]
- NM_000993 - ribosomal protein L31 (RPL31), mRNA
gi|15812219|ref|NM_000993.2|[15812219]
- 10 NM_000989 - ribosomal protein L30 (RPL30), mRNA
gi|15812218|ref|NM_000989.2|[15812218]
- NM_001006 - ribosomal protein S3A (RPS3A), mRNA
15 gi|15718688|ref|NM_001006.2|[15718688]
- NM_001005 - ribosomal protein S3 (RPS3), mRNA
gi|15718686|ref|NM_001005.2|[15718686]
- 20 NM_006013 - ribosomal protein L10 (RPL10), mRNA
gi|15718685|ref|NM_006013.2|[15718685]
- NM_002954 - ribosomal protein S27a (RPS27A), mRNA
gi|15431307|ref|NM_002954.2|[15431307]
- 25 NM_001011 - ribosomal protein S7 (RPS7), mRNA
gi|15431308|ref|NM_001011.2|[15431308]
- NM_033301 - ribosomal protein L8 (RPL8), transcript variant 2, mRNA
30 gi|15431305|ref|NM_033301.1|[15431305]
- NM_000973 - ribosomal protein L8 (RPL8), transcript variant 1, mRNA
gi|15431304|ref|NM_000973.2|[15431304]
- 35 NM_000661 - ribosomal protein L9 (RPL9), mRNA

gi|15431302|ref|NM_000661.2|[15431302]

NM_000971 - ribosomal protein L7 (RPL7), mRNA

gi|15431300|ref|NM_000971.2|[15431300]

5

NM_000980 - ribosomal protein L18a (RPL18A), mRNA

gi|15431299|ref|NM_000980.2|[15431299]

NM_000979 - ribosomal protein L18 (RPL18), mRNA

10 gi|15431298|ref|NM_000979.2|[15431298]

NM_000977 - ribosomal protein L13 (RPL13), transcript variant 1, mRNA

gi|15431296|ref|NM_000977.2|[15431296]

15 NM_033251 - ribosomal protein L13 (RPL13), transcript variant 2, mRNA

gi|15431294|ref|NM_033251.1|[15431294]

NM_002948 - ribosomal protein L15 (RPL15), mRNA

gi|15431292|ref|NM_002948.2|[15431292]

20

NM_000976 - ribosomal protein L12 (RPL12), mRNA

gi|15431291|ref|NM_000976.2|[15431291]

NM_000975 - ribosomal protein L11 (RPL11), mRNA

25 gi|15431289|ref|NM_000975.2|[15431289]

NM_007104 - ribosomal protein L10a (RPL10A), mRNA

gi|15431287|ref|NM_007104.3|[15431287]

30 NM_032241 - ribosomal protein L10 (RPL10), mRNA

gi|14149953|ref|NM_032241.1|[14149953]

NM_001012 - ribosomal protein S8 (RPS8), mRNA

gi|4506742|ref|NM_001012.1|[4506742]

35

XM_012407 - ribosomal protein L9 (RPL9), mRNA
gi|15321503|ref|XM_012407.4|[15321503]

5 XM_053465 - ribosomal protein L9 (RPL9), mRNA
gi|15321501|ref|XM_053465.1|[15321501]

XM_053100 - ribosomal protein L13 (RPL13), mRNA
gi|15317414|ref|XM_053100.1|[15317414]

10 XM_051496 - ribosomal protein S25 (RPS25), mRNA
gi|15314558|ref|XM_051496.2|[15314558]

XM_039216 - ribosomal protein S13 (RPS13), mRNA
gi|15313667|ref|XM_039216.2|[15313667]

15 XM_047576 - ribosomal protein S15 (RPS15), mRNA
gi|15309638|ref|XM_047576.2|[15309638]

XM_028963 - ribosomal protein L23 (RPL23), mRNA
20 gi|15309255|ref|XM_028963.2|[15309255]

XM_006026 - ribosomal protein S28 (RPS28), mRNA
gi|15309243|ref|XM_006026.5|[15309243]

25 XM_030050 - ribosomal protein L17 (RPL17), mRNA
gi|15306618|ref|XM_030050.2|[15306618]

XM_053077 - ribosomal protein S16 (RPS16), mRNA
gi|15306479|ref|XM_053077.1|[15306479]

30 XM_016662 - ribosomal protein L38 (RPL38), mRNA
gi|14785533|ref|XM_016662.2|[14785533]

XM_034464 - ribosomal protein S2 (RPS2), mRNA
35 gi|14779902|ref|XM_034464.1|[14779902]

XM_007920 - ribosomal protein L3-like (RPL3L), mRNA
gi|14779893|ref|XM_007920.4|[14779893]

5 XM_009998 - ribosomal protein L3 (RPL3), mRNA
gi|14779001|ref|XM_009998.4|[14779001]

XM_039345 - ribosomal protein L3 (RPL3), mRNA
gi|14778998|ref|XM_039345.1|[14778998]

10 XM_039344 - ribosomal protein L3 (RPL3), mRNA
gi|14778996|ref|XM_039344.1|[14778996]

XM_039346 - ribosomal protein L3 (RPL3), mRNA
gi|14778994|ref|XM_039346.1|[14778994]

15 XM_047467 - ribosomal protein L13 (RPL13), mRNA
gi|14776722|ref|XM_047467.1|[14776722]

20 XM_047464 - ribosomal protein L13 (RPL13), mRNA
gi|14776717|ref|XM_047464.1|[14776717]

XM_047468 - ribosomal protein L13 (RPL13), mRNA
gi|14776715|ref|XM_047468.1|[14776715]

25 XM_047465 - ribosomal protein L13 (RPL13), mRNA
gi|14776711|ref|XM_047465.1|[14776711]

30 XM_027368 - ribosomal protein S15a (RPS15A), mRNA
gi|14774916|ref|XM_027368.1|[14774916]

XM_027367 - ribosomal protein S15a (RPS15A), mRNA
gi|14774912|ref|XM_027367.1|[14774912]

35 XM_044693 - ribosomal protein L26 (RPL26), mRNA
gi|14774237|ref|XM_044693.1|[14774237]

XM_051497 - ribosomal protein S25 (RPS25), mRNA
gi|14774084|ref|XM_051497.1|[14774084]

5 XM_039215 - ribosomal protein S13 (RPS13), mRNA
gi|14772983|ref|XM_039215.1|[14772983]

XM_032124 - ribosomal protein L27 (RPL27), mRNA
gi|14772981|ref|XM_032124.1|[14772981]

10 XM_008208 - ribosomal protein L27 (RPL27), mRNA
gi|14772978|ref|XM_008208.4|[14772978]

XM_006388 - ribosomal protein S13 (RPS13), mRNA
gi|14772975|ref|XM_006388.5|[14772975]
15

XM_050589 - ribosomal protein S9 (RPS9), mRNA
gi|14769524|ref|XM_050589.1|[14769524]

XM_048412 - region containing hypothetical protein FLJ23544; ribosomal protein
20 L10; ribosomal protein L10; ribosomal protein L10 (LOC88324), mRNA
gi|14768370|ref|XM_048412.1|[14768370]

XM_048415 - region containing hypothetical protein FLJ23544; ribosomal protein
L10; ribosomal protein L10; ribosomal protein L10 (LOC88324), mRNA
25 gi|14768366|ref|XM_048415.1|[14768366]

XM_038593 - ribosomal protein L18a (RPL18A), mRNA
gi|14766237|ref|XM_038593.1|[14766237]

30 XM_045500 - Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously
expressed (fox derived); ribosomal protein S30 (FAU), mRNA
gi|14765886|ref|XM_045500.1|[14765886]

XM_006522 - Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously
35 expressed (fox derived); ribosomal protein S30 (FAU), mRNA

gi|14765881|ref|XM_006522.4|[14765881]

XM_046112 - ribosomal protein S16 (RPS16), mRNA

gi|14764309|ref|XM_046112.1|[14764309]

5

XM_017838 - ribosomal protein L27a (RPL27A), mRNA

gi|14763277|ref|XM_017838.2|[14763277]

XM_044022 - ribosomal protein S4, X-linked (RPS4X), mRNA

10 gi|14758953|ref|XM_044022.1|[14758953]

XM_044024 - ribosomal protein S4, X-linked (RPS4X), mRNA

gi|14758950|ref|XM_044024.1|[14758950]

15 XM_044025 - ribosomal protein S4, X-linked (RPS4X), mRNA

gi|14758939|ref|XM_044025.1|[14758939]

XM_050942 - ribosomal protein L6 (RPL6), mRNA

gi|14758187|ref|XM_050942.1|[14758187]

20

XM_050943 - ribosomal protein L6 (RPL6), mRNA

gi|14758163|ref|XM_050943.1|[14758163]

XM_016828 - ribosomal protein L44 (RPL44), mRNA

25 gi|14757899|ref|XM_016828.2|[14757899]

XM_035105 - ribosomal protein L7a (RPL7A), mRNA

gi|14735036|ref|XM_035105.1|[14735036]

30 XM_016869 - ribosomal protein L26 homolog (LOC51121), mRNA

gi|14723097|ref|XM_016869.2|[14723097]

XM_016124 - ribosomal protein L39 (RPL39), mRNA

gi|13651332|ref|XM_016124.1|[13651332]

35

XM_018114 - region containing hypothetical protein FLJ23544; ribosomal protein L10; ribosomal protein L10; ribosomal protein L10 (LOC88324), mRNA
gi|13649125|ref|XM_018114.1|[13649125]

- 5 XM_008294 - ribosomal protein L19 (RPL19), mRNA
gi|13632268|ref|XM_008294.3|[13632268]

XM_009693 - ribosomal protein S21 (RPS21), mRNA
gi|15304527|ref|XM_009693.3|[15304527]

10

XM_053478 - ribosomal protein L10a (RPL10A), mRNA
gi|15303249|ref|XM_053478.1|[15303249]

- XM_015318 - ribosomal protein S26 (RPS26), mRNA
15 gi|15303043|ref|XM_015318.2|[15303043]

XM_027885 - ribosomal protein L13a (RPL13A), mRNA
gi|15302570|ref|XM_027885.2|[15302570]

- 20 XM_007615 - ribosomal protein S17 (RPS17), mRNA
gi|15302513|ref|XM_007615.4|[15302513]

XM_054333 - ribosomal protein L28 (RPL28), mRNA
gi|15302226|ref|XM_054333.1|[15302226]

25

XM_031815 - ribosomal protein S20 (RPS20), mRNA
gi|15300059|ref|XM_031815.2|[15300059]

- XM_039576 - ribosomal protein S24 (RPS24), mRNA
30 gi|15299342|ref|XM_039576.2|[15299342]

XM_004020 - ribosomal protein S23 (RPS23), mRNA
gi|15297223|ref|XM_004020.2|[15297223]

- 35 XM_053824 - ribosomal protein L32 (RPL32), mRNA

gi|15296504|ref|XM_053824.1|[15296504]

XM_054368 - ribosomal protein L11 (RPL11), mRNA

gi|15296209|ref|XM_054368.1|[15296209]

5

XM_036739 - ribosomal protein S27 (metallopanstimulin 1) (RPS27), mRNA

gi|15294821|ref|XM_036739.2|[15294821]

XM_027332 - ribosomal protein L36 (RPL36), mRNA

10 gi|14786075|ref|XM_027332.1|[14786075]

XM_027331 - ribosomal protein L36 (RPL36), mRNA

gi|14786072|ref|XM_027331.1|[14786072]

15 XM_027333 - ribosomal protein L36 (RPL36), mRNA

gi|14786069|ref|XM_027333.1|[14786069]

XM_046140 - 60S ribosomal protein L30 isolog (LOC51187), mRNA

gi|14785520|ref|XM_046140.1|[14785520]

20

XM_046136 - 60S ribosomal protein L30 isolog (LOC51187), mRNA

gi|14785516|ref|XM_046136.1|[14785516]

XM_043287 - ribosomal protein S10 (RPS10), mRNA

25 gi|14782916|ref|XM_043287.1|[14782916]

XM_043285 - ribosomal protein S10 (RPS10), mRNA

gi|14782914|ref|XM_043285.1|[14782914]

30 XM_049965 - ribosomal protein L18 (RPL18), mRNA

gi|14760401|ref|XM_049965.1|[14760401]

XM_049096 - ribosomal protein S26 (RPS26), mRNA

gi|14759881|ref|XM_049096.1|[14759881]

35

XM_015328 - ribosomal protein L41 (RPL41), mRNA
gi|14759754|ref|XM_015328.2|[14759754]

5 XM_008923 - ribosomal protein S11 (RPS11), mRNA
gi|14757439|ref|XM_008923.4|[14757439]

XM_027884 - ribosomal protein L13a (RPL13A), mRNA
gi|14757411|ref|XM_027884.1|[14757411]

10 XM_027886 - ribosomal protein L13a (RPL13A), mRNA
gi|14757404|ref|XM_027886.1|[14757404]

XM_035924 - ribosomal protein L28 (RPL28), mRNA
gi|14757079|ref|XM_035924.1|[14757079]

15 XM_017626 - ribosomal protein S12 (RPS12), mRNA
gi|14756487|ref|XM_017626.2|[14756487]

XM_029926 - ribosomal protein S19 (RPS19), mRNA
20 gi|14756213|ref|XM_029926.1|[14756213]

XM_034265 - ribosomal protein S5 (RPS5), mRNA
gi|14755544|ref|XM_034265.1|[14755544]

25 XM_029544 - 40S ribosomal protein S27 isoform (LOC51065), mRNA
gi|14752644|ref|XM_029544.1|[14752644]

XM_035389 - ribosomal protein, large, P1 (RPLP1), mRNA
gi|14749908|ref|XM_035389.1|[14749908]

30 XM_035388 - ribosomal protein, large, P1 (RPLP1), mRNA
gi|14749900|ref|XM_035388.1|[14749900]

XM_035387 - ribosomal protein, large, P1 (RPLP1), mRNA
35 gi|14749891|ref|XM_035387.1|[14749891]

XM_035494 - ribosomal protein L7 (RPL7), mRNA
gi|14749839|ref|XM_035494.1|[14749839]

5 XM_035493 - ribosomal protein L7 (RPL7), mRNA
gi|14749837|ref|XM_035493.1|[14749837]

XM_035492 - ribosomal protein L7 (RPL7), mRNA
gi|14749834|ref|XM_035492.1|[14749834]

10 XM_052447 - ribosomal protein L29 (RPL29), mRNA
gi|14747560|ref|XM_052447.1|[14747560]

XM_052669 - ribosomal protein S29 (RPS29), mRNA
gi|14747175|ref|XM_052669.1|[14747175]
15

XM_044796 - ribosomal protein L35 (RPL35), mRNA
gi|14744218|ref|XM_044796.1|[14744218]

XM_039575 - ribosomal protein S24 (RPS24), mRNA
20 gi|14743725|ref|XM_039575.1|[14743725]

XM_039577 - ribosomal protein S24 (RPS24), mRNA
gi|14743718|ref|XM_039577.1|[14743718]

25 XM_039578 - ribosomal protein S24 (RPS24), mRNA
gi|14743713|ref|XM_039578.1|[14743713]

XM_046554 - ribosomal protein S8 (RPS8), mRNA
gi|14742855|ref|XM_046554.1|[14742855]
30

XM_034712 - ribosomal protein L34 (RPL34), mRNA
gi|14734144|ref|XM_034712.1|[14734144]

XM_034711 - ribosomal protein L34 (RPL34), mRNA
35 gi|14734139|ref|XM_034711.1|[14734139]

XM_042550 - ribosomal protein S14 (RPS14), mRNA
gi|14734089|ref|XM_042550.1|[14734089]

5 XM_042549 - ribosomal protein S14 (RPS14), mRNA
gi|14734082|ref|XM_042549.1|[14734082]

XM_042548 - ribosomal protein S14 (RPS14), mRNA
gi|14734076|ref|XM_042548.1|[14734076]

10 XM_015463 - ribosomal protein L24 (RPL24), mRNA
gi|14733795|ref|XM_015463.2|[14733795]

XM_040555 - ribosomal protein L24 (RPL24), mRNA
gi|14733789|ref|XM_040555.1|[14733789]

15 XM_036365 - ribosomal protein L31 (RPL31), mRNA
gi|14728681|ref|XM_036365.1|[14728681]

XM_017513 - ribosomal protein S27a (RPS27A), mRNA
20 gi|14725314|ref|XM_017513.2|[14725314]

XM_028344 - ribosomal protein L5 (RPL5), mRNA
gi|14723700|ref|XM_028344.1|[14723700]

25 XM_018268 - ribosomal protein L15 (RPL15), mRNA
gi|14723418|ref|XM_018268.2|[14723418]

XM_041875 - ribosomal protein L15 (RPL15), mRNA
gi|14723414|ref|XM_041875.1|[14723414]

30 XM_037459 - ribosomal protein S3A (RPS3A), mRNA
gi|14721867|ref|XM_037459.1|[14721867]

XM_037458 - ribosomal protein S3A (RPS3A), mRNA
35 gi|14721861|ref|XM_037458.1|[14721861]

XM_037454 - ribosomal protein S3A (RPS3A), mRNA
gi|14721857|ref|XM_037454.1|[14721857]

5 XM_003054 - ribosomal protein L32 (RPL32), mRNA
gi|13646087|ref|XM_003054.4|[13646087]

XM_016854 - ribosomal protein S18 (RPS18), mRNA
gi|13645838|ref|XM_016854.1|[13645838]

10 XM_017704 - ribosomal protein L10a (RPL10A), mRNA
gi|13642762|ref|XM_017704.1|[13642762]

XM_017770 - ribosomal protein L37 (RPL37), mRNA
gi|13641596|ref|XM_017770.1|[13641596]

15 XM_008905 - ribosomal protein L28 (RPL28), mRNA
gi|13630273|ref|XM_008905.3|[13630273]

XM_007281 - ribosomal protein L36a (RPL36A), mRNA
20 gi|12738346|ref|XM_007281.2|[12738346]

XM_002637 - ribosomal protein L37a (RPL37A), mRNA
gi|11430427|ref|XM_002637.1|[11430427]

25 XM_010467 - ribosomal protein S4, Y-linked (RPS4Y), mRNA
gi|13640136|ref|XM_010467.3|[13640136]

NM_007209 - ribosomal protein L35 (RPL35), mRNA
gi|6005859|ref|NM_007209.1|[6005859]

30 NM_002952 - ribosomal protein S2 (RPS2), mRNA
gi|15055538|ref|NM_002952.2|[15055538]

NM_001031 - ribosomal protein S28 (RPS28), mRNA
35 gi|15011938|ref|NM_001031.2|[15011938]

NM_001030 - ribosomal protein S27 (metallopanstimulin 1) (RPS27), mRNA
gi|15011937|ref|NM_001030.2|[15011937]

5 NM_001029 - ribosomal protein S26 (RPS26), mRNA
gi|15011935|ref|NM_001029.2|[15011935]

NM_001026 - ribosomal protein S24 (RPS24), transcript variant 2, mRNA
gi|14916502|ref|NM_001026.2|[14916502]

10 NM_033022 - ribosomal protein S24 (RPS24), transcript variant 1, mRNA
gi|14916500|ref|NM_033022.1|[14916500]

NM_001025 - ribosomal protein S23 (RPS23), mRNA
gi|14790142|ref|NM_001025.2|[14790142]
15

NM_016093 - ribosomal protein L26 homolog (LOC51121), mRNA
gi|7705812|ref|NM_016093.1|[7705812]

NM_015414 - ribosomal protein L36 (RPL36), mRNA
20 gi|7661637|ref|NM_015414.1|[7661637]

NM_000988 - ribosomal protein L27 (RPL27), mRNA
gi|4506622|ref|NM_000988.1|[4506622]

25 NM_000986 - ribosomal protein L24 (RPL24), mRNA
gi|4506618|ref|NM_000986.1|[4506618]

NM_003973 - ribosomal protein L14 (RPL14), mRNA
gi|4506600|ref|NM_003973.1|[4506600]
30

NM_001024 - ribosomal protein S21 (RPS21), mRNA
gi|14670385|ref|NM_001024.2|[14670385]

NM_001028 - ribosomal protein S25 (RPS25), mRNA
35 gi|14591916|ref|NM_001028.2|[14591916]

- NM_001023 - ribosomal protein S20 (RPS20), mRNA
gi|14591915|ref|NM_001023.2|[14591915]
- 5 NM_001022 - ribosomal protein S19 (RPS19), mRNA
gi|14591914|ref|NM_001022.2|[14591914]
- NM_001021 - ribosomal protein S17 (RPS17), mRNA
gi|14591913|ref|NM_001021.2|[14591913]
- 10 NM_001020 - ribosomal protein S16 (RPS16), mRNA
gi|14591912|ref|NM_001020.2|[14591912]
- NM_001018 - ribosomal protein S15 (RPS15), mRNA
gi|14591911|ref|NM_001018.2|[14591911]
- 15 NM_001017 - ribosomal protein S13 (RPS13), mRNA
gi|14591910|ref|NM_001017.2|[14591910]
- NM_000969 - ribosomal protein L5 (RPL5), mRNA
20 gi|14591908|ref|NM_000969.2|[14591908]
- NM_000978 - ribosomal protein L23 (RPL23), mRNA
gi|14591907|ref|NM_000978.2|[14591907]
- 25 NM_000985 - ribosomal protein L17 (RPL17), mRNA
gi|14591906|ref|NM_000985.2|[14591906]
- NM_012423 - ribosomal protein L13a (RPL13A), mRNA
gi|14591905|ref|NM_012423.2|[14591905]
- 30 NM_001016 - ribosomal protein S12 (RPS12), mRNA
gi|14277699|ref|NM_001016.2|[14277699]
- NM_001015 - ribosomal protein S11 (RPS11), mRNA
35 gi|14277698|ref|NM_001015.2|[14277698]

NM_001019 - ribosomal protein S15a (RPS15A), mRNA
gi|14165468|ref|NM_001019.2|[14165468]

5 NM_022551 - ribosomal protein S18 (RPS18), mRNA
gi|14165467|ref|NM_022551.2|[14165467]

NM_001013 - ribosomal protein S9 (RPS9), mRNA
gi|14141192|ref|NM_001013.2|[14141192]

10 NM_005617 - ribosomal protein S14 (RPS14), mRNA
gi|14141191|ref|NM_005617.2|[14141191]

NM_000990 - ribosomal protein L27a (RPL27A), mRNA
gi|14141189|ref|NM_000990.2|[14141189]

15 NM_001009 - ribosomal protein S5 (RPS5), mRNA
gi|13904869|ref|NM_001009.2|[13904869]

20 NM_001032 - ribosomal protein S29 (RPS29), mRNA
gi|13904868|ref|NM_001032.2|[13904868]

NM_001014 - ribosomal protein S10 (RPS10), mRNA
gi|13904867|ref|NM_001014.2|[13904867]

25 NM_000991 - ribosomal protein L28 (RPL28), mRNA
gi|13904865|ref|NM_000991.2|[13904865]

NM_000995 - ribosomal protein L34 (RPL34), mRNA
gi|4506636|ref|NM_000995.1|[4506636]

30 NM_001997 - Finkel-Biskis-Reilly murine sarcoma virus (FBR-MuSV) ubiquitously
expressed (fox derived); ribosomal protein S30 (FAU), mRNA
gi|4503658|ref|NM_001997.1|[4503658]

35 NM_022061 - ribosomal protein L17 isolog (LOC63875), mRNA

gi|11596858|ref|NM_022061.1|[11596858]

NM_021104 - ribosomal protein L41 (RPL41), mRNA

gi|10863874|ref|NM_021104.1|[10863874]

5

NM_021029 - ribosomal protein L44 (RPL44), mRNA

gi|10445222|ref|NM_021029.1|[10445222]

NM_016304 - 60S ribosomal protein L30 isolog (LOC51187), mRNA

10 gi|10047101|ref|NM_016304.1|[10047101]

NM_002295 - laminin receptor 1 (67kD, ribosomal protein SA) (LAMR1), mRNA

gi|9845501|ref|NM_002295.2|[9845501]

15 NM_016183 - 60S acidic ribosomal protein PO (LOC51154), mRNA

gi|7705874|ref|NM_016183.1|[7705874]

NM_015971 - 30S ribosomal protein S7 homolog (LOC51081), mRNA

gi|7705737|ref|NM_015971.1|[7705737]

20

NM_015920 - 40S ribosomal protein S27 isoform (LOC51065), mRNA

gi|7705705|ref|NM_015920.1|[7705705]

NM_005061 - ribosomal protein L3-like (RPL3L), mRNA

25 gi|4826987|ref|NM_005061.1|[4826987]

NM_001010 - ribosomal protein S6 (RPS6), mRNA

gi|4506730|ref|NM_001010.1|[4506730]

30 NM_001008 - ribosomal protein S4, Y-linked (RPS4Y), mRNA

gi|4506726|ref|NM_001008.1|[4506726]

NM_001007 - ribosomal protein S4, X-linked (RPS4X), mRNA

gi|4506724|ref|NM_001007.1|[4506724]

35

NM_001004 - ribosomal protein, large P2 (RPLP2), mRNA
gi|4506670|ref|NM_001004.1|[4506670]

5 NM_001003 - ribosomal protein, large, P1 (RPLP1), mRNA
gi|4506668|ref|NM_001003.1|[4506668]

NM_001002 - ribosomal protein, large, P0 (RPLP0), mRNA
gi|4506666|ref|NM_001002.1|[4506666]

10 NM_000972 - ribosomal protein L7a (RPL7A), mRNA
gi|4506660|ref|NM_000972.1|[4506660]

NM_000970 - ribosomal protein L6 (RPL6), mRNA
gi|4506656|ref|NM_000970.1|[4506656]

15 NM_000968 - ribosomal protein L4 (RPL4), mRNA
gi|4506652|ref|NM_000968.1|[4506652]

20 NM_001001 - ribosomal protein L36a (RPL36A), mRNA
gi|4506650|ref|NM_001001.1|[4506650]

NM_000967 - ribosomal protein L3 (RPL3), mRNA
gi|4506648|ref|NM_000967.1|[4506648]

25 NM_001000 - ribosomal protein L39 (RPL39), mRNA
gi|4506646|ref|NM_001000.1|[4506646]

NM_000999 - ribosomal protein L38 (RPL38), mRNA
gi|4506644|ref|NM_000999.1|[4506644]

30 NM_000998 - ribosomal protein L37a (RPL37A), mRNA
gi|4506642|ref|NM_000998.1|[4506642]

35 NM_000997 - ribosomal protein L37 (RPL37), mRNA
gi|4506640|ref|NM_000997.1|[4506640]

NM_000996 - ribosomal protein L35a (RPL35A), mRNA
gi|4506638|ref|NM_000996.1|[4506638]

5 NM_000992 - ribosomal protein L29 (RPL29), mRNA
gi|4506628|ref|NM_000992.1|[4506628]

NM_000987 - ribosomal protein L26 (RPL26), mRNA
gi|4506620|ref|NM_000987.1|[4506620]

10 NM_000984 - ribosomal protein L23a (RPL23A), mRNA
gi|4506614|ref|NM_000984.1|[4506614]

NM_000983 - ribosomal protein L22 (RPL22), mRNA
gi|4506612|ref|NM_000983.1|[4506612]

15 NM_000982 - ribosomal protein L21 (gene or pseudogene) (RPL21), mRNA
gi|4506610|ref|NM_000982.1|[4506610]

NM_000981 - ribosomal protein L19 (RPL19), mRNA
20 gi|4506608|ref|NM_000981.1|[4506608]

All of the sequences in Tables 2 and 3 are incorporated by reference in their entirety.

25 In preferred embodiments, the tagged ribosomal proteins are S6 or L37 ribosomal proteins, more preferably tagged with a Strep Tag peptide tag, most preferably with the peptide tag at the C-terminus. In another preferred embodiment, the mRNA binding protein is not polyA binding protein.

5.3. ISOLATION OF RIBOSOMES

30 Various methods exist to isolate ribosomes, particularly polysomes, from cultured cells and tissues from transformed organisms (*see, e.g., Bommer et al., 1997, Isolation and characterization of eukaryotic polysomes, in Subcellular Fractionation, Graham and Rickwood (eds.), IRL Press, Oxford, pp. 280-285; incorporated herein by reference in its entirety*). Preferably, the isolation method employed has the following characteristics:

35

- (1) Translation arresting compounds, such as emetine or cycloheximide, are added to arrest translation, if possible, as a pre-treatment even before homogenization. This prevents ribosome run-off and keeps the ribosome-mRNA complex stable, *i.e.*, the ribosome remains bound to the mRNA.
- (2) RNase inhibitors such as SUPERase•In™ RNase Inhibitor (Ambion, Austin, Texas) are added to buffers to maintain the integrity of the mRNA.
- (3) After tissue or cell homogenization, total polysomes are isolated by preparing a post-mitochondrial supernatant in the presence of at least a high concentration salt buffer, *e.g.*, 100-150 mM KCl.
- (4) Detergent is also added to the post-mitochondrial supernatant to release membrane-associated polysomes from endoplasmic reticulum membranes; total polysomes are usually collected by centrifugation through a sucrose cushion.

In certain embodiments, a variation of the above-described general method is used to isolate membrane-associated polysomes from a total pool of polysomes. This allows one to focus on the mRNA species encoding secreted or transmembrane proteins, which are often targets of choice for drug discovery. Various methods may be used to isolate membrane-associated polysomes from cultured cells and tissue, *e.g.*, methods that employ differential centrifugation (Hall C, Lim L. Developmental changes in the composition of polyadenylated RNA isolated from free and membrane-bound polyribosomes of the rat forebrain, analysed by translation in vitro. *Biochem J.* 1981 Apr 15;196(1):327-36), rate-zonal centrifugation (Rademacher and Steele, 1986, Isolation of undegraded free and membrane-bound polysomal mRNA from rat brain, *J. Neurochem.* 47(3):953-957), isopycnic centrifugation (Mechler, 1987, Isolation of messenger RNA from membrane-bound polysomes, *Methods Enzymol.* 152: 241-248), and differential extraction (Bommer *et al.*, 1997, Isolation and characterization of eukaryotic polysomes, in *Subcellular Fractionation*, Graham and Rickwood (eds.), IRL Press, Oxford, pp. 280-285; incorporated herein by reference in its entirety) to isolate the membrane-associated polysomes.

Other appropriate cell lysates or fractions may be obtained using routine biochemical methods.

Specific polysomes can also be isolated using affinity separation techniques targeting nascent polypeptides or endogenous or tagged mRNA-binding proteins using art-

known methods *e.g.*, using the methods of Lynch, 1987, Meth. Enzymol. 152: 248-253, and Brooks and Rigby, 2000, Nucleic Acids Res. 28(10): e49.

In certain embodiments, polysomes are not isolated from the post-mitochondrial supernatant or even from a cell or tissue lysate before being subject to affinity purification.

5 Once the cell lysate or fraction is obtained, the tagged ribosomes may be isolated using routine methods from untagged ribosomes and other cell components, preferably isolated from RNA, most preferably isolated from mRNA, that is not bound to molecularly tagged ribosomes or tagged mRNA binding protein, using affinity reagents that bind the tag specifically.

10 In a preferred embodiment, the ribosomes are isolated from transfected cells by scraping them into homogenization buffer (50 mM sucrose, 200 mM ammonium chloride, 7 mM magnesium acetate, 1 mM dithiothreitol, and 20 mM Tris-HCl, pH 7.6). The cells are then lysed by the addition of the detergent, NP-40 (Nonidet P40, CALBIOCHEM-NOVABIOCHEM Corporation, San Diego, California) to a concentration
15 of 0.5% followed by five strokes in a glass dounce tissue homogenizer. Unlysed cells, nuclei and mitochondria are pelleted by centrifugation at 10,000Xg for 10 minutes, at 4°C. The supernatant is removed and layered over a two-step discontinuous gradient of 1.8 M and 1.0M sucrose in 100 mM ammonium chloride, 5 mM magnesium acetate, 1 mM dithiothreitol, 20 mM Tris-HCl (pH 7.6). The gradient is centrifuged for 18 hours at
20 98,000Xg at 4°C.

Following centrifugation, the supernatants are removed, and the polysome pellet is resuspended in 100 mM ammonium chloride, 5 mM magnesium chloride, 1 mM DTT and 20 mM Tris-HCl (pH 7.6).

25 An equal volume of 2X denaturing protein electrophoresis sample buffer is added to the polysome sample. Solubilized polysomal proteins are fractionated by electrophoresis through a SDS containing 4- 20% gradient polyacrylamide gel, and transferred to a nitrocellulose filter.

30 The isolation of tagged polysomes directly from crude or post-mitochondrial supernatants (adjusted appropriately with NaCl and detergent) is also envisioned. In certain embodiments, molecular tagging is achieved through the introduction of amino acids into a ribosomal protein-encoding gene such that the amino acids form a polypeptide region (*i.e.*, a tag) that is capable of acting as a receptor or ligand for an affinity separation.

Because nascent polypeptides are attached to isolated monosomes and polysomes, the methods of the invention can also be used to isolate newly synthesized polypeptides
35 from a cell type of interest (*e.g.*, for proteomic applications).

Tagged polysomes that contain specific mRNAs (see *infra*) are isolated using antibodies that recognize specific nascent, encoded polypeptide chains (for review see Lynch DC. Use of antibodies to obtain specific polysomes. Methods Enzymol. 1987;152:248-53; Schutz G, Kieval S, Groner B, Sippel AE, Kurtz D, Feigelson P. Isolation of specific messenger RNA by adsorption of polysomes to matrix-bound antibody. Nucleic Acids Res. 1977 Jan;4(1):71-84; and Shapiro SZ, Young JR. An immunochemical method for mRNA purification. Application to messenger RNA encoding trypanosome variable surface antigen. J Biol Chem. 1981 Feb 25;256(4):1495-8). Particular mRNA species as low in abundance as 0.01-0.05% of total mRNA have been purified to near homogeneity via this approach.

Affinity methods that can be used to isolate or purify tagged ribosomes or other mRNA binding proteins taking advantage of the affinity of a reagent for the peptide tag are well known in the art including chromatography, solid phase chromatography and precipitation, matrices, precipitation, etc.

In specific embodiments, the invention provides molecularly tagged ribosomes, preferably bound to mRNA, that are bound to an affinity reagent for the molecular tag. In more specific embodiments, the molecularly tagged ribosomes are bound to an affinity reagent that is bound, preferably covalently, to a solid surface, such as a chromatography resin, *e.g.*, agarose, sepharose, and the like.

5.4. ISOLATION OF mRNA FROM PURIFIED POLYSOMES

Once the tagged ribosome or mRNA binding protein has been isolated, the associated mRNA complexed with the ribosome or mRNA binding protein may be isolated using methods well known in the art. For example, elution of mRNA is accomplished by addition of EDTA to buffers, which disrupts polysomes and allows isolation of bound mRNA for analysis (Schutz, *et al.* (1977), Nucl. Acids Res. 4:71-84; Kraus and Rosenberg (1982), Proc. Natl. Acad. Sci. USA 79:4015-4019). In addition, isolated polysomes (attached or detached from isolation matrix) can be directly input into RNA isolation procedures using reagents such as Tri-reagent (Sigma) or Triazol (Sigma). In particular embodiments, poly A⁺ mRNA is preferentially isolated by virtue of its hybridization of oligodT cellulose. Methods of mRNA isolation are described., for example, in Sambrook *et al.*, 2001, Molecular Cloning, A Laboratory Manual, Third Edition, Cold Spring Harbor Laboratory Press, N.Y.; and Ausubel *et al.*, 1989, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y., both of which are hereby incorporated by reference in their entireties.

5.5. REGULATORY SEQUENCES FOR EXPRESSION OF TAGGED RIBOSOMES

According to the methods of the invention, the tagged ribosomes are selectively expressed in a particular chosen cell type. Such expression is achieved by driving the expression of the tagged ribosomal protein or mRNA binding protein using regulatory sequences from a gene expressed in the chosen cell type.

The population of cells comprises a discernable group of cells sharing a common characteristic. Because of its selective expression, the population of cells may be characterized or recognized based on its positive expression of the characterizing gene.

- According to the methods of the invention, some or all of the regulatory sequences may be incorporated into nucleic acids of the invention (including transgenes) to regulate the expression of tagged ribosomal protein or mRNA binding protein coding sequences. In certain embodiments, a gene that is not constitutively expressed, (*i.e.*, exhibits some spatial or temporal restriction in its expression pattern) is used as a source of a regulatory sequence. In other embodiments, a gene that is constitutively expressed is used as a source of a regulatory sequence, for example, when the nucleic acids of the invention are expressed in cultured cells.

In certain embodiments, the expression of tagged ribosomal protein or mRNA binding protein coding sequences is regulated by a non-ribosomal regulatory sequence.

- Such a sequence may include, but not be limited to, parts of a ribosomal regulatory sequence (but does not include the entire ribosomal regulatory sequence), but such sequence effects a different expression pattern than the ribosomal regulatory sequence.

- Preferably, the regulatory sequence is derived from a human or mouse gene associated with an adrenergic or noradrenergic neurotransmitter pathway, *e.g.*, one of the genes listed in Table 4; a cholinergic neurotransmitter pathway, *e.g.*, one of the genes listed in Table 5; a dopaminergic neurotransmitter pathway, *e.g.*, one of the genes listed in Table 6; a GABAergic neurotransmitter pathway, *e.g.*, one of the genes listed in Table 7; a glutaminergic neurotransmitter pathway, *e.g.*, one of the genes listed in Table 8; a glycinergic neurotransmitter pathway, *e.g.*, one of the genes listed in Table 9; a histaminergic neurotransmitter pathway, *e.g.*, one of the genes listed in Table 10; a neuropeptidergic neurotransmitter pathway, *e.g.*, one of the genes listed in Table 11; a serotonergic neurotransmitter pathway, *e.g.*, one of the genes listed in Table 12; a nucleotide receptor, *e.g.*, one of the genes listed in Table 13; an ion channel, *e.g.*, one of the genes listed in Table 14; markers of undifferentiated or not fully differentiated cells, preferably nerve cells, *e.g.*, one of the genes listed in Table 15; the sonic hedgehog signaling pathway,

e.g., one of the genes in Table 16; calcium binding, *e.g.*, one of the genes listed in Table 17; or a neurotrophic factor receptor, *e.g.*, one of the genes listed in Table 18.

The ion channel encoded by or associated with the gene selected as the source of the regulatory sequence is preferably involved in generating and modulating ion flux across the plasma membrane of neurons, including, but not limited to voltage-sensitive and/or cation-sensitive channels, *e.g.*, a calcium, sodium or potassium channel.

In Tables 4-18 that follow, the common names of genes are listed, as well as their GeneCards identifiers (Rebhan *et al.*, 1997, GeneCards: encyclopedia for genes, proteins and diseases, Weizmann Institute of Science, Bioinformatics Unit and Genome Center (Rehovot, Israel). GenBank accession numbers, UniGene accession numbers, and Mouse Genome Informatics (MGI). Database accession numbers where available are also listed. GenBank is the NIH genetic sequence database, an annotated collection of all publicly available DNA sequences (Benson *et al.*, 2000, Nucleic Acids Res. 28(1): 15-18). The GenBank accession number is a unique identifier for a sequence record. An accession number applies to the complete record and is usually a combination of a letter(s) and numbers, such as a single letter followed by five digits (*e.g.*, U12345), or two letters followed by six digits (*e.g.*, AF123456).

Accession numbers do not change, even if information in the record is changed at the author's request. An original accession number might become secondary to a newer accession number, if the authors make a new submission that combines previous sequences, or if for some reason a new submission supercedes an earlier record.

UniGene (Schuler *et al.*, 1996, A gene map of the human genome, Science 274(5287):540-6) is an experimental system for automatically partitioning GenBank sequences into a non-redundant set of gene-oriented clusters for cow, human, mouse, rat, and zebrafish. Within UniGene, expressed sequence tags (ESTs) and full-length mRNA sequences are organized into clusters that each represent a unique known or putative gene. Each UniGene cluster contains related information such as the tissue types in which the gene has been expressed and map location. Sequences are annotated with mapping and expression information and cross-referenced to other resources. Consequently, the collection may be used as a resource for gene discovery.

The Mouse Genome Informatics (MGI) Database (Jackson Laboratory, Bar Harbor, Maine) contains information on mouse genetic markers, mRNA and genomic sequence information, phenotypes, comparative mapping data, experimental mapping data, and graphical displays for genetic, physical, and cytogenetic maps.

35

TABLE 4

	Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
5	ADRB1 (adrenergic beta 1)	human: J03019	MGI:87937
	ADRB2 (adrenergic beta 2)	human: M15169	MGI:87938
	ADRB3 (adrenergic beta 3)	human: NM_000025, X70811, X72861, M29932, X70812, S53291, X70812	MGI:87939
10	ADRA1A (adrenergic alpha1a)	human: D25235, U02569, AF013261, L31774, U03866 guinea pig: AF108016	
	ADRA1B (adrenergic alpha 1b)	human: U03865, L31773	MGI:104774
15	ADRA1C (adrenergic alpha 1c)	human: U08994 mouse: NM_013461	
	ADRA1D (adrenergic alpha1d)	human: M76446, U03864, L31772, D29952, S70782	MGI:106673
	ADRA2A (adrenergic alpha2A)	human: M18415, M23533	MGI:87934
20	ADRA2B (adrenergic alpha 2B)	human: M34041, AF005900	MGI:87935
	ADRA2C (adrenergic alpha 2C)	human: J03853, D13538, U72648	MGI:87936
25	SLC6A2 Norepinephrine transporter (NET)	human: X91117, M65105, AB022846, AF061198	MGI:1270850

TABLE 5

	Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
30	CHRM1 (Muscarinic Ach M1) receptor	human: X15263, M35128 Y00508, X52068	MGI:88396

35

	Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
5	CHRM2 (Muscarinic Ach M2) receptor	human: M16404, AB041391, X15264 mouse: AF264049	
	CHRM3 (Muscarinic Ach M3) receptor	human: U29589, AB041395, X15266 mouse: AF264050	
10	CHRM4 (Muscarinic Ach M4) receptor	human: X15265, M16405	MGI:88399
	CHRM5 (Muscarinic Ach M5) receptor	human: AF026263, M80333 rat: NM_017362 mouse: AI327507	
15	CHRNA1 (nicotinic alpha1) receptor	human: Y00762, X02502, S77094	MGI:87885
	CHRNA2 (nicotinic alpha2) receptor	human: U62431, Y16281	MGI:87886
	CHRNA3 (nicotinic alpha3) receptor	human: NM_000743, U62432, M37981, M86383, Y08418	
20	CHRNA4 (nicotinic alpha4) receptor	human: U62433, L35901, Y08421, X89745, X87629	MGI:87888
	CHRNA5 (nicotinic alpha5) receptor	human: U62434, Y08419, M83712	MGI:87889
25	CHRNA7 (nicotinic alpha7) receptor	human: X70297, Y08420, Z23141, U40583, U62436, L25827, AF036903	MGI:99779
	CHRNB1 (nicotinic Beta 1) receptor	human: X14830	MGI:87890
30	CHRNB2 (nicotinic Beta 2) receptor	human: U62437, X53179, Y08415, AJ001935	MGI:87891
	CHRNB3 (nicotinic Beta 3) receptor	human: Y08417, X67513, U62438, RIKEN BB284174	
35	CHRNB4 (nicotinic Beta 4) receptor	human: U48861, U62439, Y08416, X68275	MGI:87892

Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
CHRNG nicotinic gamma immature muscle receptor	human: X01715, M11811	MGI:87895
CHRNE nicotinic epsilon receptor	human: X66403 mouse: NM_009603	
CHRND nicotinic delta receptor	human: X55019	MGI:87893

TABLE 6

Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
th (tyrosine hydroxylase)	human: M17589	MGI:98735
dat (dopamine transporter)	human: NM_001044	MGI:94862
dopamine receptor 1	human UniGene: X58987, S58541, X55760, X55758	MGI:99578
dopamine receptor 2	human UniGene: X51362, M29066, AF050737, S62137, X51645, M30625, S69899	MGI:94924
dopamine receptor 3	human UniGene: U25441, U32499	MGI:94925
dopamine receptor 4	human UniGene: L12398, S76942	MGI:94926
dopamine receptor 5	human UniGene: M67439, M67439, X58454	MGI:94927
dbh dopamine beta hydroxylase	human UniGene: X13255	MGI:94864

TABLE 7

Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
GABA A A2 GABRA2 GABA receptor A2	human: S62907	MGI:95614

	Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
5	GABA A A3 GABRA3 GABA receptor A3	human: S62908	MGI:95615
	GABA A A4 GABRB4 GABA receptor A4	human: NM_000809, U30461	MGI:95616
10	GABA A A5 GABRB5 GABA receptor A5	human: NM_000810, L08485, AF061785, AF061785, AF061785	
	GABA A A6 GABRB6 GABA receptor A6	human: S81944, AF053072	MGI:95618
15	GABA B1 GABRB1 GABA receptor B1	human: X14767, M59216	MGI:95619
20	GABA B2 GABRB2 GABA receptor B2	human: S67368, S77554, S77553 mouse:MM4707	
	GABA B3 GABRB3 GABA receptor B3	human: M82919	MGI:95621
25	GABRG1 GABA-A receptor, gamma 1 subunit		MGI:103156
	GABRG2 GABA-A receptor, gamma 2 subunit	human: X15376	MGI:95623
30	GABRG3 GABA-A receptor, gamma 3 subunit	human: S82769	
35	GABRD GABA-A receptor, delta subunit	human: AF016917	MGI:95622

Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
GABRE GABA-A receptor, epsilon subunit	human: U66661, Y07637, Y09765, U92283, Y09763, U92285 mouse: NM_017369	
GABA A pi GABRP GABA-A receptor, pi subunit	human: U95367, AF009702	
GABA A theta GABA receptor theta	mouse NM_020488	
GABA R1a GABA receptor rho 1 GABRR1 GABA receptor rho 1	human: M62400	MGI:95625
GABA R2 GABA receptor a rho 2 GABRR2 GABA receptor rho 2	human: M86868	MGI:95626

TABLE 8

Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
GRIA1 GluR1	human: NM_000827, M64752, X58633 M81886 mouse: NM_008165	
GRIA2 GluR2	human: L20814 rat: M85035 mouse: AF250875	
GRIA3 GluR3	human: U10301, X82068, U10302 rat: M85036	
GRIA4 GluR4	human: U16129 rat: NM_017263	
GRIK1 glutamate ionotropic kainate 1 gluR5	human: L19058, U16125, AF107257, AF107259	MGI:95814

Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
5 GRIK2 gluR6	human: U16126 mouse: NM_010349, RIKEN BB359097	
GRIK3 gluR7	human: U16127 mouse: AF245444	
10 GRIK4 KA1	human: S67803	MGI:95817
GRIK5 KA2	human: S40369	MGI:95818
15 GRIN1 NR1nmdar1 NMDA receptor 1	human: D13515, L05666, L13268, L13266, AF015731, AF015730, U08106, L13267	MGI:95819
GRIN2A NR2A NMDA receptor 2A	human: NM_000833, U09002, U90277 mouse: NM_008170	
20 GRIN2B NR2B NMDA receptor 2B	human: NM_000834, U11287, U90278, U88963	MGI:95821
GRIN2C NR2C NMDA receptor 2C	human: U77782, L76224	MGI:95822
25 GRIN2D NR2D NMDA receptor 2D	human: U77783	MGI:95823
30 GRM1 mGluR 1a and 1b alternate splicing type I mGluR1a	human: NM_000838, L76627, AL035698, U31215, AL035698, U31216, L76631 mouse: BB275384, BB181459, BB177876	
35 GRM2 mGluR 2 type II mGluR2	human: L35318 Sheep: AF229842	

	Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
5	GRM3 mGluR3 type II mGluR3	human: X77748 mouse: AH008375; MM45836	
	GRM4 mGluR4 type III mGluR4	human: X80818	
10	GRM5 mGluR5a and 5b alt splice 32 residues mGluR5	human: D28538, D28539 mouse: AF140349	
15	GRM6 mGluR6 type III mGluR6	human: NM_000843, U82083, AJ245872, AJ245871 rat: AJ245718	
	GRM7 mGluR7 type III mGluR7	human: NM_000844, X94552 mouse: RIKEN BB357072	
20	GRM8 mGluR8 type III mGluR8	human: NM_000845, U95025, AJ236921, AJ236922, AC000099 mouse: U17252	
	GRID2 glut ionotropic delta	human: AF009014	MGI:95813
25	excitatory amino acid transporter2 glutamate/aspartate transporter II glutamate transporter GLT1 glutamate transporter SLC1A2 glial high affinity glutamate transporter	human: U03505, U01824, Z32517, D85884	MGI:101931
30	EAAC1 neural SLC1A1 neuronal/epithelial high affinity glutamate transporter	human: U08989, U03506, U06469	MGI:105083

35

Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
EEAT1 SLC1A3 glial high affinity glutamate transporter	human: D26443, AF070609, L19158, U03504, Z31713	MGI:99917
EAAT4 neural SLC1A6 high affinity aspartate/glutamate transporter	human: U18244, AC004659	MGI:1096331

TABLE 9

Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
Glycine receptors alpha 1 GLRA1	human:X52009	MGI:95747
Glycine receptors alpha 2 GLRA2	human:X52008, AF053495	MGI:95748
Glycine receptors alpha 3 GLRA3	human: AF017724, U93917, AF018157 mouse: AF214575	
Glycine receptors alpha 4 GLRA4	no human mouse: X75850, X75851, X75852, X75853	
glycine receptor beta GLRB	human: U33267, AF094754, AF094755	MGI:95751

TABLE 10

Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
Histamine H1-receptor 1	human: Z34897, D28481, X76786, AB041380, D14436, AF026261	MGI:107619
Histamine H2-receptor 2	human: M64799, AB023486, AB041384	MGI:108482
Histamine H3-receptor 3	human: NM_007232 mouse: MM31751	

TABLE 11

Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
orexin OX-A hypocretin 1 Orexin B	human: AF041240	MGI:1202306
Orexin receptor OX1R HCRTR1	human: AF041243	
Orexin receptor OX2R HCRTR2	human: AF041245	
leptinR-long Leptin receptor long form	human: U66497, U43168, U59263, U66495, U52913, U66496, U52914, U52912, U50748, AK001042	MGI:104993
MCH melanin concentrating hormone PMCH	human: M57703, S63697	
MC3R MC3 receptor melanocortin 3 receptor	human: GDB: 138780 mouse: MM57183	MGI:96929
MC4R MC4 receptor melanocortin 4 receptor	human: S77415, L08603, NM_005912	

	Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
5	MC5R MC5 receptor melanocortin 5 receptor	human: L27080, Z25470, U08353	MGI:99420
10	prepro-CRF corticotropin-releasing factor precursor CRH corticotropin releasing hormone	human: V00571 rat: X03036, M54987	
	CRHR1 CRH/CRF receptor 1	human: L23332, X72304, L23333, AF039523, U16273	MGI:88498
15	CRF R2 CRH/CRF receptor 2	human: U34587, AF019381, AF011406, AC004976, AC004976	MGI:894312
	CRHBP CRF binding protein	human: X58022, S60697	MGI:88497
	Urocortin	human: AF038633	MGI:1276123
20	POMC Pro-opiomelanocortin	human: V01510, M38297, J00292, M28636	MGI:97742
	CART cocaine and amphetamine regulated transcript	human: U20325, U16826	MGI:1351330
25	NPY Neuropeptide Y prepro NPY	human: K01911, M15789, M14298, AC004485	MGI:97374
	NPY1R NPY Y1 receptor Neuropeptide Y1 receptor	human: M88461, M84755, NM_000909	MGI:104963
30	NPY2R NPY Y2 receptor Neuropeptide Y2 receptor	human: U42766, U50146, U32500, U36269, U42389, U76254, NM_000910	MGI:108418
35	NPY Y4 receptor Npy4R Neuropeptide Y4 receptor (mouse)	human: Z66526, U35232, U42387	MGI:105374

	Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
5	NPY Y5 receptor Npy5R Neuropeptide Y5 receptor (mouse)	human: U94320, U56079, U66275 mouse: MM10685	MGI:108082
	NPY Y6 receptor Npy6r Neuropeptide Y receptor (mouse)	human: D86519, U59431, U67780	MGI:1098590
10	CCK cholecystokinin	human: NM_000729, L00354	MGI:88297
	CCKa receptor CCKAR cholecystokinin receptor	human: L19315, D85606, L13605 U23430	MGI:99478
15	CCKb receptor CCKBR cholecystokinin receptor	human: D13305, L04473, L08112, L07746, L10822, D21219, S70057, AF074029	MGI:99479
	AGRP agouti related peptide	human: NM_001138, U88063, U89485	MGI:892013
	Galanin	human: M77140, L11144	MGI:95637
20	GALP Galanin like peptide <i>See, Jureus et al., 2000, Endocrinology 141(7):2703-06.</i>		
25	GalR1 receptor GALNR1 galanin receptor1	human: NM_001480, U53511, L34339, U23854	MGI:1096364
	GalR2 receptor GALNR2 galanin receptor2	human: AF040630, AF080586, AF042782	MGI:1337018
30	GalR3 receptor GALNR3 Galr3 galanin receptor3	human: AF073799, Z97630, AF067733	MGI:1329003
35	UTS2 prepro-urotensin II	human: Z98884, AF104118	MGI:1346329

	Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
5	GPR14 Urotensin receptor	human: AI263529 mouse: AI385474	
	SST somatostatin	human: J00306	MGI:98326
	SSTR1 somatostatin receptor sst1	human: M81829	MGI:98327
10	SSTR2 somatostatin receptor sst2	human: AF184174 M81830 AF184174	MGI:98328
	SSTR3 somatostatin receptor sst3	human: M96738, Z82188	MGI:98329
	SSTR4 somatostatin receptor sst4	human: L14856, L07833, D16826, AL049651	MGI:105372
15	SSTR5somatostatin receptor sst5	human: D16827, L14865, AL031713	MGI:894282
	GPR7 G protein-coupled receptor 7 opioid-somatostatin-like receptor	human: U22491	MGI:891989
20	GPR8 G protein-coupled receptor 8 opioid-somatostatin-like receptor	human: U22492	
	PENK (pre Pro Enkephalin)	human: V00510, J00123	MGI:104629
25	PDYN (Pre pro Dynorphin)	human: K02268, AL034562, X00176	MGI:97535
	OPRM1 μ opiate receptor	human: L25119, L29301, U12569, AL132774	MGI:97441
	OPRK1 k opiate receptor	human: U11053, L37362, U17298	MGI:97439
30	OPRD1 delta opiate receptor	human: U07882, U10504, AL009181	MGI:97438
	OPRL1 ORL1 opioid receptor-like receptor	human: X77130, U30185	MGI:97440

35

	Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
5	VR1 Vanilloid receptor subtype 1	human: NM_018727, BE466577 mouse: BE623398,	
10	VRL-1 vanilloid receptor-like protein 1 VR1L1 vanilloid receptor type 1 like protein 1 VRL1 vanilloid receptor-like protein 1	human: NM_015930 rat: AB040873 mouse: NM_011706	MGI:1341836
15	VR-OAC vanilloid receptor-related osmotically activated channel	human: AC007834	
	CNR1 cannaboid receptors CB1	human: U73304, X81120, X81120, X54937, X81121	MGI:104615
	EDN1 endothelin 1 ET-1	human: J05008, Y00749, S56805, Z98050, M25380	MGI:95283
20	GHRH growth hormone releasing hormone	human: L00137, AL031659, L00137	MGI:95709
	GHRHR growth hormone releasing hormone receptor	human: AF029342, U34195, mouse: NM_010285	
25	PNOC nociceptin orphanin FQ/nocistatin	human: X97370, U48263, X97367	MGI:105308
	NPFF neuropeptide FF precursor	human: AF005271 mouse: RIKEN BB365815	
30	neuropeptide FF receptor neuropeptide AF receptor G-protein coupled receptor HLWAR77 G-protein coupled receptor NPGPR	human: AF257210, NM_004885, AF119815	

35

	Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
5	GRP gastrin releasing peptide preprogastrin-releasing peptide	human: K02054, S67384, S73265, M12512	MGI:95833
	GRPR gastrin releasing peptide receptor BB2	human: M73481, U57365	MGI:95836
10	NMB neuromedin B	human: M21551 mouse: AI327379	
	NMBR neuromedin B receptor BB1	human: M73482	MGI:1100525
15	BRS3 bombesin like receptor subtype-3 uterine bombesin receptor	human: Z97632, L08893, X76498 mouse: AB010280	
	GCG PROglucagon GLP-1 GLP-2	human: J04040, X03991, V01515	MGI:95674
20	GCGR glucagon receptor	human: U03469, L20316	MGI:99572
	GLP1R GLP1 receptor	human: AL035690, U01104, U01157, L23503, U01156, U10037	MGI:99571
25	GLP2R GLP2 receptor	human: AF105367 mouse; AF166265	
	VIP vasoactive intestinal peptide	human: M36634, M54930, M14623, M33027, M11554, L00158, M36612	MGI:98933
30	SCT secretin	mouse: NM_011328, X73580	
	PPYR1 pancreatic polypeptide receptor 1	human: Z66526, U35232, U42387	MGI:105374
35	OXT pre pro Oxytocin	human: M25650, M11186, X03173 mouse: NM_011025, M88355	

	Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
5	OXTR OTR oxytocin receptor	human: X64878	MGI:109147
	AVP Preprovasopressin	human: M25647, X03172, M11166, AF031476, X62890, X62891	MGI:88121
10	AVPR1A V1a receptor vasopressin receptor1a	human: U19906, L25615, S73899, AF030625, AF101725 mouse: NM_016847	
	AVPR1B V1b receptor vasopressin receptor1b	human: D31833, L37112, AF030512, AF101726 mouse: NM_011924	
15	AVPR2 V2 receptor vasopressin receptor2	human: Z11687, U04357, L22206, U52112, AF030626, AF032388, AF101727 ,AF101728	MGI:88123
20	NTS proneurotensin/proneuromedin N Neurotensin tridecapeptide plus neuromedin N	human: NM_006183, U91618 mouse: MM64201	
	NTSR1 Neurotensin receptor NT1	human: X70070	MGI:97386
25	NTSR2 Neurotensin receptor NT2	human: Y10148 mouse: NM_008747	
	SORT1 sortilin 1 neurotensin receptor 3	human: X98248, L10377	MGI:1338015
	BDKRB1 Bradykinin receptor 1	human: U12512, U48231, U22346, AJ238044, AF117819	MGI:88144
30	BDKRB2 Bradykinin receptor B2	human: X69680, S45489, S56772, M88714, X86164, X86163, X86165	MGI:102845
35	GNRH1 GnRH gonadotrophin releasing hormone	human: X01059, M12578, X15215	MGI:95789

	Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
5	GNRH2 GnRH gonadotrophin releasing hormone	human: AF036329	
10	GNRHR GnRH gonadotrophin releasing hormone receptor	human: NM_000406, L07949, S60587, L03380, S77472, Z81148, U19602	MGI:95790
15	CALCB calcitonin-related polypeptide, beta	human: X02404, X04861	
20	CALCA calcitonin/calcitonin-related polypeptide, alpha	human: M26095, X00356, X03662, M64486, M12667, X02330, X15943	MGI:88249
25	CALCR calcitonin receptor	human: L00587	MGI:101950
30	TAC1 (also called tac2) neurokinin A	human: X54469, U37529, AC004140	MGI:98474
	TAC3 neurokinin B	human: NM_013251 rat: NM_017053	
	TACR2 neurokinin a (subK) receptor	human: M75105, M57414, M60284	
	TACR1 tachykinin receptor NK2 (Sub P and K)	human: M84425, M74290, M81797, M76675, X65177, M84426	MGI:98475
	TACR3 tachykinin receptor NK3 (Sub P and K) neuromedin K	human: M89473 X65172	
	ADCYAP1 PACAP	human: X60435	MGI:105094

	Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
5	NPPA atrial natriuretic peptide (ANP) precursor atrial natriuretic factor (ANF) precursor pronatriodilatin precursor prepronatriodilatin	human: M54951, X01470, AL021155, M30262, K02043, K02044	MGI:97367
10	NPPB atrial natriuretic peptide (BNP) precursor	human: M25296, AL021155, M31776 mouse: NM_008726	
15	NPR1 natriuretic peptide receptor 1	human: X15357, AB010491	MGI:97371
	NPR2 natriuretic peptide receptor 2	human: L13436, AJ005282, AB005647	MGI:97372
	NPR3 natriuretic peptide receptor 3	human: M59305, AF025998, X52282	MGI:97373
20	VIPR1 VPAC1 VIP receptor 1	human: NM_004624, L13288, X75299, X77777, L20295, U11087	MGI:109272
25	VIPR2 VIP receptor 2 PACAP receptor	human: X95097, L36566, Y18423, L40764, AF027390	MGI:107166

TABLE 12

	Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
30	5HT1A serotonin receptor 1A	human: M83181, AB041403, M28269, X13556	MGI:96273
35	5HT2A serotonin receptor 2A	human: X57830	MGI:109521

	Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
5	5HT3 serotonin receptor 3	human: AJ005205, D49394, S82612, AJ005205, AJ003079, AJ005205, AJ003080, AJ003078	MGI:96282
	5HT1B 5HT1Db serotonin receptor 1B	human: M81590, M81590, D10995, M83180, L09732, M75128, AB041370, AB041377, AL049595	MGI:96274
10	5HT1D alpha serotonin receptor 1D	human: AL049576	MGI:96276
	5HT1E serotonin receptor 1E	human: NM_000865, M91467, M92826, Z11166	
	5HT2B serotonin receptor 2B	human: NM_000867, X77307, Z36748	MGI:109323
15	5HT2C serotonin receptor 2C	human: NM_000868, U49516, M81778, X80763, AF208053	MGI:96281
	5HT4 serotonin receptor 4 (has 5 subtypes isoforms)	human: Y10437, Y08756, Y09586, Y13584, Y12505, Y12506, Y12507, AJ011371, AJ243213	
20	5HT5A serotonin receptor 5A	human: X81411	MGI:96283
	5Ht5B serotonin receptor 5B	rat: L10073	
25	5HT6 serotonin receptor 6	human: L41147, AF007141	
	5HT7 serotonin receptor 7	human: U68488, U68487, L21195, X98193 mouse: MM8053	
30	sert serotonin transporter	human UniGene: L05568	MGI:96285
	TPRH TPH (Tph) tryptophan hydroxylase	human UniGene: AF057280, X52836, L29306	MGI:98796

TABLE 13

	Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
5	P2RX1 P2x1 receptor purinergic receptor P2X, ligand-gated ion channel	human: U45448, X83688, AF078925, AF020498	MGI:1098235
10	P2RX3 purinergic receptor P2X, ligand-gated ion channel, 3	human: Y07683 mouse: RIKEN BB459124, RIKEN BB452419	
	P2RX4 purinergic receptor P2X, ligand-gated ion channel, 4	human: U83993, Y07684, U87270, AF000234	MGI:1338859
15	P2RX5 purinergic receptor P2X, ligand-gated ion channel, 5	human: AF168787, AF016709, U49395, U49396, AF168787 rat: AF070573	
20	P2RXL1 purinergic receptor P2X-like 1, orphan receptor P2RX6	human UniGene: AB002058	MGI:1337113
25	P2RX7 purinergic receptor P2X, ligand-gated ion channel, 7	human: Y09561, Y12851	MGI:1339957
	P2RY1 purinergic receptor P2Y, G-protein coupled 1	human: Z49205	MGI:105049
30	P2RY2 purinergic receptor P2Y, G-protein coupled, 2	human: U07225 S74902 rat: U56839	
	P2RY4 pyrimidinergic receptor P2Y, G-protein coupled, 4	human: X91852, X96597, U40223	

Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
P2RY6 pyrimidinergic receptor P2Y, G- protein coupled, 6	human: X97058, U52464, AF007892, AF007891, AF007893	
P2RY11 purinergic receptor P2Y, G-protein coupled, 11	human: AF030335	

TABLE 14

Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
SCN1A sodium channel, voltage-gated, type I, alpha	human: X65362	MGI:98246
SCN1B sodium channel, voltage-gated, type I, beta	human: L16242, L10338, U12194, NM_001037	MGI:98247
SCN2B sodium channel, voltage-gated, type II, beta	human: AF049498, AF049497, AF007783	MGI:106921
SCN5A sodium channel, voltage-gated, type V, alpha	human: M77235	
SCN2A1 sodium channel, voltage-gated, type II, alpha 1		MGI:98248
SCN2A2 sodium channel, voltage-gated, type II, alpha 2	human: M94055, X65361, M91803	
SCN3A sodium channel, voltage-gated, type III, alpha	human: AB037777, AJ251507	MGI:98249

	Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
5	SCN4A sodium channel, voltage-gated, type IV, alpha	human: M81758, L01983, L04236, U24693	MGI:98250
	SCN6A sodium channel, voltage-gated, type VII or VI	human: M91556	
10	SCN8a SCN8A sodium channel, voltage-gated, type VIII	human: AF225988, AB027567	MGI:103169
15	SCN9A sodium channel, voltage-gated, type IX, alpha	human: X82835, RIKEN BB468679 mouse: MM40146	
	SCN10A sodium channel, voltage-gated, type X,	human :NM_006514, AF117907	
20	SCN11A sodium channel, voltage-gated, type XI, alpha	human: AF188679	MGI:1345149
	SCN12A sodium channel, voltage-gated, type XII, alpha	human: NM_014139	
25	SCNN1A sodium channel, nonvoltage- gated 1 alpha	human: X76180, Z92978, L29007, U81961, U81961, U81961, U81961, U81961	MGI:101782
	SCN4B sodium channel, voltage-gated, type IV, beta		
30	SCNN1B sodium channel, nonvoltage- gated 1, beta	human: X87159, L36593, AJ005383, AC002300, U16023	
35	SCNN1D sodium channel, nonvoltage- gated 1, delta	human: U38254	

	Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
5	SCNN1G sodium channel, nonvoltage- gated 1, gamma	human: X87160, L36592, U35630	MGI:104695
	CLCN1 chloride channel 1, skeletal muscle	human: Z25884, Z25587, M97820, Z25753	MGI:88417
10	CLCN2 chloride channel 2	human: AF026004	MGI:105061
	CLCN3 chloride channel 3 CIC3	human: X78520, AL117599, AF029346	MGI:103555
15	CLCN4 chloride channel 4	human: AB019432 X77197	MGI:104567
	CLCN5 chloride channel 5	human: X91906, X81836	MGI:99486
20	CLCN6 chloride channel 6	human: D28475, X83378, AL021155, X99473, X99474, X96391, AL021155, AL021155, X99475, AL021155	MGI:1347049
	CLCN7 chloride channel 7	human: AL031600, U88844, Z67743, AJ001910	MGI:1347048
25	CLIC1 chloride intracellular channel 1	human: X87689, AJ012008, X87689, U93205, AF129756	
	CLIC2 chloride intracellular channel 2	human: NM_001289	
	CLIC3 chloride intracellular channel 3	human: AF102166	
30	CLIC5 chloride intracellular channel 5	human: AW816405	
	CLCNKB chloride channel Kb	human: Z30644 ,S80315, U93879	
35	CLCNKA chloride channel Ka	human: Z30643, U93878	MGI:1329026

	Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
5	CLCA1 chloride channel, calcium activated, family member 1	human: AF039400, AF039401	MGI:1316732
	CLCA2 chloride channel, calcium activated, family member 2	human: AB026833	
10	CLCA3 chloride channel, calcium activated, family member 3	human:NM_004921	
	CLCA4 chloride channel, calcium activated, family member 4	human: AK000072	
15	KCNA1 kv1.1 potassium voltage-gated channel, shaker-related subfamily, member 1	human: L02750	MGI:96654
20	KCNA2 potassium voltage-gated channel, shaker-related subfamily, member 2	human: Hs.248139, L02752 mouse: MM56930	MGI:96659
25	KCNA3 potassium voltage-gated channel, shaker-related subfamily, member 3	human: M85217, L23499, M38217, M55515	MGI:96660
30	KCNA4 potassium voltage-gated channel, shaker-related subfamily, member 4	human: M55514, M60450, L02751	MGI:96661
35	KCNA4L potassium voltage-gated channel, shaker-related subfamily, member 4-like		

	Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
5	KCNA5 potassium voltage-gated channel, shaker-related subfamily, member 5	human: Hs.150208, M55513, M83254, M60451, M55513 mouse: MM1241	MGI:96662
10	KCNA6 potassium voltage-gated channel, shaker-related subfamily, member 6	human: X17622	MGI:96663
15	KCNA7 potassium voltage-gated channel, shaker-related subfamily, member 7		MGI:96664
	KCNA10 potassium voltage-gated channel, shaker-related subfamily, member 10	human: U96110	
20	KCNB1 potassium voltage-gated channel, Shab-related subfamily, member 1	human: L02840, L02840, X68302, AF026005	MGI:96666
25	KCNB2 potassium voltage-gated channel, Shab-related subfamily, member 2	human: Hs.121498, U69962 mouse: MM154372	
30	KCNC1 potassium voltage-gated channel, Shaw-related subfamily, member 1	human: L00621, S56770	MGI:96667
35	KCNC2 potassium voltage-gated channel, Shaw-related subfamily, member 2		MGI:96668

	Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
5	KCNC3 potassium voltage-gated channel, Shaw-related subfamily, member 3	human: AF055989	MGI:96669
10	KCNC4 potassium voltage-gated channel, Shaw-related subfamily, member 4	human: M64676	MGI:96670
15	KCND1 potassium voltage-gated channel, Shal-related family, member 1	human: AJ005898, AF166003	MGI:96671
	KCND2 potassium voltage-gated channel, Shal-related subfamily, member 2	human: AB028967, AJ010969, AC004888	
20	KCND3 potassium voltage-gated channel, Shal-related subfamily, member 3	human: AF120491, AF048713, AF048712, AL049557	
25	KCNE1 potassium voltage-gated channel, Isk-related family, member 1	mouse : NM_008424	
30	KCNE1L potassium voltage-gated channel, Isk-related family, member 1-like	human: AJ012743, NM_012282	
35	KCNE2 potassium voltage-gated channel, Isk-related family, member 2	human: AF302095	

	Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
5	KCNE3 potassium voltage-gated channel, Isk-related family, member 3	human: NM_005472, rat: AJ271742 mouse: MM18733	
10	KCNE4 potassium voltage-gated channel, Isk-related family, member 4	mouse: MM24386	
	KCNF1 potassium voltage-gated channel, subfamily F, member 1	human: AF033382	
15	KCNG1 potassium voltage-gated channel, subfamily G, member 1	human: AF033383, AL050404	
20	KCNG2 potassium voltage-gated channel, subfamily G, member 2	human: NM_012283	
25	KCNH1 potassium voltage-gated channel, subfamily H (eag- related), member 1	human: AJ001366, AF078741, AF078742 mouse: NM_010600	
	KCNH2 potassium voltage-gated channel, subfamily H (eag- related), member 2	human: U04270, AJ010538, AB009071, AF052728	MGI:1341722
30	KCNH3 potassium voltage-gated channel, subfamily H (eag- related), member 3	human: AB022696, AB033108, Hs.64064 mouse: NM_010601, MM100209	

	Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
5	KCNH4 potassium voltage-gated channel, subfamily H (eag- related), member 4	human: AB022698 rat: BEC2	
10	KCNH5 potassium voltage-gated channel, subfamily H (eag- related), member 5	human: Hs.27043 mouse: MM44465	
15	KCNJ1 potassium inwardly-rectifying channel, subfamily J, member 1	human: U03884, U12541, U12542, U12543 rat: NM_017023	
	KCNJ2 potassium inwardly-rectifying channel, subfamily J, member 2	human: U16861, U12507, U24055, AF011904, U22413, AF021139	MGI:104744
20	KCNJ3 potassium inwardly-rectifying channel, subfamily J, member 3	human: U50964 U39196 mouse: NM_008426	
	KCNJ4 potassium inwardly-rectifying channel, subfamily J, member 4	human: Hs.32505, U07364, Z97056, U24056, Z97056 mouse: MM104760	MGI:104743
25	KCNJ5 potassium inwardly-rectifying channel, subfamily J, member 5	human: NM_000890	MGI:104755
30	KCNJ6 potassium inwardly-rectifying channel, subfamily J, member 6	human: Hs.11173, U52153, D87327, L78480, S78685, AJ001894 mouse: NM_010606, MM4276 rat: NM_013192	
	KCNJ8 potassium inwardly-rectifying channel, subfamily J, member 8	human: D50315, D50312	MGI:1100508
35	KCNJ9 potassium inwardly-rectifying channel, subfamily J, member 9	human: U52152	MGI:108007

	Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
5	KCNJ10 potassium inwardly-rectifying channel, subfamily J, member 10	human: Hs.66727, U52155, U73192, U73193	MGI:1194504
10	KCNJ11 potassium inwardly-rectifying channel, subfamily J, member 11	human: Hs.248141, D50582 mouse: MM4722	MGI:107501
15	KCNJ12 potassium inwardly-rectifying channel, subfamily J, member 12	human: AF005214, L36069	MGI:108495
20	KCNJ13 potassium inwardly-rectifying channel, subfamily J, member 13	human: AJ007557, AB013889, AF061118, AJ006128, AF082182 rat: AB034241, AB013890, AB034242 guinea pig: AF200714	
25	KCNJ14 potassium inwardly-rectifying channel, subfamily J, member 14	human: Hs.278677 mouse: Kir2.4, MM68170	
30	KCNJ15 potassium inwardly-rectifying channel, subfamily J, member 15	human: Hs.17287, U73191, D87291, Y10745 mouse: AJ012368, kir4.2, MM44238	
35	KCNJ16 potassium inwardly-rectifying channel, subfamily J, member 1	human: NM_018658, Kir5.1 mouse: AB016197	
	KCNK1 potassium channel, subfamily K, member 1 (TWIK-1)	human: U76996, U33632, U90065	MGI:109322

	Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
5	KCNK2 potassium channel, subfamily K, member 2 (TREK-1)	human: AF004711, RIKEN BB116025	
	KCNK3 potassium channel, subfamily K, member 3 (TASK)	human: AF006823	MGI:1100509
10	KCNK4 potassium inwardly-rectifying channel, subfamily K, member 4	human: AF247042, AL117564 mouse: NM_008431	
15	KCNK5 potassium channel, subfamily K, member 5 (TASK-2)	human: NM_003740, AK001897 mouse: AF259395	
	KCNK6 potassium channel, subfamily K, member 6 (TWIK-2)	human: AK022344	
20	KCNK7 potassium channel, subfamily K, member 7	human: NM_005714 mouse: MM23020	MGI:1341841
	KCNK8 potassium channel, subfamily K, member 8	mouse: NM_010609	
25	KCNK9 potassium channel, subfamily K, member 9	human: AF212829 guinea pig: AF212828	
	KCNK10 potassium channel, subfamily K, member 10 (TREK2)	human: AF279890	
30			
35	KCNN1 potassium intermediate/small conductance calcium-activated channel, subfamily N, member 1	human: NM_002248, U69883	

	Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
5	KCNN2 potassium intermediate/small conductance calcium-activated channel, subfamily member 2 (hsk2)	mouse: MM63515	
10	KCNN4 potassium intermediate/small conductance calcium-activated channel, subfamily N, member 4	human: Hs.10082, AF022797, AF033021, AF000972, AF022150 mouse: MM9911	MGI:1277957
15	KCNQ1 potassium voltage-gated channel, KQT-like subfamily, member 1	human: U89364, AF000571, AF051426, AJ006345, AB015163, AB015163, AJ006345	MGI:108083
20	KCNQ2 potassium voltage-gated channel, KQT-like subfamily, member 2	human: Y15065, D82346, AF033348, AF074247, AF110020	MGI:1309503
25	KCNQ3 potassium voltage-gated channel, KQT-like subfamily, member 3	human: NM_004519, AF033347, AF071491	MGI:1336181
30	KCNQ4 potassium voltage-gated channel, KQT-like subfamily, member 4	human: Hs.241376, AF105202, AF105216 mouse: AF249747	
35	KCNQ5 potassium voltage-gated channel, KQT-like subfamily, member 5	human: NM_019842	

	Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
5	KCNS1 potassium voltage-gated channel, delayed-rectifier, subfamily S, member 1	human: AF043473 mouse: NM_008435	
10	KCNS2 potassium voltage-gated channel, delayed-rectifier, subfamily S, member 2	mouse: NM_008436	
15	KCNS3 potassium voltage-gated channel, delayed-rectifier, subfamily S, member 3	human: AF043472	
	KCNAB1 potassium voltage-gated channel, shaker-related subfamily, beta member 1	L39833, U33428, L47665, X83127, U16953	MGI:109155
20	KCNAB2 potassium voltage-gated channel, shaker-related subfamily, beta member 2	human: U33429, AF044253, AF029749 mouse: NM_010598	
25	KCNAB3 potassium voltage-gated channel, shaker-related subfamily, beta member 3	human: NM_004732 mouse: MM57241	MGI:1336208
30	KCNJN1 potassium inwardly-rectifying channel, subfamily J, inhibitor 1	human: Hs.248143, U53143	
	KCNMA1 potassium large conductance calcium-activated channel, subfamily M, alpha member 1	human: U11058, U13913, U11717, U23767, AF025999	MGI:99923

	Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
5	kcnma3 potassium large conductance calcium-activated channel, subfamily M, alpha member 3	mouse: NM_008432	
10	KCNMB1 potassium large conductance calcium-activated channel, subfamily M, beta member 1	rat: NM_019273	
15	KCNMB2 potassium large conductance calcium-activated channel, subfamily M, beta member 2	human: AF209747 mouse: NM_005832	
20	KCNMB3L potassium large conductance calcium-activated channel, subfamily M, beta member 3- like	human: AP000365	
25	KCNMB3 potassium large conductance calcium-activated channel	human: NM_014407, AF214561	
30	KCNMB4 potassium large conductance calcium-activated channel, sub M, beta 4	human: AJ271372, AF207992, RIKEN BB329438, RIKEN BB265233	
35	HCN1 hyperpolarization activated cyclic nucleotide-gated potassium channel 1		MGI:1096392
	Cav1.1 α 1 1.1 CACNA1S calcium channel, voltage- dependent, L type, alpha 1S subunit	human: L33798, U30707	MGI:88294

	Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
5	Cav1.2 α 1 1.2 CACNA1C calcium channel, voltage- dependent, L type, alpha 1C subunit	human: Z34815, L29536, Z34822, L29534, L04569, Z34817, Z34809, Z34813, Z34814, Z34820, Z34810, Z34811, L29529, Z34819, Z74996 ,Z34812, Z34816, AJ224873, Z34818 , Z34821, AF070589, Z26308, M92269	
10	Cav1.3 α 1 1.3 CACNA1D calcium channel, voltage- dependent, L type, alpha 1D subunit	human: M83566, M76558, D43747, AF055575	MGI:88293
15	Cav1.4 α 1 1.4 CACNA1F calcium channel, voltage- dependent, L type, alpha 1F subunit	human: AJ224874, AF235097, AJ006216, AF067227, U93305	MGI:1859639
20	Cav2.1 α 1 2.1 CACNA1A P/Q type calcium channel, voltage- dependent, P/Q type, alpha 1A subunit	human: U79666, AF004883, AF004884, X99897, AB035727, U79663, U79665, U79664, U79667, U79668, AF100774	MGI:109482
25	Cav2.2 α 1 2.2 CACNA1B calcium channel, voltage- dependent, L type, alpha 1B subunit	human: M94172, M94173, U76666	MGI:88296
	Cav2.3 α 1 2.3 CACNA1E calcium channel, voltage- dependent, alpha 1E subunit	human: L29385, L29384, L27745	MGI:106217
30	Cav3.1 α 1 3.1 CACNA1G calcium channel, voltage- dependent, alpha 1G subunit	human: AB012043, AF190860, AF126966, AF227746, AF227744, AF134985, AF227745, AF227747, AF126965, AF227749, AF134986, AF227748, AF227751, AF227750, AB032949, AF029228	MGI:1201678
35			

Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
Cav3.2 α 1 3.2 CACNA1H calcium channel, voltage- dependent, alpha 1H subunit	human: AF073931, AF051946, AF070604	
Cav3.3 α 1 3.3 CACNA1I calcium channel, voltage- dependent, alpha 1I subunit	human: AF142567, AL022319, AF211189, AB032946	

TABLE 15

Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
NES (nestin)	no human	MGI:101784
scip	human: L26494	MGI:101896

TABLE 16

Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
Shh (Sonic Hedgehog)	human: L38518	MGI:98297
Smoothened Shh receptor	human: U84401, AF114821	MGI:108075
Patched Shh binding protein	human: NM_000264 rat: AF079162	

TABLE 17

Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
CALB1 (calbindin d28 K)	human: X06661, M19879,	MGI:88248

Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
CALB2 (calretinin)	human: NM_001740, X56667, X56668	MGI:101914
PVALB (parvalbumin)	human: X63578, X63070, Z82184, X52695, Z82184	MGI:97821

TABLE 18

Gene	GenBank and /or UniGene Accession Number	MGI Database Accession Number
NTRK2 (Trk B)	human: U12140, X75958, S76473, S76474	MGI:97384
GFRA1 (GFR alpha 1)	human: NM_005264, AF038420, AF038421, U97144, AF042080, U95847, AF058999	MGI:1100842
GFRA2 (GFRalpha 2)	human: U97145, AF002700, U93703	MGI:1195462
GFRA3 (GFRalpha 3)	human: AF051767	MGI:1201403
trka Neurotrophin receptor	human: M23102, X03541, X04201, X06704, X62947, M23102, X62947, M23102, AB019488, M12128	MGI:97383
trkc Neurotrophin receptor	human: U05012, U05012, S76475, AJ224521, S76476, AF052184	MGI:97385
ret Neurotrophic factor receptor	human: S80552	MGI:97902

All of the sequences identified by the sequence database identifiers in Tables 4-18 are hereby incorporated by reference in their entireties.

In yet another aspect of the invention, a promoter directs tissue-specific expression of the tagged ribosomal protein or mRNA binding protein sequence to which it is operably linked. For example, expression of the tagged ribosomal protein or mRNA binding protein coding sequences may be controlled by any tissue-specific promoter/enhancer element known in the art. Promoters that may be used to control expression include, but are not

limited to, the following animal transcriptional control regions that exhibit tissue specificity and that have been utilized in transgenic animals: elastase I gene control region, which is active in pancreatic acinar cells (Swift *et al.*, 1984, Cell 38:639-646; Ornitz *et al.*, 1986, Cold Spring Harbor Symp. Quant. Biol. 50:399-409; MacDonald, 1987, Hepatology 7:425-515); enolase promoter, which is active in brain regions, including the striatum, cerebellum, CA1 region of the hippocampus, or deep layers of cerebral neocortex (Chen *et al.*, 1998, Molecular Pharmacology 54(3): 495-503); insulin gene control region, which is active in pancreatic beta cells (Hanahan, 1985, Nature 315:115-22); immunoglobulin gene control region, which is active in lymphoid cells (Grosschedl *et al.*, 1984, Cell 38:647-58; Adames *et al.*, 1985, Nature 318:533-38; Alexander *et al.*, 1987, Mol. Cell. Biol. 7:1436-44); mouse mammary tumor virus control region, which is active in testicular, breast, lymphoid and mast cells (Leder *et al.*, 1986, Cell 45:485-95); albumin gene control region, which is active in liver (Pinkert *et al.*, 1987, Genes and Devel. 1:268-76); alpha-fetoprotein gene control region which is active in liver (Krumlauf *et al.*, 1985, Mol. Cell. Biol. 5:1639-48; Hammer *et al.*, 1987, Science 235:53-58); alpha 1-antitrypsin gene control region, which is active in the liver (Kelsey *et al.*, 1987, Genes and Devel. 1:161-71); β -globin gene control region, which is active in myeloid cells (Mogam *et al.*, 1985, Nature 315:338-40; Kollias *et al.*, 1986, Cell 46:89-94); myelin basic protein gene control region, which is active in oligodendrocyte cells in the brain (Readhead *et al.*, 1987, Cell 48:703-12); myosin light chain-2 gene control region, which is active in skeletal muscle (Sani, 1985, Nature 314:283-86); and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason *et al.*, 1986, Science 234:1372-78).

In other embodiments, the gene sequence from which the regulatory sequence derives is protein kinase C, gamma (GenBank Accession Number: Z15114 (human); MGI Database Accession Number: MGI:97597); fos (UniGene No. MM5043 (mouse)); TH-elastin; Pax7 (Mansouri, 1998, The role of Pax3 and Pax7 in development and cancer, Crit. Rev. Oncog. 9(2):141-9); Eph receptor (Mellitzer *et al.*, 2000, Control of cell behaviour by signalling through Eph receptors and ephrins; Curr. Opin. Neurobiol. 10(3):400-08; Suda *et al.*, 2000, Hematopoiesis and angiogenesis, Int. J. Hematol. 71(2):99-107; Wilkinson, 2000, Eph receptors and ephrins: regulators of guidance and assembly, Int. Rev. Cytol. 196:177-244; Nakamoto, 2000, Eph receptors and ephrins, Int. J. Biochem. Cell Biol. 32(1):7-12; Tallquist *et al.*, 1999, Growth factor signaling pathways in vascular development, Oncogene 18(55):7917-32); islet-1 (Bang *et al.*, 1996, Regulation of vertebrate neural cell fate by transcription factors, Curr. Opin. Neurobiol. 6(1):25-32; Ericson *et al.*, 1995, Sonic hedgehog: a common signal for ventral patterning along the

rostrocaudal axis of the neural tube, J. Dev. Biol. 39(5):809-16; β -actin; thy-1 (Caroni, 1997, Overexpression of growth-associated proteins in the neurons of adult transgenic mice, J. Neurosci. Methods 71(1):3-9).

Nucleic acids of the invention may include all or a portion of the upstream
5 regulatory sequences of the selected gene. The characterizing gene regulatory sequences preferably direct expression of the tagged ribosomal protein or mRNA binding protein sequences in substantially the same pattern as the endogenous characterizing gene within transgenic organism, or tissue derived therefrom.

In certain embodiments, the nucleic acids encoding the molecularly tagged
10 ribosomal proteins or mRNA binding proteins may be selectively expressed in random but distinct subsets of cells, as described in Feng *et al.* (2000, Imaging neuronal subsets in transgenic mice expressing multiple spectral variants of GFP, Neuron 28(1):41-51, which is hereby incorporated by reference in its entirety). Using such methods, independently generated transgenic lines may express the nucleic acids encoding the molecularly tagged
15 ribosomal proteins or mRNA binding proteins in a unique pattern, even though all incorporate identical regulatory elements.

5.6. INTRODUCTION OF VECTORS INTO HOST CELLS

In one aspect of the invention, a vector containing the nucleic acid encoding the
20 tagged ribosomal protein or tagged mRNA binding protein and regulatory sequences (preferably characterizing gene regulatory sequences) can be introduced transiently or stably into the genome of a host cell or be maintained episomally. In another aspect of the invention, the vector can be transiently transfected wherein it is not integrated, but is maintained as an episome.

25 The terms "host cell" and "recombinant host cell" are used interchangeably herein. It is understood that such terms refer not only to the particular subject cell but to the progeny or potential progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the
30 term as used herein.

A host cell can be any prokaryotic (*e.g.*, bacterium such as *E. coli*) or eukaryotic cell (*e.g.*, a cell from a yeast, plant, insect (*e.g.*, *Drosophila*), amphibian, amniote, or mammal, to name but a few), preferably a vertebrate cell, more preferably a mammalian cell, and most preferably, a mouse cell. In certain embodiments, the host cell is a human cell, either
35 a cultured cell, or in certain embodiments, an immortalized cultured cell or primary human

cell. In specific embodiments, the host cells are human embryonic stem cells, or other human stem cells (or murine stem cells, including embryonic stem cells), tumor cells or cancer cells (particularly circulating cancer cells such as those resulting from leukemias and other blood system cancers). Host cells intended to be part of the invention include ones
5 that comprise nucleic acids encoding one or more tagged ribosomal or tagged mRNA binding proteins and, optionally, operably associated with characterizing gene sequences that have been engineered to be present within the host cell (*e.g.*, as part of a vector). The invention encompasses genetically engineered host cells that contain any of the foregoing tagged ribosomal protein or tagged mRNA binding protein coding sequences, optionally
10 operatively associated with a regulatory element (preferably from a characterizing gene, as described above) that directs the expression of the coding sequences in the host cell. Both cDNA and genomic sequences can be cloned and expressed. In a preferred aspect, the host cell is recombination deficient, *i.e.*, Rec⁻, and used for BAC recombination. In specific embodiments the host cell may contain more than one type of ribosomal or mRNA binding
15 protein fusion, where the fusion of the different ribosomal and mRNA binding proteins is to the same or different peptide tags.

A vector containing a nucleotide sequence of the invention can be introduced into the desired host cell by methods known in the art, *e.g.*, transfection, transformation, transduction, electroporation, infection, microinjection, cell fusion, DEAE dextran, calcium
20 phosphate precipitation, liposomes, LIPOFECTINTM (source), lysosome fusion, synthetic cationic lipids, use of a gene gun or a DNA vector transporter, such that the nucleotide sequence is transmitted to offspring in the line. For various techniques for transformation or transfection of mammalian cells, see Keown *et al.*, 1990, *Methods Enzymol.* 185: 527-37; Sambrook *et al.*, 2001, *Molecular Cloning, A Laboratory Manual*, Third Edition, Cold
25 Spring Harbor Laboratory Press, N.Y.

In certain embodiments, the vector is introduced into a cultured cell. In other embodiments, the vector is introduced into a proliferating cell (or population of cells), *e.g.*, a tumor cell, a stem cell, a blood cell, a bone marrow cell, a cell derived from a tissue biopsy, etc.

30 Particularly preferred embodiments of the invention encompass methods of introduction of the vector containing the nucleic acid of the invention, using pronuclear injection of a nucleic acid construct of the invention into the mononucleus of a mouse embryo and infection with a viral vector comprising the construct. Methods of pronuclear injection into mouse embryos are well-known in the art and described in Hogan *et al.* 1986,
35 *Manipulating the Mouse Embryo*, Cold Spring Harbor Laboratory Press, New York, NY

and Wagner *et al.*, U.S. Patent No. 4,873,191, issued October 10, 1989, herein incorporated by reference in their entireties.

In preferred embodiments, a vector containing the nucleic acid of the invention is introduced into any genetic material which ultimately forms a part of the nucleus of the zygote of the animal to be made transgenic, including the zygote nucleus. In one embodiment, the nucleic acid of the invention can be introduced in the nucleus of a primordial germ cell which is diploid, *e.g.*, a spermatogonium or oogonium. The primordial germ cell is then allowed to mature to a gamete which is then united with another gamete or source of a haploid set of chromosomes to form a zygote. In another embodiment, the vector containing the nucleic acid of the invention is introduced in the nucleus of one of the gametes, *e.g.*, a mature sperm, egg or polar body, which forms a part of the zygote. In preferred embodiments, the vector containing the nucleic acid of the invention is introduced in either the male or female pronucleus of the zygote. More preferably, it is introduced in either the male or the female pronucleus as soon as possible after the sperm enters the egg. In other words, right after the formation of the male pronucleus when the pronuclei are clearly defined and are well separated, each being located near the zygote membrane.

In a most preferred embodiment, the vector containing the nucleic acid of the invention is added to the male DNA complement, or a DNA complement other than the DNA complement of the female pronucleus, of the zygote prior to its being processed by the ovum nucleus or the zygote female pronucleus. In an alternate embodiment, the vector containing the nucleic acid of the invention could be added to the nucleus of the sperm after it has been induced to undergo decondensation. Additionally, the vector containing the transgene may be mixed with sperm and then the mixture injected into the cytoplasm of an unfertilized egg. Perry *et al.*, 1999, Science 284:1180-1183. Alternatively, the vector may be injected into the vas deferens of a male mouse and the male mouse mated with normal estrus females. Huguet *et al.*, 2000, Mol. Reprod. Dev. 56:243-247.

Preferably, the nucleic acid of the invention is introduced using any technique so long as it is not destructive to the cell, nuclear membrane or other existing cellular or genetic structures. The nucleic acid of the invention is preferentially inserted into the nucleic genetic material by microinjection. Microinjection of cells and cellular structures is known and is used in the art. Also known in the art are methods of transplanting the embryo or zygote into a pseudopregnant female where the embryo is developed to term and the nucleic acid of the invention is integrated and expressed. See, *e.g.*, Hogan *et al.* 1986, *Manipulating the Mouse Embryo*, Cold Spring Harbor Laboratory Press, New York, NY.

Viral methods of inserting nucleic acids are known in the art.

For stable transfection of cultured mammalian cells, only a small fraction of cells may integrate the foreign DNA into their genome. The efficiency of integration depends upon the vector and transfection technique used. In order to identify and select integrants, a gene that encodes a selectable marker (*e.g.*, for resistance to antibiotics) is generally introduced into the host cells along with a nucleotide sequence of the invention. Preferred selectable markers include those which confer resistance to drugs, such as G418, hygromycin and methotrexate. Cells stably transfected with the introduced nucleic acid can be identified by drug selection (*e.g.*, cells that have incorporated the selectable marker gene will survive, while the other cells die). Such methods are particularly useful in methods involving homologous recombination in mammalian cells (*e.g.*, in murine ES cells) prior to introducing the recombinant cells into mouse embryos to generate chimeras.

A number of selection systems may be used to select transformed host cells. In particular, the vector may contain certain detectable or selectable markers. Other methods of selection include but are not limited to selecting for another marker such as: the herpes simplex virus thymidine kinase (Wigler *et al.*, 1977, Cell 11: 223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska and Szybalski, 1962, Proc. Natl. Acad. Sci. USA 48: 2026), and adenine phosphoribosyltransferase (Lowy *et al.*, 1980, Cell 22: 817) genes can be employed in tk-, hgp^{rt}- or ap^{rt}- cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler *et al.*, 1980, Natl. Acad. Sci. USA 77: 3567; O'Hare *et al.*, 1981, Proc. Natl. Acad. Sci. USA 78: 1527); gpt, which confers resistance to mycophenolic acid (Mulligan and Berg, 1981, Proc. Natl. Acad. Sci. USA 78: 2072); neo, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin *et al.*, 1981, J. Mol. Biol. 150: 1); and hygro, which confers resistance to hygromycin (Santerre *et al.*, 1984, Gene 30: 147).

5.7. METHODS OF PRODUCING TRANSFORMED ORGANISMS

The nucleic acid of the invention may integrate into the genome of the founder organism (or an oocyte or embryo that gives rise to the founder organism), preferably by random integration. If random, the integration preferably does not knock out, *e.g.*, insert into, an endogenous gene(s) such that the endogenous gene is not expressed or is mis-expressed.

In other embodiments, the nucleic acid of the invention may integrate by a directed method, *e.g.*, by directed homologous recombination ("knock-in"), Chappel, U.S. Patent No. 5,272,071; and PCT publication No. WO 91/06667, published May 16, 1991; U.S. Patent 5,464,764; Capecchi *et al.*, issued November 7, 1995; U.S. Patent 5,627,059,

Capecchi *et al.* issued, May 6, 1997; U.S. Patent 5,487,992, Capecchi *et al.*, issued January 30, 1996). Preferably, when homologous recombination is used, it does not knock out or replace the host's endogenous copy of the characterizing gene (or characterizing gene ortholog).

5 Methods for generating cells having targeted gene modifications through homologous recombination are known in the art. The construct will comprise at least a portion of the characterizing gene with a desired genetic modification, *e.g.*, insertion of the nucleotide sequence coding for the tagged ribosomal protein and will include regions of homology to the target locus, *i.e.*, the endogenous copy of the characterizing gene in the
10 host's genome. DNA constructs for random integration need not include regions of homology to mediate recombination. Markers can be included for performing positive and negative selection for insertion of the nucleic acid of the invention.

 To create a homologous recombinant organism, a homologous recombination vector is prepared in which the nucleotide sequence encoding the tagged ribosomal protein is
15 flanked at its 5' and 3' ends by characterizing gene sequences to allow for homologous recombination to occur between the exogenous gene carried by the vector and the endogenous characterizing gene in an embryonic stem cell. The additional flanking nucleic acid sequences are of sufficient length for successful homologous recombination with the endogenous characterizing gene. Typically, several kilobases of flanking DNA (both at the
20 5' and 3' ends) are included in the vector. Methods for constructing homologous recombination vectors and homologous recombinant animals are described further in Thomas and Capecchi, 1987, Cell 51: 503; Bradley, 1991, Curr. Opin. Bio/Technol. 2: 823-29; and PCT Publication Nos. WO 90/11354, WO 91/01140, WO 92/0968, and WO 93/04169.

25 A transgenic animal is a non-human animal, preferably a mammal, more preferably a rodent such as a rat or mouse, in which one or more of the cells of the animal includes a nucleic acid of the invention, *i.e.*, has a non-endogenous (*i.e.*, heterologous) nucleic acid sequence present as an extrachromosomal element in a portion of its cell or stably integrated into its germ line DNA (*i.e.*, in the genomic sequence of most or all of its cells). Other
30 examples of transgenic animals include non-human primates, sheep, dogs, cows, goats, chickens, amphibians, etc. The invention also includes transgenic plants and fungi (including yeast). Unless otherwise indicated, it will be assumed that a transgenic animal comprises stable changes to the germline sequence. Heterologous nucleic acid is introduced into the germ line of such a transgenic animal by genetic manipulation of, for example,
35 embryos or embryonic stem cells of the host animal.

As discussed above, transformed organisms of the invention, *e.g.*, transgenic animals, are preferably generated by random integration of a vector containing a nucleic acid of the invention into the genome of the organism, for example, by pronuclear injection in an animal zygote as described above. Other methods involve introducing the vector into
5 cultured embryonic cells, for example ES cells, and then introducing the transformed cells into animal blastocysts, thereby generating a "chimeras" or "chimeric animals", in which only a subset of cells have the altered genome. Chimeras are primarily used for breeding purposes in order to generate the desired transgenic animal. Animals having a heterozygous alteration are generated by breeding of chimeras. Male and female heterozygotes are
10 typically bred to generate homozygous animals.

A homologously recombinant organism may include, but is not limited to, a recombinant animal, such as a non-human animal, preferably a mammal, more preferably a mouse, in which an endogenous gene has been altered by homologous recombination between the endogenous gene and an exogenous DNA molecule introduced into a cell of the
15 animal, *e.g.*, an embryonic cell of the animal, prior to development of the animal.

In a preferred embodiment, a transgenic animal of the invention is created by introducing a nucleic acid of the invention, encoding the characterizing gene regulatory sequences operably linked to nucleotide sequences encoding a tagged ribosomal protein, into the male pronuclei of a fertilized oocyte, *e.g.*, by microinjection or retroviral infection,
20 and allowing the oocyte to develop in a pseudopregnant female foster animal. Methods for generating transgenic animals via embryo manipulation and microinjection, particularly animals such as mice, have become conventional in the art and are described, for example, in U.S. Patent Nos. 4,736,866 and 4,870,009, U.S. Patent No. 4,873,191, in Hogan, Manipulating the Mouse Embryo, (Cold Spring Harbor Laboratory Press, Cold Spring
25 Harbor, N.Y., 1986) and in Wakayama *et al.*, 1999, *Proc. Natl. Acad. Sci. USA*, 96:14984-89. Similar methods are used for production of other transgenic animals.

A transgenic founder animal can be identified based upon the presence of the nucleic acid of the invention in its genome and/or expression of mRNA encoding the nucleic acid of the invention in tissues or cells of the animals. A transgenic founder animal can then be
30 used to breed additional animals carrying the nucleic acid of the invention as described *supra*. Moreover, transgenic animals carrying the nucleic acid of the invention can further be bred to other transgenic animals carrying other nucleic acids of the invention.

In another embodiment, the nucleic acid of the invention is inserted into the genome of an embryonic stem (ES) cell, followed by injection of the modified ES cell into a
35

blastocyst-stage embryo that subsequently develops to maturity and serves as the founder animal for a line of transgenic animals.

In another embodiment, a vector bearing a nucleic acid of the invention is introduced into ES cells (*e.g.*, by electroporation) and cells in which the introduced gene has homologously recombined with the endogenous gene are selected. *See, e.g.*, Li *et al.*, 1992, Cell 69:915. For embryonic stem (ES) cells, an ES cell line may be employed, or embryonic cells may be obtained freshly from a host, *e.g.* mouse, rat, guinea pig, etc.

After transformation, ES cells are grown on an appropriate feeder layer, *e.g.*, a fibroblast-feeder layer, in an appropriate medium and in the presence of appropriate growth factors, such as leukemia inhibiting factory (LIF). Cells that contain the construct may be detected by employing a selective medium. Transformed ES cells may then be used to produce transgenic animals via embryo manipulation and blastocyst injection. (*See, e.g.*, U.S. Pat. Nos. 5,387,742, 4,736,866 and 5,565,186 for methods of making transgenic animals.)

Stable expression of the construct is preferred. For example, ES cells that stably express a nucleotide sequence encoding a tagged ribosomal protein may be engineered. Rather than using vectors that contain viral origins of replication, ES host cells can be transformed with DNA, *e.g.*, a plasmid, controlled by appropriate expression control elements (*e.g.*, promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered ES cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and expanded into cell lines. This method may advantageously be used to engineer ES cell lines that express a nucleotide sequence encoding a tagged ribosomal protein.

The selected ES cells are then injected into a blastocyst of an animal (*e.g.*, a mouse) to form aggregation chimeras. *See, e.g.*, Bradley, 1987, in *Teratocarcinomas and Embryonic Stem Cells: A Practical Approach*, Robertson, ed., IRL, Oxford, 113-52. Blastocysts are obtained from 4 to 6 week old superovulated females. The ES cells are trypsinized, and the modified cells are injected into the blastocoel of the blastocyst. After injection, the blastocysts are implanted into the uterine horns of suitable pseudopregnant female foster animal. Alternatively, the ES cells may be incorporated into a morula to form a morula aggregate which is then implanted into a suitable pseudopregnant female foster animal.

35

Females are then allowed to go to term and the resulting litters screened for mutant cells having the construct.

The chimeric animals are screened for the presence of the modified gene. By providing for a different phenotype of the blastocyst and the ES cells, chimeric progeny can be readily detected. Males and female chimeras having the modification are mated to produce homozygous progeny. Only chimeras with transformed germline cells will generate homozygous progeny. If the gene alterations cause lethality at some point in development, tissues or organs can be maintained as allergenic or congenic grafts or transplants, or in *in vitro* culture.

Progeny harboring homologously recombined or integrated DNA in their germline cells can be used to breed animals in which all cells of the animal contain the homologously recombined DNA by germline transmission of the nucleic acid of the invention.

Clones of the non-human transgenic animals described herein can also be produced according to the methods described in Wilmut *et al.*, 1997, Nature 385: 810-13 and PCT Publication NOS. WO 97/07668 and WO 97/07669.

Once the transgenic mice are generated they may be bred and maintained using methods well known in the art. By way of example, the mice may be housed in an environmentally controlled facility maintained on a 10 hour dark: 14 hour light cycle. Mice are mated when they are sexually mature (6 to 8 weeks old). In certain embodiments, the transgenic founders or chimeras are mated to an unmodified animal (*i.e.*, an animal having no cells containing the nucleic acid of the invention). In a preferred embodiment, the transgenic founder or chimera is mated to C57BL/6 mice (Jackson Laboratories). In a specific embodiment where the nucleic acid of the invention is introduced into ES cells and a chimeric mouse is generated, the chimera is mated to 129/Sv mice, which have the same genotype as the embryonic stem cells. Protocols for successful creation and breeding of transgenic mice are known in the art (Manipulating the Mouse Embryo. A Laboratory Manual, 2nd edition. B. Hogan, Beddington, R., Costantini, F. and Lacy, E., eds. 1994. Cold Spring Harbor Laboratory Press: Plainview, NY). Preferably, a founder male is mated with two females and a founder female is mated with one male. Preferably two females are rotated through a male's cage every 1-2 weeks. Pregnant females are housed 1 or 2 per cage. Preferably, pups are ear tagged, genotyped, and weaned at 21 days. Males and females are housed separately. Preferably log sheets are kept for any mated animal, by example and not limitation, information should include pedigree, birth date, sex, ear tag number, source of mother and father, genotype, dates mated and generation.

More specifically, founder animals heterozygous for the nucleic acid of the invention may be mated to generate a homozygous line as follows: A heterozygous founder animal, designated as the P₁ generation, is mated with an offspring from a mating with a non-transgenic mouse, designated as the F₁ generation, transgenic mouse of the opposite sex which is heterozygous for the nucleic acid of the invention (backcross). Based on classical genetics, one fourth of the results of this backcross are homozygous for the nucleic acid of the invention. In a preferred embodiment, transgenic founders are individually backcrossed to an inbred or outbred strain of choice. Different founders should not be intercrossed, since different expression patterns may result from separate nucleic acid integration events.

The determination of whether a transgenic mouse is homozygous or heterozygous for the nucleic acid of the invention is as follows:

An offspring of the above described breeding cross is mated to a normal control non-transgenic animal. The offspring of this second mating are analyzed for the presence of the nucleic acid of the invention by the methods described below. If all offspring of this cross test positive for the nucleic acid of the invention, the mouse in question is homozygous for the nucleic acid of the invention. If, on the other hand, some of the offspring test positive for the nucleic acid of the invention and others test negative, the mouse in question is heterozygous for the nucleic acid of the invention.

An alternative method for distinguishing between a transgenic animal which is heterozygous and one which is homozygous for the nucleic acid of the invention is to measure the intensity with radioactive probes following Southern blot analysis of the DNA of the animal. Animals homozygous for the nucleic acid of the invention would be expected to produce higher intensity signals from probes specific for the nucleic acid of the invention than would heterozygote transgenic animals.

In a preferred embodiment, the transgenic mice are so highly inbred to be genetically identical except for sexual differences. The homozygotes are tested using backcross and intercross analysis to ensure homozygosity. Homozygous lines for each integration site in founders with multiple integrations are also established. Brother/sister matings for 20 or more generations define an inbred strain. In another preferred embodiment, the transgenic lines are maintained as hemizygotes.

In an alternative embodiment, individual genetically altered mouse strains are also cryopreserved rather than propagated. Methods for freezing embryos for maintenance of founder animals and transgenic lines are known in the art. Gestational day 2.5 embryos are isolated and cryopreserved in straws and stored in liquid nitrogen. The first straw and the last straw are subsequently thawed and transferred to foster females to demonstrate viability

of the line with the assumption that all embryos frozen between the first straw and the last straw will behave similarly. If viable progeny are not observed a second embryo transfer will be performed. Methods for reconstituting frozen embryos and bringing the embryos to term are known in the art.

5 The nucleic acid encoding the molecularly tagged ribosomal protein or mRNA binding protein may be introduced into the genome of a founder plant (or embryo that gives rise to the founder plant) using methods well known in the art (Newell, 2000, Plant transformation technology. Developments and applications, Mol. Biotechnol. 16(1):53-65; Kumar and Fladung, 2001, Controlling transgene integration in plants, Trends in Plant
10 Science 6 (4): 155-159). The nucleic acid encoding the molecularly tagged ribosomal protein or mRNA binding protein may be introduced into the genome of bacteria and yeast using methods described in Ausubel *et al.*, 1989, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y., Chapters 1 and 13, respectively).

15 **5.7.1. HOMOLOGOUS RECOMBINATION IN BACTERIAL ARTIFICIAL CHROMOSOMES**

 The invention provides transformed organisms, *e.g.*, transgenic mice, that express a tagged ribosomal protein within a chosen cell type (see *infra*). In preferred embodiments, BAC-mediated recombination (Yang, *et al.*, 1997, Nat. Biotechnol. 15(9):859-865) is used
20 to create the transformed organism. Such expression is achieved by using the endogenous regulatory sequences of a particular gene, wherein the expression of gene is a defining characteristic of the chosen cell type (as also described in PCT/US02/04765, entitled "Collections of Transgenic Animal Lines (Living Library)" by Serafini, published as WO
25 02/064749 on August 22, 2002, which is incorporated by reference herein in its entirety). In another preferred embodiment, a collection of transgenic mice expressing tagged ribosomal proteins within a set of chosen cell types is assembled, as described *infra*.

 Vectors used in the methods of the invention preferably can accommodate, and in certain embodiments comprise, large pieces of heterologous DNA such as genomic
30 sequences. Such vectors can contain an entire genomic locus, or at least sufficient sequence to confer endogenous regulatory expression pattern and to insulate the expression of coding sequences from the effect of regulatory sequences surrounding the site of integration of the nucleic acid of the invention in the genome to mimic better wild type expression. When
entire genomic loci or significant portions thereof are used, few, if any, site-specific
35 expression problems of a nucleic acid of the invention are encountered, unlike insertions of nucleic acids into smaller sequences. In a preferred embodiment, the vector is a BAC

containing genomic sequences into which a selected sequence encoding a molecular tag, *e.g.*, an epitope tag, has been inserted by directed homologous recombination in bacteria, *e.g.*, by the methods of Heintz WO 98/59060; Heintz *et al.*, WO 01/05962; Yang *et al.*, 1997, Nature Biotechnol. 15: 859-865; Yang *et al.*, 1999, Nature Genetics 22: 327-35;

5 which are incorporated herein by reference in their entireties.

Using such methods, a BAC can be modified directly in a recombination-deficient *E. coli* host strain by homologous recombination.

In a preferred embodiment, homologous recombination in bacteria is used for target-directed insertion of a sequence encoding a molecularly tagged ribosomal protein into the genomic DNA encoding sufficient regulatory sequences (termed “characterizing gene sequences”) to promote expression of the tagged ribosomal protein in the endogenous expression pattern of the characterizing gene, which sequences have been inserted into the BAC. The BAC comprising the molecularly tagged ribosomal protein sequence under the regulation of this characterizing gene sequence is then recovered and introduced into the genome of a potential founder organism for a line of transformed organisms.

Preferably, the tagged ribosomal protein encoding sequence is inserted into the characterizing gene sequences using 5' direct fusion without the use of an IRES, *i.e.*, such that the tagged ribosomal protein encoding sequence(s) is fused directly in frame to the nucleotide sequence encoding at least the first codon of the characterizing gene coding sequence and even the first two, four, five, six, eight, ten or twelve codons. In other embodiments, the tagged ribosomal protein encoding sequence is inserted into the 3' UTR of the characterizing gene and has its own IRES. In yet another specific embodiment, the tagged ribosomal protein encoding sequence is inserted into the 5' UTR of the characterizing gene with an IRES controlling the expression of the tagged ribosomal protein encoding sequence.

In a preferred aspect of the invention, the molecularly tagged ribosomal protein encoding sequence is introduced into a BAC containing characterizing gene regulatory sequences by the methods of Heintz *et al.* WO 98/59060 and Heintz *et al.*, WO 01/05962, both of which are incorporated herein by reference in their entireties. The molecularly tagged sequence is introduced by performing selective homologous recombination on a particular nucleotide sequence contained in a recombination deficient host cell, *i.e.*, a cell that cannot independently support homologous recombination, *e.g.*, Rec A⁻. The method preferably employs a recombination cassette that contains a nucleic acid containing the molecular-tag coding sequence that selectively integrates into a specific site in the characterizing gene by virtue of sequences homologous to the characterizing gene flanking

the molecular-tag gene coding sequences on the shuttle vector when the recombination deficient host cell is induced to support homologous recombination (for example by providing a functional RecA gene on the shuttle vector used to introduce the recombination cassette).

- 5 In a preferred aspect, the particular nucleotide sequence that has been selected to undergo homologous recombination is contained in an independent origin based cloning vector introduced into or contained within the host cell, and neither the independent origin based cloning vector alone, nor the independent origin based cloning vector in combination with the host cell, can independently support homologous recombination (*e.g.*, is RecA).
- 10 Preferably, the independent origin based cloning vector is a BAC or a bacteriophage-derived artificial chromosome (BBPAC) and the host cell is a host bacterium, preferably *E. coli*.

In another preferred aspect, sufficient characterizing gene sequences flank the tagged ribosomal protein encoding sequence to accomplish homologous recombination and target the insertion of the molecularly tagged ribosomal protein coding sequences to a particular

15 location in the characterizing gene. The tagged ribosomal protein coding sequence and the homologous characterizing gene sequences are preferably present on a shuttle vector containing appropriate selectable markers and the RecA gene, optionally with a temperature sensitive origin of replication (see Heintz *et al.* WO 98/59060 and Heintz *et al.*, WO 01/05962 such that the shuttle vector only replicates at the permissive temperature and can

20 be diluted out of the host cell population at the non-permissive temperature. When the shuttle vector is introduced into the host cell containing the BAC, the RecA gene is expressed and recombination of the homologous shuttle vector and BAC sequences can occur, thus targeting the tagged ribosomal protein encoding sequence (along with the shuttle vector sequences and flanking characterizing gene sequences) to the characterizing gene

25 sequences in the BAC.

The BACs can be selected and screened for integration of the molecularly tagged ribosomal protein coding sequences into the selected site in the characterizing gene sequences using methods well known in the art (*e.g.*, methods described in Section 5, *infra*, and in Heintz *et al.*, WO 98/59060 entitled “Methods of preforming (*sic*) homologous

30 recombination based modification of nucleic acids in recombination deficient cells and use of the modified nucleic acid products thereof,” and Heintz *et al.*, WO 01/05962, entitled “Conditional homologous recombination of large genomic vector inserts”). Optionally, the shuttle vector sequences not containing the molecularly tagged ribosomal protein coding sequences (including the RecA gene and any selectable markers) can be removed from the

35

BAC by resolution as described in Section 5 and in Heintz *et al.* WO 98/59060 and Heintz *et al.*, WO 01/05962.

If the shuttle vector contains a negative selectable marker, cells can be selected for loss of the shuttle vector sequences. In an alternative embodiment, the functional RecA
5 gene is provided on a second vector and removed after recombination, *e.g.*, by dilution of the vector or by any method known in the art. The exact method used to introduce the tagged ribosomal protein encoding sequence and to remove (or not) the RecA (or other appropriate recombination enzyme) will depend upon the nature of the BAC library used (for example, the selectable markers present on the BAC vectors) and such modifications
10 are within the skill in the art.

Once the BAC containing the characterizing gene regulatory sequences and molecularly tagged ribosomal protein coding sequences in the desired configuration is identified, it can be isolated from the host *E. coli* cells using routine methods and used to make transformed organisms as described *infra*).

15 BACs to be used in the methods of the invention are selected and/or screened using the methods described *supra*.

Alternatively, the BAC can also be engineered or modified by "E-T cloning," as described by Muyrers *et al.* (1999, Nucleic Acids Res. 27(6): 1555-57, incorporated herein by reference in its entirety). Using these methods, specific DNA may be engineered into a
20 BAC independently of the presence of suitable restriction sites. This method is based on homologous recombination mediated by the recE and recT proteins ("ET-cloning") (Zhang *et al.*, 1998, Nat. Genet. 20(2): 123-28; incorporated herein by reference in its entirety). Homologous recombination can be performed between a PCR fragment flanked by short homology arms and an endogenous intact recipient such as a BAC. Using this method,
25 homologous recombination is not limited by the disposition of restriction endonuclease cleavage sites or the size of the target DNA. A BAC can be modified in its host strain using a plasmid, *e.g.*, pBAD- $\alpha\beta\gamma$, in which recE and recT have been replaced by their respective functional counterparts of phage lambda (Muyrers *et al.*, 1999, Nucleic Acids Res. 27(6): 1555-57). Preferably, a BAC is modified by recombination with a PCR product containing
30 homology arms ranging from 27-60 bp. In a specific embodiment, homology arms are 50 bp in length.

In another embodiment, a nucleic acid of the invention is inserted into a yeast artificial chromosome (YAC) (Burke *et al.*, 1987 Science 236: 806-12; and Peterson *et al.*, 1997, Trends Genet. 13: 61).

35

In other embodiments, the nucleic acid of the invention is inserted into another vector developed for the cloning of large segments of mammalian DNA, such as a cosmid or bacteriophage P1 (Sternberg *et al.*, 1990, Proc. Natl. Acad. Sci. USA 87: 103-07). The approximate maximum insert size is 30-35 kb for cosmids and 100 kb for bacteriophage P1.

5 In another embodiment, the nucleic acid of the invention is inserted into a P-1 derived artificial chromosome (PAC) (Mejia *et al.*, 1997, Retrofitting vectors for Escherichia coli-based artificial chromosomes (PACs and BACs) with markers for transfection studies, Genome Res. 7(2):179-86). The maximum insert size is 300 kb.

10 5.8. METHODS OF SCREENING FOR EXPRESSION OF NUCLEIC ACIDS OF THE INVENTION

Potential founder organisms for a line of transformed organisms can be screened for expression of the tagged ribosomal protein gene sequence in the population of cells characterized by expression of the endogenous characterizing gene.

15 Transformed organisms that exhibit appropriate expression (*e.g.*, detectable expression having substantially the same expression pattern as the endogenous characterizing gene in a corresponding non-transgenic organism or anatomical region thereof, *i.e.*, detectable expression in at least 80%, 90% or, preferably, 95% of the cells shown to express the endogenous gene by *in situ* hybridization) are selected as lines of
20 transformed organisms.

In a preferred embodiment, immunohistochemistry using an antibody specific for the epitope tag is used to detect expression of the tagged ribosomal fusion protein product.

25 5.9. EXPRESSION OF A TAGGED RIBOSOMAL PROTEIN IN A POPULATION OF CELLS

The nucleic acid of the invention containing the nucleotide sequence encoding the tagged ribosomal protein can be expressed in the cell type of interest using methods well known in the art for recombinant gene expression. The choice of which method to use to
30 express a DNA sequence encoding a tagged ribosomal protein in a chosen population of cells depends upon the population.

In certain embodiments, the chosen population of cells is a particular population of cells in culture that have been transfected with the construct encoding the tagged ribosomal protein, the expression construct is chosen to allow efficient and high-level expression in
35 the type of cells present in culture, with the mRNA of the transfected population being isolated according to the methods described herein.

This mode of the invention would be particularly useful if one wanted to study global gene expression changes in cultured cells in response to the expression of a particular gene product, co-expressed with a tagged ribosomal subunit to allow isolation of mRNA from co-expressing cells.

5 In another embodiment, the expression construct can be contained within a viral vector or virus, which is introduced into the desired host cell as described above. This embodiment permits study of mRNA populations from transduced or infected cells, *in vitro* or *in vivo*.

10 In another embodiment, expression of the tagged ribosomal protein is driven in populations of cells by the characterizing gene regulatory element.

In another embodiment, the gene sequences encoding the characterizing gene regulatory element and the tagged ribosomal protein is introduced by homologous recombination.

15 In another embodiment, homologous recombination is used to introduce only the epitope tag gene coding sequences.

Methods for selecting for cells containing and expressing the nucleotide sequences encoding the fusion proteins of the invention are well known in the art. For example, in eukaryotic cells, the nucleotide sequence encoding the fusion protein is associated with (for example, present on the same vector as) a selectable marker such as dhfr. Cells having the
20 dhfr selectable marker are resistant to the drug methotrexate. Increasing levels of methotrexate can also lead to amplification of the selectable marker (and, concomitantly, the sequence encoding the fusion protein of the invention). Once the selectable marker sequences have integrated into the host cell chromosome, the selectable marker sequences (and the sequences encoding the fusion protein of the invention) will be maintained by the
25 host cells even in the absence of selection (e.g., in the absence of methotrexate when the selectable marker is dhfr).

5.10. NUCLEIC ACID CONSTRUCTS

The invention provides vectors and lines of organisms that contain a nucleic acid
30 construct, e.g., a transgene, that comprises the coding sequence for a peptide tag-ribosomal fusion protein or peptide tag-mRNA binding protein fusion protein under the control of a regulatory sequences for a "characterizing gene." The regulatory sequence is e.g., an endogenous promoter of a characterizing gene. This characterizing gene is endogenous to a host cell or host organism (or is an ortholog of an endogenous gene) and is expressed in a
35 particular select population of cells of the organism. Expression of the nucleic acid

construct is such that the nucleic acid construct has substantially the same expression pattern as the endogenous characterizing gene.

A transgene is a nucleotide sequence that has been or is designed to be incorporated into a cell, particularly a mammalian cell, that in turn becomes or is incorporated into a living animal such that the nucleic acid containing the nucleotide sequence is expressed (*i.e.*, the mammalian cell is transformed with the transgene).

The characterizing gene sequence is preferably endogenous to the transformed organism, or is an ortholog of an endogenous gene, *e.g.*, the human ortholog of a gene endogenous to the animal to be made transgenic. A nucleic acid construct comprising the tagged ribosomal protein and optionally, the characterizing gene sequence may be present as an extrachromosomal element in some or all of the cells of a transformed organisms such as a transgenic animal or, preferably, stably integrated into some or all of the cells, more preferably into the germ line DNA of the animal (*i.e.*, such that the nucleic acid construct is transmitted to all or some of the animal's progeny), thereby directing expression of an encoded gene product (*i.e.*, the tagged ribosomal protein gene product) in one or more cell types or tissues of the transformed organism. Unless otherwise indicated, it will be assumed that a transformed organism, *e.g.*, a transgenic animal, comprises stable changes to the chromosomes of germline cells. In a preferred embodiment, the nucleic acid construct is present in the genome at a site other than where the endogenous characterizing gene is located. In other embodiments, the nucleic acid construct is incorporated into the genome of the organism at the site of the endogenous characterizing gene, for example, by homologous recombination.

In certain embodiments, transformed organisms are created by introducing a nucleic acid construct of the invention into its genome using methods routine in the art, for example, the methods described in Section 5.7, *supra*. A construct is a recombinant nucleic acid, generally recombinant DNA, generated for the purpose of the expression of a specific nucleotide sequence(s), or is to be used in the construction of other recombinant nucleotide sequences.

A transgenic construct of the invention includes at least the coding region for a peptide tag fused to the coding region for a ribosomal protein, operably linked to all or a portion of the regulatory sequences, *e.g.* a promoter and/or enhancer, of the characterizing gene. The transgenic construct optionally includes enhancer sequences and coding and other non-coding sequences (including intron and 5' and 3' untranslated sequences) from the characterizing gene such that the tagged ribosomal fusion protein gene is expressed in the same subset of cells as the characterizing gene. The tagged ribosomal fusion protein gene

coding sequences and the characterizing gene regulatory sequences are operably linked, meaning that they are connected in such a way so as to permit expression of the tagged ribosomal protein gene when the appropriate molecules (*e.g.*, transcriptional activator proteins) are bound to the characterizing gene regulatory sequences. Preferably the linkage is covalent, most preferably by a nucleotide bond. The promoter region is of sufficient length to promote transcription, as described in Alberts *et al.* (1989) in *Molecular Biology of the Cell*, 2d Ed. (Garland Publishing, Inc.).

In one aspect of the invention, the regulatory sequence is the promoter of a characterizing gene. Other promoters that direct tissue-specific expression of the coding sequences to which they are operably linked are also contemplated in the invention. In specific embodiments, a promoter from one gene and other regulatory sequences (such as enhancers) from other genes are combined to achieve a particular temporal and spatial expression pattern of the tagged ribosomal protein gene.

Methods that are well known to those skilled in the art can be used to construct vectors containing tagged ribosomal protein gene coding sequences operatively associated with the appropriate transcriptional and translational control signals of the characterizing gene. These methods include, for example, *in vitro* recombinant DNA techniques and *in vivo* genetic recombination. See, for example, the techniques described in Sambrook *et al.*, 2001, *Molecular Cloning, A Laboratory Manual*, Third Edition, Cold Spring Harbor Laboratory Press, N.Y.; and Ausubel *et al.*, 1989, *Current Protocols in Molecular Biology*, Green Publishing Associates and Wiley Interscience, N.Y., both of which are hereby incorporated by reference in their entireties.

The tagged ribosomal protein gene coding sequences may be incorporated into some or all of the characterizing gene sequences such that the tagged ribosomal protein gene is expressed in substantially same expression pattern as the endogenous characterizing gene in the transformed organism, or at least in an anatomical region or tissue of the organisms (by way of example, in the brain, spinal chord, heart, skin, bones, head, limbs, blood, muscle, peripheral nervous system, etc. of an animal) containing the population of cells to be marked by expression of the tagged ribosomal protein gene coding sequences. By "substantially the same expression pattern" is meant that the tagged ribosomal protein gene coding sequences are expressed in at least 80%, 85%, 90%, 95%, and preferably 100% of the cells shown to express the endogenous characterizing gene by *in situ* hybridization. Because detection of the tagged ribosomal protein gene expression product may be more sensitive than *in situ* hybridization detection of the endogenous characterizing gene messenger RNA, more cells may be detected to express the tagged ribosomal protein gene

product in the transformed organism than are detected to express the endogenous characterizing gene by in situ hybridization or any other method known in the art for in situ detection of gene expression.

For example, the nucleotide sequences encoding the tagged ribosomal protein gene
5 protein product may replace the characterizing gene coding sequences in a genomic clone of the characterizing gene, leaving the characterizing gene regulatory non-coding sequences. In other embodiments, the tagged ribosomal protein gene coding sequences (either genomic or cDNA sequences) replace all or a portion of the characterizing gene coding sequence and the nucleotide sequence only contains the upstream and downstream characterizing gene
10 regulatory sequences.

In a preferred embodiment, the tagged ribosomal protein gene coding sequences are inserted into or replace transcribed coding or non-coding sequences of the genomic characterizing gene sequences, for example, into or replacing a region of an exon or of the 3' UTR of the characterizing gene genomic sequence. Preferably, the tagged ribosomal
15 protein gene coding sequences are not inserted into or replace regulatory sequences of the genomic characterizing gene sequences. Preferably, the tagged ribosomal protein gene coding sequences are also not inserted into or replace characterizing gene intron sequences.

In a preferred embodiment, the tagged ribosomal protein gene coding sequence is inserted into or replaces a portion of the 3' untranslated region (UTR) of the characterizing
20 gene genomic sequence. In another preferred embodiment, the coding sequence of the characterizing gene is mutated or disrupted to abolish characterizing gene expression from the nucleic acid construct without affecting the expression of the tagged ribosomal protein gene. In certain embodiments, the tagged ribosomal protein gene coding sequence has its own internal ribosome entry site (IRES). For descriptions of IRESes, *see, e.g.,* Jackson *et al.*, 1990, Trends Biochem Sci. 15(12):477-83; Jang *et al.*, 1988, J. Virol. 62(8):2636-43; Jang *et al.*, 1990, Enzyme 44(1-4):292-309; and Martinez-Salas, 1999, Curr. Opin.
25 Biotechnol. 10(5):458-64.

In another embodiment, the tagged ribosomal protein gene is inserted at the 3' end of the characterizing gene coding sequence. In a specific embodiment, the tagged ribosomal
30 protein coding sequences are introduced at the 3' end of the characterizing gene coding sequence such that the nucleotide sequence encodes a fusion of the characterizing gene and the tagged ribosomal protein gene sequences.

Preferably, the tagged ribosomal protein gene coding sequences are inserted using 5' direct fusion wherein the tagged ribosomal protein gene coding sequences are inserted in-
35 frame adjacent to the initial ATG sequence (or adjacent the nucleotide sequence encoding

the first two, three, four, five, six, seven or eight amino acids of the characterizing gene protein product) of the characterizing gene, so that translation of the inserted sequence produces a fusion protein of the first methionine (or first few amino acids) derived from the characterizing gene sequence fused to the tagged ribosomal protein gene protein. In this embodiment, the characterizing gene coding sequence 3' of the tagged ribosomal protein gene coding sequences are not expressed. In yet another specific embodiment, a tagged ribosomal protein gene is inserted into a separate cistron in the 5' region of the characterizing gene genomic sequence and has an independent IRES sequence.

In certain embodiments, an IRES is operably linked to the tagged ribosomal protein gene coding sequence to direct translation of the tagged ribosomal protein gene. The IRES permits the creation of polycistronic mRNAs from which several proteins can be synthesized under the control of an endogenous transcriptional regulatory sequence. Such a construct is advantageous because it allows marker proteins to be produced in the same cells that express the endogenous gene (Heintz, 2000, Hum. Mol. Genet. 9(6): 937-43; Heintz *et al.*, WO 98/59060; Heintz *et al.*, WO 01/05962; which are incorporated herein by reference in their entireties).

Shuttle vectors containing an IRES, such as the pLD53 shuttle vector (see Heintz *et al.*, WO 01/05962), may be used to insert the tagged ribosomal protein gene sequence into the characterizing gene. The IRES in the pLD53 shuttle vector is derived from EMCV (encephalomyocarditis virus) (Jackson *et al.*, 1990, Trends Biochem Sci. 15(12):477-83; and Jang *et al.*, 1988, J. Virol. 62(8):2636-43, both of which are hereby incorporated by reference). The common sequence between the first and second IRES sites in the shuttle vector is shown below. This common sequence also matches pIRES (Clontech) from 1158-1710.

TAACGTTACTGGCCGAAGCCGCTTGGGAATAAGGCCGGTGTGCGTTTGTCTATAT
GTTATTTTCCACCATATTGCCGTCTTTTGGCAATGTGAGGGCCCGGAAACCTGG
CCCTGTCTTCTTGACGAGCATTCTAGGGGTCTTTCCCTCTCGCCAAAGGAATG
CAAGGTCTGTTGAATGTCGTGAAGGAAGCAGTTCCTCTGGAAGCTTCTTGAAGA
CAAACAACGTCTGTAGCGACCCTTTGCAGGCAGCGGAACCCCCACCTGGCGA
CAGGTGCCTCTGCGGCCAAAAGCCACGTGTATAAGATACACCTGCAAAGGCGG
CACAACCCAGTGCCACGTTGTGAGTTGGATAGTTGTGGAAAGAGTCAAATGG
CTCTCCTAAGCGTATTCAACAAGGGGCTGAAGGATGCCCAGAAGGTACTCCATT
GTATGGGATCTGATCTGGGGCCTCGGTGCACATGCTTTACATGTGTTTAGTCGA
GGTTAAAAAACGTCTAGGCCCCCGAACCACGGGGACGTGGTTTTCTTTGAA
AAACACCATGATA (SEQ ID NO: 6)

In a specific embodiment, the EMCV IRES is used to direct independent translation of the tagged ribosomal protein gene coding sequences (Gorski and Jones, 1999, *Nucleic Acids Research* 27(9):2059-61).

5 In another embodiment, more than one IRES site is present in a nucleic acid of the invention to direct translation of more than one coding sequence. However, in this case, each IRES sequence must be a different sequence.

In certain embodiments where a tagged ribosomal protein gene is expressed conditionally, the tagged ribosomal protein gene coding sequence is embedded in the genomic sequence of the characterizing gene and is inactive unless acted on by a
10 transactivator or recombinase, whereby expression of the tagged ribosomal protein gene can then be driven by the characterizing gene regulatory sequences.

In other embodiments the tagged ribosomal protein gene is expressed conditionally, through the activity of a gene that is an activator or suppressor of gene expression. In this case, the gene encodes a transactivator, e.g., tetR, or a recombinase, e.g., FLP, whose
15 expression is regulated by the characterizing gene regulatory sequences. The tagged ribosomal protein gene is linked to a conditional element, e.g., the tet promoter, or is flanked by recombinase sites, e.g., FRT sites, and may be located any where within the genome. In such a system, expression of the transactivator gene, as regulated by the characterizing gene regulatory sequences, activates the expression of the tagged ribosomal
20 protein gene.

In certain embodiments, exogenous translational control signals, including, for example, the ATG initiation codon, can be provided by the characterizing gene or some other heterologous gene. The initiation codon must be in phase with the reading frame of the desired coding sequence of the tagged ribosomal protein gene to ensure translation of
25 the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (see Bittner *et al.*, 1987, *Methods in Enzymol.* 153: 516-44).

The construct can also comprise one or more selectable markers that enable
30 identification and/or selection of recombinant vectors. The selectable marker may be the tagged ribosomal protein gene product itself or an additional selectable marker not necessarily tied to the expression of the characterizing gene.

In a specific embodiment, a nucleic acid of the invention is expressed conditionally, using any type of inducible or repressible system available for conditional expression of
35 genes known in the art, e.g., a system inducible or repressible by tetracycline ("tet system");

interferon; estrogen, ecdysone, or other steroid inducible system; Lac operator, progesterone antagonist RU486, or rapamycin (FK506). For example, a conditionally expressible nucleic acid of the invention can be created in which the coding region for the tagged ribosomal protein gene (and, optionally also the characterizing gene) is operably linked to a genetic switch, such that expression of the tagged ribosomal protein gene can be further regulated. One example of this type of switch is a tetracycline-based switch (see *infra*). In a specific embodiment, the tagged ribosomal protein gene product is the conditional enhancer or suppressor which, upon expression, enhances or suppresses expression of a selectable or detectable marker present either in the nucleic acid of the invention or elsewhere in the genome of the transformed organism.

A conditionally expressible nucleic acid of the invention can be site-specifically inserted into an untranslated region (UTR) of genomic DNA of the characterizing gene, *e.g.*, the 3' UTR or the 5' region, so that expression of the nucleic acid via the conditional expression system is induced or abolished by administration of the inducing or repressing substance, *e.g.*, administration of tetracycline or doxycycline, ecdysone, estrogen, etc., without interfering with the normal profile of gene expression (see, *e.g.*, Bond *et al.*, 2000, Science 289: 1942-46; incorporated herein by reference in its entirety). In the case of a binary system, the detectable or selectable marker operably linked to the conditional expression elements is present in the nucleic acid of the invention, but outside the characterizing gene coding sequences and not operably linked to characterizing gene regulatory sequences or, alternatively, on another site in the genome of the transformed organism.

Preferably, the nucleic acid of the invention comprises all or a significant portion of the genomic characterizing gene, preferably, at least all or a significant portion of the 5' regulatory sequences of the characterizing gene, most preferably, sufficient sequence 5' of the characterizing gene coding sequence to direct expression of the tagged ribosomal protein gene coding sequences in the same expression pattern (temporal and/or spatial) as the endogenous counterpart of the characterizing gene. In certain embodiments, the nucleic acid of the invention comprises one exon, two exons, all but one exon, or all but two exons, of the characterizing gene.

Nucleic acids comprising the characterizing gene sequences and tagged ribosomal protein gene coding sequences can be obtained from any available source. In most cases, all or a portion of the characterizing gene sequences and/or the tagged ribosomal protein gene coding sequences are known, for example, in publicly available databases such as GenBank, UniGene and the Mouse Genome Informatic (MGI) Database to name just a few, or in

private subscription databases. With a portion of the sequence in hand, hybridization probes (for filter hybridization or PCR amplification) can be designed using highly routine methods in the art to identify clones containing the appropriate sequences (preferred methods for identifying appropriate BACs are discussed in Section 5.7.1, *supra*) for example in a library or other source of nucleic acid. If the sequence of the gene of interest from one species is known and the counterpart gene from another species is desired, it is routine in the art to design probes based upon the known sequence. The probes hybridize to nucleic acids from the species from which the sequence is desired, for example, hybridization to nucleic acids from genomic or DNA libraries from the species of interest.

By way of example and not limitation, genomic clones can be identified by probing a genomic DNA library under appropriate hybridization conditions, *e.g.*, high stringency conditions, low stringency conditions or moderate stringency conditions, depending on the relatedness of the probe to the genomic DNA being probed. For example, if the probe and the genomic DNA are from the same species, then high stringency hybridization conditions may be used; however, if the probe and the genomic DNA are from different species, then low stringency hybridization conditions may be used. High, low and moderate stringency conditions are all well known in the art.

Procedures for low stringency hybridization are as follows (see also Shilo and Weinberg, 1981, Proc. Natl. Acad. Sci. USA 78:6789-6792): Filters containing DNA are pretreated for 6 hours at 40°C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0.1% PVP, 0.1% Ficoll, 1% BSA, and 500 µg/ml denatured salmon sperm DNA. Hybridizations are carried out in the same solution with the following modifications: 0.02% PVP, 0.02% Ficoll, 0.2% BSA, 100 µg/ml salmon sperm DNA, 10% (wt/vol) dextran sulfate, and 5-20 X 10⁶ cpm ³²P-labeled probe is used. Filters are incubated in hybridization mixture for 18-20 hours at 40°C, and then washed for 1.5 hours at 55°C in a solution containing 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS. The wash solution is replaced with fresh solution and incubated an additional 1.5 hours at 60°C. Filters are blotted dry and exposed for autoradiography. If necessary, filters are washed for a third time at 65-68°C and reexposed to film.

Procedures for high stringency hybridizations are as follows: Prehybridization of filters containing DNA is carried out for 8 hours to overnight at 65°C in buffer composed of 6X SSC, 50 mM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% Ficoll, 0.02% BSA, and 500 µg/ml denatured salmon sperm DNA. Filters are hybridized for 48 hours at 65°C in prehybridization mixture containing 100 µg/ml denatured salmon sperm DNA and 5-20 X 10⁶ cpm of ³²P-labeled probe. Washing of filters is done at 37°C for 1 hour in a solution

containing 2X SSC, 0.01% PVP, 0.01% Ficoll, and 0.01% BSA. This is followed by a wash in 0.1 X SSC at 50°C for 45 minutes before autoradiography.

Moderate stringency conditions for hybridization are as follows: Filters containing DNA are pretreated for 6 hours at 55°C in a solution containing 6X SSC, 5X Denhardt's solution, 0.5% SDS, and 100 µg/ml denatured salmon sperm DNA. Hybridizations are carried out in the same solution and 5-20 X 10⁶ CPM ³²P-labeled probe is used. Filters are incubated in the hybridization mixture for 18-20 hours at 55°C, and then washed twice for 30 minutes at 60°C in a solution containing 1 X SSC and 0.1% SDS.

With respect to the characterizing gene, all or a portion of the genomic sequence is preferred, particularly, the sequences 5' of the coding sequence that contain the regulatory sequences. A preferred method for identifying BACs containing appropriate and sufficient characterizing gene sequences to direct the expression of the tagged ribosomal protein gene coding sequences in substantially the same expression pattern as the endogenous characterizing gene is described in Section 5.7.1, *supra*.

Briefly, the characterizing gene genomic sequences are preferably in a vector that can accommodate significant lengths of sequence (for example, 10 kb's of sequence), such as cosmids, YACs, and, preferably, BACs, and encompass at least 50, 70, 80, 100, 120, 150, 200, 250 or 300 kb of sequence that comprises all or a portion of the characterizing gene sequence. The larger the vector insert, the more likely it is to identify a vector that contains the characterizing gene sequences of interest. Vectors identified as containing characterizing gene sequences can then be screened for those that are most likely to contain sufficient regulatory sequences from the characterizing gene to direct expression of the tagged ribosomal protein gene coding sequences in substantially the same pattern as the endogenous characterizing gene. In general, it is preferred to have a vector containing the entire genomic sequence for the characterizing gene. However, in certain cases, the entire genomic sequence cannot be accommodated by a single vector or such a clone is not available. In these instances (or when it is not known whether the clone contains the entire genomic sequence), preferably the vector contains the characterizing gene sequence with the start, *i.e.*, the most 5' end, of the coding sequence in the approximate middle of the vector insert containing the genomic sequences and/or has at least 20 kb, 30 kb, 40 kb, 50 kb, 60 kb, 80 kb or 100 kb of genomic sequence on either side of the start of the characterizing gene coding sequence. This can be determined by any method known in the art, for example, but not by way of limitation, by sequencing, restriction mapping, PCR amplification assays, etc. In certain cases, the clones used may be from a library that has been characterized (*e.g.*, by sequencing and/or restriction mapping) and the clones identified

can be analyzed, for example, by restriction enzyme digestion and compared to database information available for the library. In this way, the clone of interest can be identified and used to query publicly available databases for existing contigs correlated with the characterizing gene coding sequence start site. Such information can then be used to map
5 the characterizing gene coding sequence start site within the clone. Alternatively, the tagged ribosomal protein gene sequences (or any other heterologous sequences) can be targeted to the 5' end of the characterizing gene coding sequence by directed homologous recombination (for example as described in Section 5.7) in such a way that a restriction site unique or at least rare in the characterizing gene clone sequence is introduced. The position
10 of the integrated tagged ribosomal protein gene coding sequences (and, thus, the 5' end of the characterizing gene coding sequence) can be mapped by restriction endonuclease digestion and mapping. The clone may also be mapped using internally generated fingerprint data and/or by an alternative mapping protocol based upon the presence of restriction sites and the T7 and SP6 promoters in the BAC vector, as described in Section
15 5.7.1, *supra*.

In certain embodiments, the tagged ribosomal protein gene coding sequences are to be inserted in a site in the characterizing gene sequences other than the 5' start site of the characterizing gene coding sequences, for example, in the 3' most translated or untranslated regions. In these embodiments, the clones containing the characterizing gene should be
20 mapped to insure the clone contains the site for insertion in as well as sufficient sequence 5' of the characterizing gene coding sequences library to contain the regulatory sequences necessary to direct expression of the tagged ribosomal protein gene sequences in the same expression pattern as the endogenous characterizing gene.

Once such an appropriate vector containing the characterizing gene sequences, the
25 tagged ribosomal protein gene can be incorporated into the characterizing gene sequence by any method known in the art for manipulating DNA. In a preferred embodiment, homologous recombination in bacteria is used for target-directed insertion of the tagged ribosomal protein gene sequence into the genomic DNA encoding the characterizing gene and sufficient regulatory sequences to promote expression of the characterizing gene in its
30 endogenous expression pattern, which characterizing gene sequences have been inserted into a BAC (see Section 5.7.1, *supra*). The BAC comprising the tagged ribosomal protein gene and characterizing gene sequences is then introduced into the genome of a potential founder organism for generating a line of transformed organisms, using methods well known in the art, *e.g.*, those methods described in Section 5.7, *supra*. Such transformed
35 organisms are then screened for expression of the tagged ribosomal protein gene coding

sequences that mimics the expression of the endogenous characterizing gene. Several different constructs containing nucleic acids of the invention may be introduced into several potential founder organisms and the resulting transformed organisms are then screened for the best, (*e.g.*, highest level) and most accurate (best mimicking expression of the endogenous characterizing gene) expression of the tagged ribosomal protein gene coding sequences.

The nucleic acid construct can be used to transform a host or recipient cell or organism using well known methods, *e.g.*, those described in Section 5.6, *supra*.

Transformation can be either a permanent or transient genetic change, preferably a permanent genetic change, induced in a cell following incorporation of new DNA (*i.e.*, DNA exogenous to the cell). Where the cell is a mammalian cell, a permanent genetic change is generally achieved by introduction of the DNA into the genome of the cell. In one aspect of the invention, a vector is used for stable integration of the nucleic acid construct into the genome of the cell. Vectors include plasmids, retroviruses and other animal viruses, BACs, YACs, and the like.

5.11. EXPRESSION USING A BINARY SYSTEM

Since the level of expression of the tagged ribosomal protein within a cell may be important in the efficiency of the isolation procedure, in certain embodiments of the invention, a binary system can be used, in which the endogenous promoter drives expression of a protein that then activates a second expression construct. This second expression construct uses a strong promoter to drive expression of the tagged ribosomal protein at higher levels than is possible using the endogenous promoter itself.

In certain embodiments, a particular population-specific gene drives expression of a molecular switch (*e.g.*, a recombinase, a transactivator) in a population-specific manner. This switch then activates high-level expression through a second regulatory element regulating expression of the tagged ribosomal protein.

For example, the molecularly tagged ribosomal protein coding sequence may be expressed conditionally, through the activity of a molecular switch gene which is an activator or suppressor of gene expression. In this case, the second gene encodes a transactivator, *e.g.*, tetR, a recombinase, or FLP, whose expression is regulated by the characterizing gene regulatory sequences. The gene encoding the molecularly tagged ribosomal protein is linked to a conditional element, *e.g.*, the tet promoter, or is flanked by recombinase sites, *e.g.*, FRT sites, and may be located any where within the genome. In

such a system, expression of the molecular switch gene, as regulated by the characterizing gene regulatory sequences, activates the expression of the molecular tag.

5.12. CONDITIONAL TRANSCRIPTIONAL REGULATION SYSTEMS

5 In certain embodiments, the tagged ribosomal protein gene can be expressed conditionally by operably linking at least the coding region for the tagged ribosomal protein gene to all or a portion of the regulatory sequences from the characterizing gene, and then operably linking the tagged ribosomal protein gene coding sequences and characterizing gene sequences to an inducible or repressible transcriptional regulation system.

10 Transactivators in these inducible or repressible transcriptional regulation systems are designed to interact specifically with sequences engineered into the vector. Such systems include those regulated by tetracycline ("tet systems"), interferon, estrogen, ecdysone, Lac operator, progesterone antagonist RU486, and rapamycin (FK506) with tet systems being particularly preferred (see, e.g., Gingrich and Roder, 1998, Annu. Rev.

15 Neurosci. 21: 377-405; incorporated herein by reference in its entirety). These drugs or hormones (or their analogs) act on modular transactivators composed of natural or mutant ligand binding domains and intrinsic or extrinsic DNA binding and transcriptional activation domains. In certain embodiments, expression of the detectable or selectable marker can be regulated by varying the concentration of the drug or hormone in medium *in vitro* or in the diet of the transformed organism *in vivo*.

The inducible or repressible genetic system can restrict the expression of the detectable or selectable marker either temporally, spatially, or both temporally and spatially.

In a preferred embodiment, the control elements of the tetracycline-resistance operon of *E. coli* is used as an inducible or repressible transactivator or transcriptional regulation
25 system ("tet system") for conditional expression of the detectable or selectable marker. A tetracycline-controlled transactivator can require either the presence or absence of the antibiotic tetracycline, or one of its derivatives, e.g., doxycycline (dox), for binding to the tet operator of the tet system, and thus for the activation of the tet system promoter (Ptet). Such an inducible or repressible tet system is preferably used in a mammalian cell.

30 In a specific embodiment, a tetracycline-repressed regulatable system (TrRS) is used (Agha-Mohammadi and Lotze, 2000, J. Clin. Invest. 105(9): 1177-83; incorporated herein by reference in its entirety). This system exploits the specificity of the tet repressor (tetR) for the tet operator sequence (tetO), the sensitivity of tetR to tetracycline, and the activity of the potent herpes simplex virus transactivator (VP16) in eukaryotic cells. The TrRS uses a
35 conditionally active chimeric tetracycline-repressed transactivator (tTA) created by fusing

the COOH-terminal 127 amino acids of vision protein 16 (VP16) to the COOH terminus of the tetR protein (which may be the tagged ribosomal protein gene). In the absence of tetracycline, the tetR moiety of tTA binds with high affinity and specificity to a tetracycline-regulated promoter (tRP), a regulatory region comprising seven repeats of tetO placed
5 upstream of a minimal human cytomegalovirus (CMV) promoter or β -actin promoter (β -actin is preferable for neural expression). Once bound to the tRP, the VP16 moiety of tTA transactivates the detectable or selectable marker gene by promoting assembly of a transcriptional initiation complex. However, binding of tetracycline to tetR leads to a conformational change in tetR accompanied with loss of tetR affinity for tetO, allowing
10 expression of the tagged ribosomal protein gene to be silenced by administering tetracycline. Activity can be regulated over a range of orders of magnitude in response to tetracycline.

In another specific embodiment, a tetracycline-induced regulatable system is used to regulate expression of a detectable or selectable marker, *e.g.*, the tetracycline transactivator
15 (tTA) element of Gossen and Bujard (1992, Proc. Natl. Acad. Sci. USA 89: 5547-51; incorporated herein by reference in its entirety).

In another specific embodiment, the improved tTA system of Shockett *et al.* (1995, Proc. Natl. Acad. Sci. USA 92: 6522-26, incorporated herein by reference in its entirety) is used to drive expression of the marker. This improved tTA system places the tTA gene
20 under control of the inducible promoter to which tTA binds, making expression of tTA itself inducible and autoregulatory.

In another embodiment, a reverse tetracycline-controlled transactivator, *e.g.*, rtTA2 S-M2, is used. rtTA2 S-M2 transactivator has reduced basal activity in the absence doxycycline, increased stability in eukaryotic cells, and increased doxycycline sensitivity
25 (Urlinger *et al.*, 2000, Proc. Natl. Acad. Sci. USA 97(14): 7963-68; incorporated herein by reference in its entirety).

In another embodiment, the tet-repressible system described by Wells *et al.* (1999, Transgenic Res. 8(5): 371-81; incorporated herein by reference in its entirety) is used. In one aspect of the embodiment, a single plasmid Tet-repressible system is used. Preferably,
30 a "mammalianized" TetR gene, rather than a wild-type TetR gene (tetR) is used (Wells *et al.*, 1999, Transgenic Res. 8(5): 371-81).

In other embodiments, expression of the tagged ribosomal protein gene is regulated by using a recombinase system that is used to turn on or off tagged ribosomal protein gene expression by recombination in the appropriate region of the genome in which the marker
35 gene is inserted. Such a recombinase system, in which a gene that encodes a recombinase

can be used to turn on or off expression of the tagged ribosomal protein gene (for review of temporal genetic switches and “tissue scissors” using recombinases, see Hennighausen and Furth, 1999, *Nature Biotechnol.* 17: 1062-63). Exclusive recombination in a selected cell type may be mediated by use of a site-specific recombinase such as Cre, FLP-wild type (wt), FLP-L or FLPe. Recombination may be effected by any art-known method, *e.g.*, the method of Doetschman *et al.* (1987, *Nature* 330: 576-78; incorporated herein by reference in its entirety); the method of Thomas *et al.*, (1986, *Cell* 44: 419-28; incorporated herein by reference in its entirety); the Cre-loxP recombination system (Sternberg and Hamilton, 1981, *J. Mol. Biol.* 150: 467-86; Lakso *et al.*, 1992, *Proc. Natl. Acad. Sci. USA* 89: 6232-36; which are incorporated herein by reference in their entireties); the FLP recombinase system of *Saccharomyces cerevisiae* (O’Gorman *et al.*, 1991, *Science* 251: 1351-55); the Cre-loxP-tetracycline control switch (Gossen and Bujard, 1992, *Proc. Natl. Acad. Sci. USA* 89: 5547-51); and ligand-regulated recombinase system (Kellendonk *et al.*, 1999, *J. Mol. Biol.* 285: 175-82; incorporated herein by reference in its entirety). Preferably, the recombinase is highly active, *e.g.*, the Cre-loxP or the FLPe system, and has enhanced thermostability (Rodríguez *et al.*, 2000, *Nature Genetics* 25: 139-40; incorporated herein by reference in its entirety).

In certain embodiments, a recombinase system can be linked to a second inducible or repressible transcriptional regulation system. For example, a cell-specific Cre-loxP mediated recombination system (Gossen and Bujard, 1992, *Proc. Natl. Acad. Sci. USA* 89: 5547-51) can be linked to a cell-specific tetracycline-dependent time switch detailed above (Ewald *et al.*, 1996, *Science* 273: 1384-1386; Furth *et al.* *Proc. Natl. Acad. Sci. U.S.A.* 91: 9302-06 (1994); St-Onge *et al.*, 1996, *Nucleic Acids Research* 24(19): 3875-77; which are incorporated herein by reference in their entireties).

In one embodiment, an altered *cre* gene with enhanced expression in mammalian cells is used (Gorski and Jones, 1999, *Nucleic Acids Research* 27(9): 2059-61; incorporated herein by reference in its entirety).

In a specific embodiment, the ligand-regulated recombinase system of Kellendonk *et al.* (1999, *J. Mol. Biol.* 285: 175-82; incorporated herein by reference in its entirety) can be used. In this system, the ligand-binding domain (LBD) of a receptor, *e.g.*, the progesterone or estrogen receptor, is fused to the Cre recombinase to increase specificity of the recombinase.

5.13. METHODS OF SCREENING FOR EXPRESSION OF MOLECULARLY TAGGED RIBOSOMAL PROTEIN CODING SEQUENCES

In preferred embodiments, the invention provides a collection of lines of transformed organisms that contain a selected subset of cells or cell population expressing molecularly-tagged ribosomes. The collection comprises at least two individual lines, preferably at least five individual lines. Each individual line is selected for the collection based on the identity of the subset of cells in which the molecularly tagged ribosomes are expressed.

Potential founder organisms for a line of transformed organisms can be screened for expression of the molecularly tagged ribosomal protein coding sequence by ribosomes in the population of cells characterized by expression of the endogenous characterizing gene.

Transformed organisms that exhibit appropriate expression (*e.g.*, detectable expression having substantially the same expression pattern as the endogenous characterizing gene in a corresponding non-transformed organism or anatomical region thereof, *i.e.*, detectable expression in at least 80%, 90% or, preferably, 95% of the cells shown to express the endogenous gene by *in situ* hybridization) are selected as lines of transformed organisms.

In a preferred embodiment, immunohistochemistry using an antibody specific for the molecular tag or a marker activated or repressed thereby is used to detect expression of the molecular tag.

5.14. PROFILING OF mRNA SPECIES

Once isolated, the mRNA bound by the tagged ribosomal proteins or mRNA binding proteins of the invention can be analyzed by any method known in the art. In one aspect of the invention, the gene expression profile of cells expressing the tagged ribosomal proteins or mRNA binding proteins is analyzed using any number of methods known in the art, for example but not by way of limitation, by isolating the mRNA and constructing cDNA libraries or by labeling the RNA for gene expression analysis.

In a preferred embodiment, poly-A⁺ RNA (mRNA) is isolated from the tagged ribosomal proteins or mRNA binding proteins of the invention, and converted to cDNA through a reverse transcription reaction primed by a first primer that comprises an oligo-dT sequence. The first primer is contacted with the poly-A⁺ RNA under conditions that allow the oligo-dT site to hybridize to the first selected sequence (*i.e.*, the poly-A sequence).

Alternatively, the first primer comprises a sequence that is the reverse complement of a specific selected sequence (for example, a sequence characteristic of a family of mRNAs).

The first primer is then used to prime synthesis of a first-strand cDNA by reverse transcription of the source single-stranded nucleic acid. When the source nucleic acid is mRNA, a RNA-dependent DNA polymerase activity is required to convert the primer-source mRNA hybrid to a first-strand cDNA- source mRNA hybrid. A reverse transcriptase can be used to catalyze RNA-dependent DNA polymerase activity.

Reverse transcriptase is found in all retroviruses and is commonly derived from Moloney murine leukemia virus (M-MLV-RT), avian myeloblastosis virus (AMV-RT), bovine leukemia virus (BLV-RT), Rous sarcoma virus (RSV-RT), and human immunodeficiency virus (HIV-RT); enzymes from these sources are commercially available (*e.g.*, Life Technologies-Gibco BRL, Rockville, MD; Roche Molecular Biochemicals, Indianapolis, IN; PanVera, Madison WI).

A single reverse transcriptase or a combination of two or more reverse transcriptases (*e.g.*, M-MLV-RT and AMV-RT) can be used to catalyze reverse transcription and first-strand cDNA synthesis. Such reverse transcriptases are used to convert a primer-single-stranded nucleic acid (mRNA) hybrid to a first-strand cDNA-primer-single-stranded nucleic acid hybrid in the presence of additional reagents that include, but are not limited to: dNTPs; monovalent and divalent cations, *e.g.*, KCl, MgCl₂ ; sulfhydryl reagents, *e.g.*, dithiothreitol (DTT); and buffering agents, *e.g.*, Tris-Cl.

As described below (second-strand cDNA synthesis), the catalytic activities required to convert a first-strand cDNA-single-stranded nucleic acid hybrid to ds cDNA are an RNase H activity and a DNA-dependent DNA polymerase activity. Most reverse transcriptases, such as the ones described above (*i.e.*, M-MLV-RT, AMV-RT, BLV-RT, RSV-RT, and HIV-RT) also catalyze each of these activities. Therefore, in certain embodiments, the reverse transcriptase employed for first-strand cDNA synthesis remains in the reaction mixture where it can also serve to catalyze second-strand cDNA synthesis. Alternatively, a variety of proteins that catalyze one or two of these activities can be added to the cDNA synthesis reaction. Such proteins may be added together during a single reaction step, or added sequentially during two or more substeps.

Preferably a reverse transcriptase lacking RNase H activity is used, in particular when long transcripts are desired. For example, M-MLV reverse transcriptase lacking RNase H activity (Kotewicz *et al.*, U.S. Patent No. 5,405,776, issued April 11, 1995; commercially available as SUPERScript II™ (Life Technologies - Gibco BRL) can be used to catalyze both RNA-dependent DNA polymerase activity and DNA-dependent DNA

polymerase activity. In a preferred embodiment, SUPERScript II™ (Life Technologies - Gibco BRL) is used as a source of DNA polymerase activity. This DNA polymerase can be used to synthesize a complementary DNA strand from single-stranded RNA, DNA, or an RNA:DNA hybrid. SUPERScript II™ is genetically engineered by the introduction of point mutations that greatly reduce its RNase H activity but preserve full DNA polymerase activity. The structural modification of the enzyme therefore eliminates almost all degradation of RNA molecules during first-strand cDNA synthesis.

In certain embodiments, the reverse transcriptase is inactivated after first-strand synthesis. The reverse transcriptase may be rendered inactive using any convenient protocol. The transcriptase may be irreversibly or reversibly rendered inactive. Where the transcriptase is reversibly rendered inactive, the transcriptase is physically or chemically altered so as to no longer be able to catalyze RNA-dependent DNA polymerase activity.

The reverse transcriptase may be irreversibly inactivated by any convenient means. In certain embodiments, the reverse transcriptase is heat inactivated. The reaction mixture is subjected to heating to a temperature sufficient to inactivate the reverse transcriptase prior to commencement of the transcription step. In these embodiments, the temperature of the reaction mixture, and therefore the reverse transcriptase present therein, is typically raised to 55°C to 70°C for 5 to 60 minutes, preferably to about 65°C for 15 minutes. In a preferred embodiment, the transcriptase is inactivated by adding 1M KOH to the reaction mixture, preferably to make a final concentration of 50 mM KOH in the reaction mixture, and by incubating at 65°C for 15 min prior to commencement of the transcription step. This step ensures that contaminating non-poly-A RNA is removed from the sample, making the subsequent tailing reaction more efficient.

Alternatively, reverse transcriptase may irreversibly inactivated by introducing a reagent into the reaction mixture that chemically alters the protein so that it no longer has RNA-dependent DNA polymerase activity.

In a preferred embodiment, the reverse transcription reaction to synthesize the first-strand cDNA proceeds at 42°C for 30-40 min using SUPERScript II™ as the source of reverse transcriptase / DNA polymerase.

The transcribed first-strand cDNA may be isolated from the source RNA to which it is hybridized by any of wide variety of established methods. For example, the isolation method may involve treating the RNA with a nuclease such as RNase H, a denaturant such as heat or an alkali, etc., and/or separating the strands by electrophoresis. The second strand of cDNA can be synthesized using methods well known in the art, for example using

reverse transcriptase which primes from the hairpin loop structure that forms at the 3' end of the first strand of cDNA.

Gene expression in cells treated and not treated with a compound of interest or in cells from animals treated or untreated with a particular treatment, *e.g.*, pharmaceutical or surgical treatment, may be compared. In addition, mRNA bound by the tagged ribosomal proteins or mRNA binding proteins may also be analyzed, for example by northern blot analysis, PCR, RNase protection, etc., for the presence of mRNAs encoding certain protein products and for changes in the presence or levels of these mRNAs depending on the treatment of the cells. In specific embodiments, the mRNA is isolated from different populations of cells or from populations of cells exposed to different stimuli.

In another aspect, mRNA bound by the tagged ribosomal proteins or mRNA binding proteins may be used to produce a cDNA library and, in fact, a collection of such cell type specific cDNA libraries may be generated from different populations of isolated cells. Such cDNA libraries are useful to analyze gene expression, isolate and identify cell type-specific genes, splice variants and non-coding RNAs. In another aspect, such cell-type specific libraries prepared from mRNA bound by, and isolated from, the tagged ribosomal proteins or mRNA binding proteins from treated and untreated transgenic animals of the invention or from transgenic animals of the invention having and not having a disease state can be used, for example in subtractive hybridization procedures, to identify genes expressed at higher or lower levels in response to a particular treatment or in a disease state as compared to untreated transgenic animals. The mRNA isolated from the tagged ribosomal proteins or mRNA binding proteins may also be analyzed using particular microarrays generated and analyzed by methods well known in the art. Gene expression analysis using microarray technology is well known in the art. Methods for making microarrays are taught, for example, in United States Patent No. 5,700,637 by Southern, United States Patent No. 5,510,270 by Fodor *et al.* and PCT publication WO 99/35293 by Albrecht *et al.*, which are incorporated by reference in their entireties. By probing a microarray with various populations of mRNAs, transcribed genes in certain cell populations can be identified. Moreover, the pattern of gene expression in different cell types of cell states may be readily compared.

Data from such analyses may be used to generate a database of gene expression analysis for different populations of cells in the animal or in particular tissues or anatomical regions, for example, in the brain. Using such a database together with bioinformatics tools, such as hierarchical and non-hierarchical clustering analysis and principal components

analysis, cells are "fingerprinted" for particular indications from healthy and disease-model animals or tissues.

In yet another embodiment, specific cells or cell populations that express a potential a molecularly tagged ribosomal protein or mRNA binding protein are isolated from the collection and analyzed for specific protein-protein interactions or an entire protein profile using proteomics methods known in the art, for example, chromatography, mass spectroscopy, 2D gel analysis, etc.

Other types of assays may be used to analyze the cell population expressing the molecularly tagged ribosomal protein or mRNA binding protein, either *in vivo*, in explanted or sectioned tissue or in the isolated cells, for example, to monitor the response of the cells to a certain treatment or candidate compound or to compare the response of the animals, tissue or cells to expression of the target or inhibitor thereof, with animals, tissue or cells from animals not expressing the target or inhibitor thereof. The cells may be monitored, for example, but not by way of limitation, for changes in electrophysiology, physiology (for example, changes in physiological parameters of cells, such as intracellular or extracellular calcium or other ion concentration, change in pH, change in the presence or amount of second messengers, cell morphology, cell viability, indicators of apoptosis, secretion of secreted factors, cell replication, contact inhibition, etc.), morphology, etc.

In particular embodiments, the isolated mRNA is used to probe a comprehensive expression library (see, *e.g.*, Serafini *et al.*, United States Patent No. 6,110,711, issued August 29, 2000, which is incorporated by reference herein). The library may be normalized and presented in a high density array. Because approximately one tenth of the mRNA species in a typical somatic cell constitute 50% to 65% of the mRNA present, the cDNA library may be normalized using reassociation-kinetics based methods. (See Soares, 1997, Curr. Opin. Biotechnol. 8:542-546).

In a particular embodiment, a subpopulation of cells expressing a molecularly tagged ribosomal protein or mRNA binding protein is identified and/or gene expression analyzed using the methods of Serafini *et al.*, WO 99/29877 entitled "Methods for defining cell types," which is hereby incorporated by reference in its entirety.

6. EXAMPLE 1: TAGGING OF RIBOSOMAL PROTEINS

6.1. ISOLATION OF RIBOSOMAL PROTEIN-ENCODING cDNAs

This example demonstrates the successful introduction of a Strep-tag into ribosomal subunit protein-encoding cDNAs.

Oligonucleotides complementary to the sequence of ribosomal subunit proteins, S6, and L37 were designed to permit PCR amplification of the cDNAs from reverse transcribed mRNA. EcoRI and NotI restrictions sites were incorporated into the 5' terminal ends of the 5' and 3' specific oligonucleotides to facility the subcloning of the amplified cDNAs into the expression vector pCDNA3.1+. The sequence of the oligonucleotide sets were as follows:

S6

5' oligo. GGAATTCATTCAAGATGAAGCTGAACATCTCCTTCCC (SEQ ID NO: 7)

3' oligo. GCGGCCGCTTTTCTGACTGGATTGAGACTTAGAAGTAGAAGCT (SEQ ID NO: 8)

L37

5' oligo. GGAATTCCTCGGCGACATGGCTAAACGCACCAAGAAGG (SEQ ID NO: 9)

3' oligo. GCGGCCGCTCTGGTCTTTCAGTTCCTTCAGTCTTCTGAT (SEQ ID NO: 10)

S20

5' oligo. GGAATTCGCGCGCAACAGCCATGGCTTTTAAGGATAC (SEQ ID NO: 11)

3' oligo. GCGGCCGCTAGCATCTGCAATGGTGACTTCCACCTCAAC (SEQ ID NO: 12)

L32

5' oligo. GGAATTCGGCATCATGGCTGCCCTTCGGCCTCTGGTG (SEQ ID NO: 13)

3' oligo. GCGGCCGCTTTCATTCTCTTCGCTGCGTAGCCTGGC (SEQ ID NO: 14)

Mouse brain cDNA (Clontech) was used as the template for a polymerase chain reaction (PCR). 50 mL PCR aliquots were prepared for each set of primer pairs. Each reaction consisted of 40 mL PCR-grade water, 5 mL 10X Advantage 2 PCR Buffer (Clontech), 1 mL mouse brain cDNA template, 1 mL each 5' and 3' oligonucleotide primer (10 mM), 1 mL dNTP mix (10 mM each dATP, dCTP, dTTP, and dGTP), and 1 mL 50X Advantage 2 Polymerase Mix.

The PCR reaction was carried out under the following conditions:

1. 95°C for 1 minute
2. 30 cycles of 95°C for 15 seconds and 68°C for 1 minute

10 mL of each reaction was analyzed by electrophoresis through a 1.2% agarose gel in TAE. The remainder of the reaction was purified using a QIAGEN QUICKSPIN PCR reaction purification kit following the manufacturer's protocol.

Purified DNA was digested with EcoRI and NotI followed by electrophoresis through a 1.2% agarose gel, isolation of the DNA fragment, and extraction of the DNA from the gel using a QIAGEN QUICKSPIN Gel isolation kit following the manufacturer's protocol.

Each cDNA fragment was ligated to pCDNA3.1+, which had been digested with EcoRI and NotI. Ligated DNA was used to transform chemically competent DH5a bacteria. Transformed bacteria were plated onto LB plates containing 100 mg/mL ampicillin. For each ligation, 3 ampicillin resistant colonies were picked, grown in 5 mL LB cultures containing 100 mg/mL ampicillin.

The cultures were incubated for 16 hours on a shaking platform at 37°C. Plasmid DNA was isolated from the cultures using a QIAGEN miniprep kit following the manufacturer's protocol. Plasmid DNA was digested with PmeI and analyzed on a 1.2% agarose gel to identify plasmids that contain the cDNA insert.

6.2. ADDITION OF STREP-TAG TO THE RIBOSOMAL SUBUNIT PROTEINS

The amino acid sequence Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO: 17) represents Strep-tag II, a peptide that is able to bind with high affinity to the protein Streptavidin. Proteins that contain the Strep-tag II can be identified and isolated through affinity to Streptavidin. Strep-tag II was added to each of the ribosomal subunit proteins, S6, S20, L32, and L37, at the C-terminus of the protein. Two complementary oligonucleotide adaptors were designed that encode for Strep-tag II. These complementary oligonucleotide adaptors, when hybridized to form a double stranded DNA, can be ligated in-frame to the ribosomal subunit cDNAs in the vector pCDNA3.1+.

The sequences of the Strep-tag II oligonucleotides were:

Upper strand oligonucleotide

5' GGCCGCAGCGCTTGGAGCCACCCGCAGTTCGAAAAATAA 3' (SEQ ID NO: 15)

Bottom strand oligonucleotide

5' TCGATTATTTTTCGAAGTGCAGGGTGGCTCCAAGCGCTGC 3' (SEQ ID NO: 16)

35

Each of the plasmids containing the ribosomal subunit protein-encoding cDNAs was digested with NotI and XhoI. The upper strand and bottom strand oligonucleotides were mixed in equal molar ratios, heated to 70°C, and allowed to cool to room temperature. The hybridized oligonucleotides were then ligated to the NotI and XhoI digested plasmids. The ligation reactions were transformed into competent DH5a bacteria and plated onto LB plates supplemented with 100 mg/mL ampicillin.

For each ligation, five ampicillin resistant colonies were picked into 5 mL LB cultures containing 100 mg/mL ampicillin. The cultures were grown at 37°C for 16 hours. Plasmid DNA was harvested, cut with PmeI, and analyzed by electrophoresis through 5% non denaturing polyacrylamide gels. Untagged ribosomal subunit protein encoding cDNAs were also digested with PmeI, and run side by side with the tagged versions to identify the cDNAs that contained the strep-tagII sequence. All tagged cDNAs were then sequenced to confirm the sequence of each cDNA.

7. EXAMPLE 2: ISOLATION AND IMMUNOPRECIPITATION OF POLYSOMES

7.1. POLYSOME ISOLATION

Plasmid constructs expressing tagged ribosomal proteins were transfected into Human Embryonic Kidney (HEK293) cells using the transfection reagent FuGENE 6 (Roche Applied Science) following the manufacturer's procedures. Briefly, for each transfection, 100 mL of serum free medium (DMEM) was placed into a sterile tube, followed by the addition of three mL of Fugene 6 and 1 mg of plasmid DNA. The Fugene 6/DNA mixture was allowed to incubate at room temperature for 15 minutes before being added to a 60 mm plate of HEK293 cells grown in DMEM supplemented with 10% fetal calf serum, glutamine, and antibiotics.

Three days after transfection, the cells were harvested by scraping into homogenization buffer (50 mM sucrose, 200 mM ammonium chloride, 7 mM magnesium acetate, 1 mM dithiothreitol, and 20 mM Tris-HCl, pH 7.6). The cells were lysed by the addition of the detergent, NP-40, to a concentration of 0.5% followed by five strokes in a glass dounce tissue homogenizer. Unlysed cells, nuclei and mitochondria were pelleted by centrifugation at 10,000Xg for 10 minutes, at 4°C. The supernatant was carefully removed and layered over a two-step discontinuous gradient of 1.8 M and 1.0M sucrose in 100 mM ammonium chloride, 5 mM magnesium acetate, 1 mM dithiothreitol, 20 mM Tris-HCl (pH 7.6). The gradient was centrifuged for 18 hours at 98,000Xg at 4°C.

Following centrifugation, the supernatants were carefully removed, and the polysome pellet was resuspended in 100 mM ammonium chloride, 5 mM magnesium chloride, 1 mM DTT and 20 mM Tris-HCl (pH 7.6).

An equal volume of 2X denaturing protein electrophoresis sample buffer was added to each of the polysome samples. Solubilized polysomal proteins were fractionated by electrophoresis through a SDS containing 4-20% gradient polyacrylamide gel, and transferred to a nitrocellulose filter. The filter was quenched for 1 hour in PBS containing 5% dry milk followed by incubation with rabbit antisera specific for the strep-tag II amino acid sequence epitope Trp-Ser-His-Pro-Gln-Phe-Glu-Lys (SEQ ID NO: 17). The filters were rinsed three times in PBS for 20 minutes each, followed by a one hour incubation with a goat anti-rabbit antisera that had been conjugated to horse radish peroxidase (HRP), in PBS containing 10% dry milk. The filters were then washed for three times in PBS. The HRP was detected by incubating the filter in 20 mL of PBS, containing 4-chloronaphtol and hydrogen peroxidase.

As seen in FIG. 1, polysomes from cells transfected with plasmids expressing tagged versions of ribosomal proteins S6 (lane 2, in duplicate), L32 (lane 4, in duplicate, not easily seen in the reproduction), and L37 (lane 5, in duplicate) contain proteins that are reactive to the anti-streptag II antibodies. These proteins correspond to the predicted molecular weights of the S6 (34 kDa), L32 (52kDa), and L37 (9kDa). The S6 and L37 proteins appear to be more abundantly represented in the polysomal fraction compared to the L32 protein, which is difficult to visualize in the figure but is present upon close inspection of the original filter. Tagged S20 (lane 3, in duplicate) does not appear to be present in the polysomal fraction. Polysomes from untransfected cells (lane 1, in duplicate) do not display any immunoreactive material.

7.2. POLYSOME IMMUNOPRECIPITATION

HEK 293 cells were transfected with plasmid constructs expressing tagged ribosomal proteins S6 or L37 and homogenized as above. Unlysed cells, nuclei, and mitochondria were removed by centrifugation at 10,000 X g for 10 minutes. 5 micrograms of an anti-streptag rabbit polyclonal antisera was added to the supernatant and incubated at 4°C for 72 hours. 100 microliters of a protein A sepharose slurry was then added and incubation continued at 4°C for one hour. The sepharose beads were pelleted by centrifugation at 1,000 X g for 5 minutes. The supernatant was removed, and the pellet was resuspended in 10 mLs of fresh homogenization buffer. This procedure was repeated three times.

RNA was harvested from the protein A sepharose pellet using an RNA isolation kit (Ambion). Briefly, the pellets were solubilized in 600 microliters of homogenization buffer, followed by the addition of 600 microliters of 64% EtOH. This mixture was applied to the spin column provided by the kit, followed by centrifugation at 10,000 X g for 1 minute. The column was sequentially washed in the two wash buffers provided with the kit. RNA bound to the column was released by the addition of elution buffer heated to 95°C. RNA was visualized by electrophoresis through an ethidium bromide containing agarose gel.

As seen in FIG. 2, ribosomal RNA is present (arrow) in material immunoprecipitated from tagged S6 (lane 2) transfectants. Such RNA is also present at low levels in material from tagged L37 transfectants (lane 3; not easily seen in reproduction). Such RNA is not present in material from untransfected cells (lane 1).

All references cited herein are incorporated herein by reference in their entireties and for all purposes to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety for all purposes.

The citation of any publication is for its disclosure prior to the filing date and should not be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention.

Many modifications and variations of this invention can be made without departing from its spirit and scope, as will be apparent to those skilled in the art. The specific embodiments described herein are offered by way of example only, and the invention is to be limited only by the terms of the appended claims along with the full scope of equivalents to which such claims are entitled.

WHAT IS CLAIMED IS:

1. A method of isolating mRNA from a population of cells, said method comprising
 - 5 (a) contacting a lysate or fraction of said population of cells with a reagent, wherein said population of cells contains one or more cells having tagged ribosomes comprising a ribosomal protein, or functional fragment thereof, fused to a peptide tag, said peptide tag in said tagged ribosome binding specifically to said reagent, and said peptide tag not being a ribosomal protein or fragment thereof; and wherein said tagged ribosome is bound to
10 said mRNA;
 - (b) isolating said tagged ribosomes bound by said reagent; and
 - (c) isolating said mRNA from said tagged ribosomes.
- 15 2. The method of claim 1 wherein the peptide tag is streptavidin and the reagent specifically binds streptavidin.
3. The method of claim 1 wherein the ribosomal protein is S6, L32, or L37.
- 20 4. The method of claim 1 wherein the population of cells comprises two or more cell types and wherein said tagged ribosomes are present only in one cell type in said population.
5. The method of claim 1 wherein the ribosomal protein fused to a peptide tag
25 is encoded by a nucleic acid comprising a first nucleotide sequence encoding the ribosomal protein, or functional fragment thereof, fused to a second nucleotide sequence encoding the peptide tag, wherein the expression of the nucleic acid is regulated by a non-ribosomal protein regulatory sequence.
- 30 6. A method of isolating mRNA from a population of cells, said method comprising
 - (a) contacting a lysate or fraction of said population of cells with a reagent, wherein said population of cells contains one or more cells having tagged
35 mRNA binding proteins comprising a mRNA binding protein, or functional fragment thereof, fused to a peptide tag, said peptide tag on said tagged

mRNA binding protein binding specifically to said reagent, and said peptide tag not being a mRNA binding protein; and wherein said tagged mRNA binding protein is bound to said mRNA;

(b) isolating said tagged mRNA binding protein bound by said reagent; and

5 (c) isolating said mRNA from said tagged mRNA binding protein.

7. The method of claim 6 wherein the mRNA binding protein is not polyA binding protein.

10 8. The method of claim 6 wherein the peptide tag is streptavidin and the reagent specifically binds streptavidin.

9. The method of claim 6 wherein the population of cells comprises two or more cell types and wherein said tagged mRNA binding protein is present only in one cell
15 type in said population.

10. The method of claim 6 wherein the tagged mRNA binding protein is encoded by a nucleic acid comprising a first nucleotide sequence encoding the mRNA binding protein, or functional fragment thereof, fused to a second nucleotide sequence encoding the
20 peptide tag, wherein the expression of the nucleic acid is regulated by a non-mRNA binding protein regulatory sequence.

11. A non-human transgenic animal comprising a transgene comprising a nucleotide sequence encoding a ribosomal protein fusion protein, wherein the ribosomal
25 protein fusion protein comprises a ribosomal protein, or functional fragment thereof, fused to a peptide tag, which peptide tag is not a ribosomal protein or portion thereof; wherein when said ribosomal protein fusion protein is present in a ribosome, said peptide tag is bound by a reagent that specifically binds said peptide tag, and said ribosome containing said ribosomal protein fusion protein binds mRNA; and wherein expression of said
30 nucleotide sequence is controlled by a regulatory sequence such that said nucleotide sequence is expressed in a population of cells of said non-human transgenic animal.

12. The non-human transgenic animal of claim 11 wherein said reagent does not specifically bind to any other component of said one or more cells.

35

13. The non-human transgenic animal of claim 11 wherein the transgenic animal is a mouse.

14. The non-human transgenic animal of claim 11 wherein the transgenic animal
5 is a *Drosophila*.

15. The non-human transgenic animal of claim 11 wherein the peptide tag is streptavidin and the reagent specifically binds streptavidin.

10 16. A non-human transgenic animal comprising a transgene comprising a nucleotide sequence encoding a mRNA binding protein fusion protein, wherein the mRNA binding protein fusion protein comprises a mRNA binding protein, or functional fragment thereof, fused to a peptide tag, which peptide tag is not a mRNA binding protein or
15 fragment thereof; wherein when said mRNA binding protein fusion protein is present in a ribosome, said peptide tag is bound by a reagent that specifically binds said peptide tag, and said ribosome containing said mRNA binding protein fusion protein binds mRNA; and wherein expression of said nucleotide sequence is controlled by a regulatory sequence such that said nucleotide sequence is expressed in a population of cells of said non-human
transgenic animal.

20

17. The non-human transgenic animal of claim 16 wherein said mRNA binding protein is not polyA binding protein.

18. The non-human transgenic animal of claim 16 wherein said reagent does not
25 specifically bind to any other component of said one or more cells.

19. The non-human transgenic animal of claim 16 wherein the transgenic animal is a mouse.

30 20. The non-human transgenic animal of claim 16 wherein the transgenic animal is a *Drosophila*.

21. The non-human transgenic animal of claim 16 wherein the peptide tag is streptavidin and the reagent specifically binds streptavidin.

35

22. A transgenic plant comprising a transgene comprising a nucleotide sequence encoding a ribosomal protein fusion protein, wherein the ribosomal protein fusion protein comprises a ribosomal protein, or functional fragment thereof, fused to a peptide tag, which peptide tag is not a ribosomal protein or portion thereof; wherein when said ribosomal protein fusion protein is present in a ribosome, said peptide tag is bound by a reagent that specifically binds said peptide tag, and said ribosome containing said ribosomal protein fusion protein binds mRNA; and wherein expression of said nucleotide sequence is controlled by a regulatory sequence such that said nucleotide sequence is expressed in a population of cells of said transgenic plant.

23. A transgenic plant comprising a transgene comprising a nucleotide sequence encoding a mRNA binding protein fusion protein, wherein the mRNA binding protein fusion protein comprises a mRNA binding protein, or functional fragment thereof, fused to a peptide tag, which peptide tag is not a mRNA binding protein or fragment thereof; wherein when said mRNA binding protein fusion protein is present in a ribosome, said peptide tag is bound by a reagent that specifically binds said peptide tag, and said ribosome containing said mRNA binding protein fusion protein binds mRNA; and wherein expression of said nucleotide sequence is controlled by a regulatory sequence such that said nucleotide sequence is expressed in a population of cells of said transgenic plant.

24. A transgenic yeast cell comprising a transgene comprising a nucleotide sequence encoding a ribosomal protein fusion protein, wherein the ribosomal protein fusion protein comprises a ribosomal protein, or functional fragment thereof, fused to a peptide tag, which peptide tag is not a ribosomal protein or portion thereof; wherein when said ribosomal protein fusion protein is present in a ribosome, said peptide tag is bound by a reagent that specifically binds said peptide tag, and said ribosome containing said ribosomal protein fusion protein binds mRNA; and wherein expression of said nucleotide sequence is controlled by a regulatory sequence such that said nucleotide sequence is expressed in said transgenic yeast cell.

25. A transgenic yeast cell comprising a transgene comprising a nucleotide sequence encoding a mRNA binding protein fusion protein, wherein the mRNA binding protein fusion protein comprises a mRNA binding protein, or functional fragment thereof, fused to a peptide tag, which peptide tag is not a mRNA binding protein or fragment thereof; wherein when said mRNA binding protein fusion protein is present in a ribosome,

said peptide tag is bound by a reagent that specifically binds said peptide tag, and said ribosome containing said mRNA binding protein fusion protein binds mRNA; and wherein expression of said nucleotide sequence is controlled by a regulatory sequence such that said nucleotide sequence is expressed in said transgenic yeast cell.

5

26. A cultured cell comprising a transgene comprising a nucleotide sequence encoding a ribosomal protein fusion protein, wherein the ribosomal protein fusion protein comprises a ribosomal protein, or functional fragment thereof, fused to a peptide tag, which peptide tag is not a ribosomal protein or portion thereof; wherein when said ribosomal
10 protein fusion protein is present in a ribosome, said peptide tag is bound by a reagent that specifically binds said peptide tag, and said ribosome containing said ribosomal protein fusion protein binds mRNA; and wherein expression of said nucleotide sequence is controlled by a regulatory sequence such that said nucleotide sequence is expressed in said cultured cell.

15

27. The cultured cell of claim 26 which is a mammalian cell.

28. A cultured cell comprising a transgene comprising a nucleotide sequence encoding a mRNA binding protein fusion protein, wherein the mRNA binding protein
20 fusion protein comprises a mRNA binding protein, or functional fragment thereof, fused to a peptide tag, which peptide tag is not a mRNA binding protein or fragment thereof; wherein when said mRNA binding protein fusion protein is present in a ribosome, said peptide tag is bound by a reagent that specifically binds said peptide tag, and said ribosome containing said mRNA binding protein fusion protein binds mRNA; and wherein expression
25 of said nucleotide sequence is controlled by a regulatory sequence such that said nucleotide sequence is expressed in said cultured cell.

29. The cultured cell of claim 28 which is a mammalian cell.

30. A method of isolating mRNA from a population of cells from the transgenic animal of claim 11, wherein one or more cells in said population express said ribosomal protein fusion protein, said method comprising contacting a lysate or fraction of said population of cells with a reagent which binds to said peptide tag; isolating the ribosomes containing said peptide tag bound to said reagent from said lysate or fraction; and isolating
35 said mRNA from said ribosomes.

31. A method of isolating mRNA from a population of cells from the transgenic animal of claim 16, wherein one or more cells in said population express said mRNA binding protein fusion protein, said method comprising contacting a lysate or fraction of said population of cells with a reagent which binds to said peptide tag; isolating the mRNA binding protein fusion proteins bound to said reagent from said lysate or fraction; and isolating said mRNA from said mRNA binding protein fusion protein.

32. A method of isolating mRNA from a population of cells from the transgenic plant of claim 22, wherein one or more cells in said population express said ribosomal protein fusion protein, said method comprising contacting a lysate or fraction of said population of cells with a reagent which binds to said peptide tag; isolating the ribosomes containing said ribosomal fusion protein bound to said reagent from said lysate or fraction; and isolating said mRNA from said ribosomes.

33. A method of isolating mRNA from a population of cells from the transgenic plant of claim 23, wherein one or more cells in said population express said mRNA binding protein fusion protein, said method comprising contacting a lysate or fraction of said population of cells with a reagent which binds to said peptide tag; isolating said mRNA binding protein fusion protein bound to said reagent from said lysate or fraction; and isolating said mRNA from said mRNA binding protein fusion protein.

34. A method of isolating mRNA from the transgenic yeast cell of claim 24, said method comprising contacting a lysate or fraction of said transgenic yeast cell with a reagent which binds to said peptide tag; isolating the ribosomes containing said ribosomal protein fusion protein bound to said reagent from said lysate or fraction; and isolating said mRNA from said ribosomes.

35. A method of isolating mRNA from the transgenic yeast cell of claim 25, said method comprising contacting a lysate or fraction of said transgenic yeast cell with a reagent which binds to said peptide tag; isolating said mRNA binding protein fusion protein bound to said reagent from said lysate or fraction; and isolating said mRNA from said mRNA binding protein fusion protein.

36. A method of isolating mRNA from the cultured cell of claim 26, said method comprising contacting a lysate or fraction of said cultured cell with a reagent which binds to

said peptide tag; isolating the ribosomes containing said ribosomal fusion protein bound to said reagent from said lysate or fraction; and isolating said mRNA from said ribosomes.

37. A method of isolating mRNA from the cultured cell of claim 28, said method comprising contacting a lysate or fraction of said cultured cell with a reagent which binds to said peptide tag; isolating said mRNA binding protein fusion protein bound to said reagent from said lysate or fraction; and isolating said mRNA from said mRNA binding protein fusion protein.

38. An isolated ribosome-reagent complex comprising

- (1) a tagged ribosome, comprising a ribosomal protein fusion protein, said ribosomal protein fusion protein comprising a ribosomal protein, or functional fragment thereof, and a peptide tag, which peptide tag is not a ribosomal protein or fragment thereof;
- (2) a mRNA bound to said ribosomal protein fusion protein; and
- (3) a reagent specifically bound to said peptide tag.

39. The isolated ribosome-reagent complex of claim 38 wherein said reagent is bound to a solid support.

40. An isolated mRNA binding protein-mRNA-reagent complex comprising

- (1) a tagged mRNA binding protein comprising a mRNA binding protein, or functional fragment thereof, and a peptide tag, which peptide tag is not a mRNA binding protein or fragment thereof;

- (2) a mRNA bound to said tagged mRNA binding protein; and
- (3) a reagent specifically bound to said peptide tag.

41. The isolated mRNA binding protein-mRNA-reagent complex of claim 40 wherein said reagent is bound to a solid support.




FIG. 1




FIG. 2

SEQUENCE LISTING

<110> Renovis, Inc.
Heintz, Nathaniel
Serafini, Tito
Shyjan, Andrew

<120> METHOD FOR ISOLATING CELL-TYPE SPECIFIC mRNAs

<130> 10239-024-228

<140>
<141>

<150> 60/340,689
<151> 2001-10-29

<160> 17

<170> PatentIn version 3.0

<210> 1
<211> 9
<212> PRT
<213> Influenza virus

<400> 1
Tyr Pro Tyr Asp Val Pro Asp Tyr Ala
1 5
<210> 2
<211> 10
<212> PRT
<213> Homo sapiens

<400> 2
Glu Gln Lys Leu Ile Ser Glu Glu Asp Leu
1 5 10
<210> 3
<211> 6
<212> PRT
<213> Bluetongue virus

<400> 3
Gln Tyr Pro Ala Leu Thr
1 5
<210> 4
<211> 8
<212> PRT
<213> Artificial

<220>
<223> Description of Artificial Sequence: Flag peptide used for
identification

<400> 4
Asp Tyr Lys Asp Asp Asp Asp Lys
1 5
<210> 5
<211> 9
<212> PRT
<213> Artificial

<220>

<223> Description of Artificial Sequence: Strep-tag peptide used for identification

<400> 5

Ala Trp Arg His Pro Gln Phe Gly Gly

1

5

<210> 6

<211> 551

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: Shuttle Vector

<400> 6

taacgttact	ggccgaagcc	gcttgggaata	aggccggtgt	gcgtttgtct	atatgttatt	60
ttccaccata	ttgccgtctt	ttggcaatgt	gagggcccgg	aaacctggcc	ctgtcttctt	120
gacgagcatt	cctaggggtc	tttcccctct	cgccaaagga	atgcaaggtc	tggtgaatgt	180
cgtgaaggaa	gcagttcctc	tggaagcttc	ttgaagacaa	acaacgtctg	tagcgaccct	240
ttgcaggcag	cggaaccocc	cacctggcga	caggtgcctc	tgcggccaaa	agccacgtgt	300
ataagataca	cctgcaaagg	cggcacaacc	ccagtgccac	gttgtgagtt	ggatagttgt	360
ggaaagagtc	aaatggctct	cctaagcgta	ttcaacaagg	ggctgaagga	tgcccagaag	420
gtactccatt	gtatgggata	tgatctgggg	cctcggtgca	catgctttac	atgtgttttag	480
tcgaggttaa	aaaaacgtct	aggccccccg	aaccacgggg	acgtggtttt	cctttgaaaa	540
acaccatgat	a					551

<210> 7

<211> 37

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: PCR Primer

<400> 7

ggaattcatt caagatgaag ctgaacatct ccttccc 37

<210> 8

<211> 43

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: PCR Primer

<400> 8

gcggcgcgtt ttctgactgg attcagactt agaagtagaa gct 43

<210> 9

<211> 37

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: PCR Primer

<400> 9

ggaattcccg gcgacatggc taaacgcacc aagaagg 37

<210> 10

<211> 39

<212> DNA
 <213> Artificial

<220>
 <223> Description of Artificial Sequence: PCR Primer

<400> 10
 gcggccgctc tggctctttca gttccttcag tcttctgat 39

<210> 11
 <211> 37
 <212> DNA
 <213> Artificial

<220>
 <223> Description of Artificial Sequence: PCR Primer

<400> 11
 ggaattcgcg cgcaacagcc atggctttta aggatac 37

<210> 12
 <211> 39
 <212> DNA
 <213> Artificial

<220>
 <223> Description of Artificial Sequence: PCR Primer

<400> 12
 gcggccgcta gcatctgcaa tgggtgacttc cacctcaac 39

<210> 13
 <211> 37
 <212> DNA
 <213> Artificial

<220>
 <223> Description of Artificial Sequence: PCR Primer

<400> 13
 ggaattcggc atcatggctg cccttcggcc tctgggtg 37

<210> 14
 <211> 36
 <212> DNA
 <213> Artificial

<220>
 <223> Description of Artificial Sequence: PCR Primer

<400> 14
 gcggccgctt tcattctctt cgtgcgtag cctggc 36

<210> 15
 <211> 39
 <212> DNA
 <213> Artificial

<220>
 <223> Description of Artificial Sequence: PCR Primer

<400> 15

ggccgcagcg cttggagcca cccgcagttc gaaaaataa

39

<210> 16

<211> 39

<212> DNA

<213> Artificial

<220>

<223> Description of Artificial Sequence: PCR Primer

<400> 16

tcgattatattt ttcgaaactgc ggggtggctcc aagcgctgc

39

<210> 17

<211> 8

<212> PRT

<213> Artificial

<220>

<223> Description of Artificial Sequence: Tag used for identification

<400> 17

Trp Ser His Pro Gln Phe Glu Lys

1

5